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ABSTRACT	  
The	  Enhanced	  Permeability	  and	  Retention	  (EPR)	  effect	  is	  widely	  known	  to	  allow	  for	  
enhanced	  delivery	  of	  nanoparticles	  to	  tumors.	  	  This	  has	  been	  harnessed	  for	  delivery	  
of	  chemotherapeutics	  to	  tumors	  in	  multiple	  FDA	  approved	  nanomedicines,	  including	  
DOXIL®,	  a	  doxorubicin-­‐loaded	  liposome.	  	  Nanomedicines	  enable	  the	  modulation	  of	  
drug	   delivery	   parameters	   to	   tailor	   the	   pharmacokinetics.	   	   In	   this	   project,	   we	  
quantitatively	   evaluate	   the	   EPR	   effect	   by	   analysis	   and	   comparison	   of	   the	  
pharmacokinetics	   of	  DOXIL-­‐like	   liposomes	   in	   tumor-­‐bearing	   and	   tumor-­‐free	  mice.	  	  
Additionally,	  tumor	  accumulation	  is	  evaluated.	  	  We	  have	  modeled	  this	  system	  using	  
a	  2-­‐compartment	  model	  for	  tumor-­‐free	  mice	  and	  a	  3-­‐compartment	  model	  for	  tumor-­‐
bearing	  mice.	  	  This	  allows	  us	  to	  fit	  the	  model	  to	  our	  data	  in	  order	  to	  determine	  rate	  
constants	  for	  liposomal	  distribution.	  	  The	  majority	  of	  data	  is	  compared	  with	  LS	  174T	  
colon	   adenocarcenoma	   cells	   with	   selective	   comparison	   to	   MDA-­‐MB-­‐231	   breast	  
adenocarcinoma	  and	  Capan-­‐1	  pancreatic	  adenocarcinoma.	   	   It	   is	   seen	   that	  LS	  174T	  
xenografts	  have	   the	  highest	   tumor	  accumulation,	  20x	  higher	  at	  24	  h	   than	  Capan-­‐1	  
xenografts.	  
Next,	   we	   evaluate	   the	   impact	   of	   altering	   a	   nanomedicine’s	   physicochemical	  
properties	   on	   the	   nanomedicine’s	   pharmacokinetics	   and	   tumor	   accumulation.	  	  
These	   predictions	   might	   be	   used	   to	   guide	   future	   development	   of	   nanomedicines.	  	  
	   iii	  
Doing	  this,	  we	  find	  that	  increasing	  the	  nanomedicine’s	  evasion	  of	  the	  mononuclear	  
phagocyte	  system	  (MPS)	  will	  realize	  the	  highest	  increase	  the	  tumor	  accumulation	  at	  
long	  time	  points.	  	  	  
Finally,	   we	   evaluate	   encapsulation	   of	   a	   near-­‐infrared	   (NIR)	   imaging	   agent	   within	  
liposomes	   for	   semi-­‐quantitative	   evaluation	   of	   a	   liposomal	   platform.	   	  We	   examine	  
liposome	   distribution	   and	   tumor	   accumulation	   over	   time	   in	   mice	   containing	   LS	  
174T	  subcutaneous	  xenografts	  and	  compare	  this	  data	  with	  the	  quantitative	  data	  we	  
have	   gained	   from	   analogous	   doxorubicin-­‐loaded	   liposomes.	   	   We	   find	   that	   this	  
platform	  could	  be	  used	   for	  a	  more	  expedient	  and	  efficient	  nanoparticle	  evaluation	  
for	  more	  expedient	  feedback	  to	  assist	  with	  design	  of	  nanomedicines.	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Chapter	  1 :	  Introduction	  to	  Nanomedicines	  
1.1	  Nanomedicines	  for	  Cancer	  Therapy	  
Cytotoxic	  small	  molecules	  such	  as	  alkylating	  agents	  (e.g.	  cisplatin),	  anti-­‐metabolites	  
(e.g.	   gemcitabine),	   anti-­‐microtubule	   agents	   (e.g.	   paclitaxel,	   vincristine),	  
topoisomerase	  inhibitors	  (e.g.	  topotecan),	  and	  cytotoxic	  inhibitors	  (e.g.	  doxorubicin)	  
are	  involved	  in	  drug	  therapies	  for	  cancer.	  	  These	  target	  and	  kill	  highly	  proliferative	  
cells,	  consequently	  they	  preferentially	  attack	  cancers	  cells.	  	  However,	  it	  also	  leads	  to	  
increased	   cell	   death	   in	   other	   highly	   proliferative	   cells	   in	   bone	   marrow,	   the	  
gastrointestinal	   tract,	   and	   hair	   follicles,	   resulting	   in	   the	   common	   side	   effects	   of	  
compromised	  immune	  system;	  inflammation	  and	  ulceration	  of	  the	  GI	  tract;	  and	  hair	  
loss.	   	   Incorporation	   of	   these	   drugs	   into	   a	   larger	   drug	   delivery	   system	   enables	   a	  
reduction	   in	   rate	   at	   which	   the	   drug	   can	   escape	   circulation	   into	   the	   surrounding	  
tissues.	  	  This	  provides	  the	  ability	  to	  reduce	  unwanted	  side	  effects	  by	  decoupling	  the	  
design	  constraints	  of	  the	  nanomedicines.	  
Biocompatibility	   and	   stability	   in	   circulation	   will	   be	   important	   toward	   improved	  
nanomedicines;	   however,	   an	   additional	   key	   goal	   in	   improving	   drug	   efficacy	   is	  
increasing	   the	   amount	   of	   drug	   delivered	   to	   tumor	   tissues	   while	   minimizing	   the	  
amount	   of	   drug	   delivered	   to	   healthy	   tissues.	   	   To	   bolster	   the	   efficiency	   of	  
nanomedicines	  accumulation	  at	   the	  tumor	  site,	  extravasation	   from	  the	  vasculature	  
to	  the	  tumor	  is	  increased	  with	  larger	  sized	  drugs.	  	  These	  drugs	  enter	  the	  tumor	  via	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enhanced	  permeability	  and	  retention	   (EPR)	  effect	  or	  a	   targeting	  agent	   is	  added	   to	  
the	  drug	  to	  provide	  active	  targeting.	  	  It	  is	  possible	  to	  further	  reduce	  a	  drug’s	  toxicity	  
by	  encapsulating	  it	  within	  a	  nanomedicines	  (e.g.	  liposomes)	  or	  by	  locally	  activating	  
the	  drug	  at	  the	  tumor	  site	  (a	  prodrug).	  	  	  	  	  
1.1.1	  The	  enhanced	  permeability	  and	  retention	  (EPR)	  effect	  
As	   solid	   tumors	   grow,	   the	   formation	   of	   new	   vessels	   is	   promoted	   by	   the	   up-­‐
regulation	   of	   angiogenic	   factors	   and	   the	   down-­‐regulation	   of	   angiogenic	   inhibitors.	  	  
Through	   this	   process,	   matrix	   metalloproteinases	   (MMPs)	   degrade	   basement	  
membrane	   and	   extracellular	   matrix	   (ECM),	   and	   the	   smooth	   muscle	   cells	   are	  
removed	   locally.	   	   Simultaneously,	   tumor	   cell	   proliferation	   causes	   the	   tumor	  
microenvironment	   to	   expand,	   locally	   generating	   compressive	   forces.[1]	   	   These	  
compressive	   forces	   lead	   to	   the	   contraction	   of	   blood	   vessels,	   contributing	   to	   an	  
increased	   resistance	   to	   flow.	   	   Furthermore,	   the	   compressive	   forces	   on	   lymphatic	  
vessels	   lead	   to	   poor	   lymphatic	   drainage	   and	   increased	   interstitial	   fluid	   pressure.	  	  
This	  environment	  consists	  of	  both	  mechanical	  and	  biochemical	   factors	  that	   lead	  to	  
irregular	  vasculature	  architecture,	  higher	  resistance	   to	  blood	   flow,	  poor	  perfusion,	  
and	   higher	   permeability.	   	   This	   is	   known	   as	   the	   EPR	   effect	   and	   yields	   leakiness	   in	  
tumor	   vasculature	   that	   is	   key	   for	   systemic	   delivery	   of	   anticancer	   drugs	   to	   a	   solid	  
tumor.[2-­‐4]	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1.1.2	  FDA-­‐approved	  nanomedicines	  
The	  nanomedicines	  that	  are	  currently	  FDA-­‐approved	  for	  treatment	  of	  solid	  tumors	  
have	   exhibited	   both	   benefits	   and	   challenges.	   	   These	   allow	   for	   high	   drug	   loading,	  
increased	   bioavailability,	   active	   targeting,	   and	   enhancing	   drug	   solubility.[5]	  	  
However,	   much	   of	   the	   development	   of	   develop	   drug	   delivery	   systems	   remains	  
empirical	  and	  a	   lack	  of	   standardization	  of	  pre-­‐clinical	   studies	  remains	  a	  barrier	   to	  
fully	   exploiting	   advances	   in	   nanotechnology	   and	   bioengineering	   for	   significant	  
improvement	  in	  patient	  survival	  rates.	  	  	  
Currently,	  six	  nanomedicines	  have	  been	  approved	  by	  the	  FDA	  for	  treatment	  of	  solid	  
tumors	   (Table	   1-­‐1):	   	   Brentuximab	   vedotin	   and	   Trastuzumab	   emtansine,	   Doxil,	  
DaunoXome,	   Marqibo,	   and	   Abraxane.[5]	   	   These	   fall	   into	   three	   main	   categories:	  
antibody-­‐drug	  conjugates	  (ADCs),	  liposomes,	  and	  protein	  carriers.	  
ADCs	   include	   Brentuximab	   vedotin	   and	   Trastuzumab	   emtansine.	   	   Conceptually,	  
these	  may	  be	  the	  simplest	  nanomedicines	  with	  an	  anticancer	  drug	  conjugated	  to	  the	  
targeting	   molecule,	   an	   antibody.	   	   In	   each	   case,	   the	   anticancer	   drug,	   monomethyl	  
auristan	  E	   (MMAE)	  and	  mertansine,	   respectively,	   is	   too	  potent	   to	  be	  used	  without	  
the	   addition	   of	   a	   targeting	   moiety	   to	   guide	   it	   to	   the	   tumor	   site,	   consequently	  
reducing	  the	  side	  effects.	  	  Brentuximab	  targets	  a	  glycosylated	  phosphoprotein,	  CD30,	  
expressed	  by	  B	  cells,	   including	  B-­‐cell	   lymphomas,	   some	   leukemias,	   and	  melanoma	  
cancer	   stem	   cells.	   [6-­‐8]	   Trastuzumab	   targets	   the	   human	   epidermal	   growth	   factor	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receptor	   2	   (HER2)	   that	   is	   overexpressed	   in	   HER2	   positive	   breast	   cancer.	   [9,	   10]	  	  
Each	   antibody	   has	   multiple	   sites	   for	   drug	   conjugation.	   	   MMAE	   is	   conjugated	   to	  
Brentuximab	   via	   a	   valine-­‐citrulline	   cleavable	   linker	   for	   brentuximab	   vedotin.	   	   For	  
Trastuzumab	  emtansine,	  mertansine	  is	  conjugated	  to	  the	  Trastuzumab	  antibody	  via	  
a	   covalent	   linkage	   that	   is	   enzymatically	   degraded	   in	   endosomes	   following	   cellular	  
uptake.	  	  The	  small	  number	  of	  ADC’s	  that	  have	  achieved	  FDA	  approval	  highlights	  how	  
difficult	  is	  can	  be	  to	  translate	  even	  relatively	  simple	  nanomedicines	  to	  the	  clinic.	  [11]	  
Table	  1-­1.	  	  Summary	  of	  FDA-­approved	  nanomedicines	  for	  treatment	  of	  solid	  tumors.	  	  
Six	  nanomedicines	  have	  currently	  been	  approved	  for	  treatment	  of	  solid	  tumors	  including	  two	  ADC’s	  
(Brentuximab	   vedotin	   and	   Trastuzumab	   emtansine),	   three	   liposomes	   (Doxil,	   DaunoXome,	   and	  
Marqibo),	  and	  one	  protein	  carrier	  (Abraxane).	  










~ 10 ≤ 8 valine-citrulline linker 
cleaved by cathepsin in 
endosomes 
monomethyl auristan 
E (MMAE) is too toxic 
to be used alone 
Trastuzumab 
emtansine 
ADC mertansine ~ 10 ≤ 8 non-cleavable linker; 
release of drug by 
proteolytic degradation of 
antibody in endosomes 
mertansine is too toxic 
to be used alone 
Doxil liposome doxorubicin 100 10,000 -
15,000 
lipid encapsulation for high 
drug/carrier ratio, 
polyethylene glycol coating 
to evade MPS, 
crystallization of drug in 
liposome minimizes 
escape during circulation 
drug toxicity and 
adverse cardiac side 
effects 
DaunoXome liposome daunorubicin 50 ~ 10,000 no polyethylene glycol 
coating, targeted by MPS 
resulting in slow release 
into circulation 
drug toxicity and 
adverse cardiac side 
effects 
Marqibo liposome vincristine 100 ~ 10,000 no polyethylene glycol 
coating, targeted by MPS 
resulting in slow release 
into circulation 
drug toxicity and 
adverse side effects 
Abraxane protein 
carrier 
paclitaxel 130 >10,000 non-specific binding of 
paclitaxel to albumin 
overcomes very low 
solubility of paclitaxel 
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FDA-­‐approved	  liposomal	  nanomedicines	  include	  Doxil,	  DaunoXome,	  and	  Marqibo.	  	  A	  
generic	  equivalent	  of	  Doxil	  was	  FDA	  approved	  in	  2013,	  3	  years	  after	  the	  Doxil	  patent	  
expired.	  	  Doxil	  encapsulates	  approximately	  10,000	  doxorubicin	  molecules	  within	  an	  
approximately	   100	   nm	   diameter,	   pegylated	   liposome.	   [12]	   	   Encapsulation	   of	   the	  
chemotherapeutic	   minimizes	   side	   effects	   including	   the	   cardiotoxicity	   associated	  
with	   free	   doxorubicin.	   	   Doxorubicin	   within	   the	   liposomes	   forms	   a	   solid	   crystal	  
because	   the	   concentration	   is	   greater	   than	   the	   solubility	   limit	   of	   doxorubicin.[12]	  	  
Cholesterol	   is	   incorporated	   into	   the	   lipid	   bilayer	   in	   order	   to	   increase	   the	   bilayer	  
cohesiveness	  and	  decrease	  the	  leakage	  of	  doxorubicin	  from	  the	  liposome.	  	  This	  leads	  
to	   increased	   stability	   in	   circulation,	   with	   greater	   than	   98%	   of	   circulating	  
doxorubicin	   remaining	  within	   the	   liposome.	   [13-­‐15]	   	   The	   coating	   of	   polyethylene	  
glycol	  (PEG)	  increases	  the	  circulation	  half-­‐time,	  hence	  the	  amount	  of	  accumulation	  
in	  the	  tumor	  is	  increased	  by	  the	  EPR	  effect.	  [16,	  17]	  	  The	  exact	  mechanism	  of	  uptake	  
and	   release	   is	   not	   know,	   but	   there	   is	   evidence	   to	   suggest	   that	   the	   liposomes	   are	  
endocytosed.	  [18]	  
The	   liposomal	   formulation	   of	   daunorubicin	   is	   DaunoXome[19-­‐21],	   and	   the	  
liposomal	   form	   of	   vincristine	   is	  Marqibo[22,	   23].	   	   In	   contrast	   to	   Doxil,	   neither	   of	  
these	  liposomal	  formulations	  include	  pegylation.[19,	  20,	  23]	  	  They	  instead	  impart	  a	  
tactic	   similar	   to	   slow	   infusion	   where	   they	   have	   promoted	   uptake	   by	   the	  
mononuclear	  phagocyte	  system	  (MPS),	  allowing	  drug	  to	  be	  freed	  from	  the	  liposomes	  
and	  slowly	  enter	  circulation.	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The	  final	  FDA-­‐approved	  nanomedicines	  is	  Abraxane,	  or	  nanoparticle	  albumin	  
bound	   paclitaxel	   (or	   nab-­‐paclitaxel).	   	   This	   consists	   of	   lyophilized	   human	   serum	  
albumin	  non-­‐specifically	  bound	  to	  pacitaxel.[24]	  	  Paclitaxel	  is	  typically	  administered	  
with	   the	   toxic	   non-­‐ionic	   solvent	   Cremophor	   to	   overcome	   the	   low	   solubility	   of	  
paclitaxel;	  however,	   this	  can	  lead	  to	  a	  wide	  variety	  of	  allergic	  reactions.	   	  Abraxane	  
provides	   an	   alternative	   to	   over	   come	   this	   solubility	   issue	   without	   the	   use	   of	  
Cremophor.	  	  Upon	  entering	  circulation	  after	  injection,	  Abraxane	  particles	  dissociate	  
into	  unbound	  paclitaxel	  or	  smaller	  albumin-­‐paclitaxel	  complexes.[25]	  	  This	  provides	  
a	   non-­‐toxic	   platform	   for	   the	   solubilization	   of	   paclitaxel	   due	   to	   the	   abundunce	   of	  
albumin	  already	  in	  circulation.[24]	  
1.1.3	  The	  pharmacokinetics	  of	  nanomedicines	  
For	   each	   of	   the	   FDA-­‐approved	   nanomedicines,	   their	   design	   is	   reflected	   in	   their	  
pharmacokinetic	   behavior	   (Table	   1-­‐2).	   	   The	   ADCs,	   Brentuximab	   vedotin	   and	  
Trastuzimab	   emtansine,	   have	   low	   clearance,	   3-­‐4	   day	   elimination	   half-­‐times,	   and	  
moderate	   AUCs.	   [9,	   26-­‐29]	   	   The	   pegylated	   surface	   of	   Doxil	   facilitates	   extended	  
evasion	  of	  the	  MPS	  and	  minimized	  uptake	  into	  healthy	  tissue,	  [14,	  30-­‐33]	  resulting	  
in	  high	  AUC,	  low	  clearance,	  a	  small	  distribution	  volume,	  and	  a	  long	  elimination	  half-­‐
time.	  [12]	  
For	   liposomes	   that	   are	   not	   pegylated,	  DaunoXome	   and	  Marqibo,	   the	   aim	   is	   not	   to	  
evade	   the	  MPS,	   and	   consequently	   these	   feature	   clearance	   rates	   about	   an	   order	   of	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magnitude	   above	   ADCs	   and	  Doxil,	   along	  with	   low	   distribution	   volumes	   and	   short	  
elimination	  half	  times	  (approximately	  10	  h).	  [19-­‐21,	  23]	  	  In	  this	  case,	  DaunoXome	  is	  
administered	  at	  a	  higher	  dose	  than	  is	  Marqibo;	  this	  is	  reflected	  in	  a	  higher	  AUC	  for	  
DaunoXome	  than	  Marqibo.	  	  	  
Table	  1-­2.	  Pharmacokinetics	  of	  FDA-­approved	  nanomedicines	  and	  corresponding	  free	  drugs.	  
Data	   is	   from	   human	   clinical	   trials,	   typically	   representing	   the	   range	   of	   mean	   or	   median	   values	  
obrained	  from	  different	  doses.	  	  If	  unit	  conversion	  was	  necessary,	  an	  average	  body	  surface	  area	  of	  1.7	  
m2,	  weight	  of	  60	  kg,	  and	  blood	  volume	  of	  5	  L	  was	  used.	  
	  
Abraxane’s	   clearance	   rate	   is	   relatively	   rapid,	   approximately	   two	   orders	   of	  
magnitude	   larger	   than	  DaunoXome	   or	  Marqibo,	   but	  with	   an	   elimination	   half-­‐time	  
similar	  to	  DaunoXome	  and	  Marqibo,	  and	  a	  large	  distribution	  volume.	  [34,	  35]	  	  These	  















vedotin 90 - 110 3.2 - 4.9 
0.071 - 
0.075 8.2 - 10.2 106 - 144 [26, 29] 
Trastuzumab 
emtansine 10 - 160 0.6 - 28 
0.023 - 
0.070 1.7 - 3.5 31 - 98 [9, 27, 28] 
Doxil 25 - 80 600 - 4900 0.023 - 0.045 2.1 - 6.4 42 - 90 [14, 30-33] 
DaunoXome 10 - 190 17 - 1700 0.40 - 0.94 2.9 - 4.1 2.8 - 8.3 [19-21] 
Marqibo 2.0 - 2.25 5 - 15 0.36 - 0.38 2.6 - 2.9 9.6 - 12 [22, 23] 
Abraxane 150 - 300 4 - 10 31 - 67 900 - 1700 11 - 26 [34, 35] 
Doxorubicin 15 - 72 0.5 - 3.8 25 - 72 250 - 1800 9 - 29 [14, 36-38] 
Daunorubicin 40 - 120 1 - 19 110 - 150 200 - 450 9 - 24 [19, 39] 
Paclitaxel 170 - 330 6 - 40 15 - 50 160 - 530 7.2 - 7.6 [35] 
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pharmacokinetics	   are	   actually	   similar	   to	   free	   paclitaxel	   and	   other	   free	   drugs:	   low	  
AUC,	  high	  clearance	  rate,	  high	  distribution	  volume,	  and	  short	  elimination	  half-­‐time.	  
It	  is	  expected	  that	  increasing	  the	  elimination	  half-­‐time	  will	  enable	  increased	  tumor	  
accumulation	  via	  the	  EPR	  effect.	  	  However,	  this	  increased	  tumor	  accumulation	  may	  
not	  directly	  correlate	  with	  improved	  clinical	  efficacy	  because	  other	  processes	  such	  
as	   transport,	   uptake,	   drug	   release,	   and	   delivery	   to	   the	   optimum	   cellular	  
compartment	  are	  all	  downstream	  of	  extravasation	  by	  the	  EPR	  effect.	  	  	   	  
1.1.4	  Tumor	  accumulation	  and	  targeting	  efficiency	  
In	  preclinical	  studies,	  a	  drug’s	  efficacy	  is	  determined	  from	  the	  drug’s	  effect	  on	  tumor	  
size	   or	   from	   the	   fraction	   of	   animals	   that	   survive	   treatment	   (Figure	   1-­‐1).	   	   These	  
parameters	   are	   useful	   for	   determining	   the	   potential	   therapeutic	   benefit	   of	   a	   drug	  
delivery	  system,	  but	  the	  many	  factors	  between	  the	  administration	  and	  the	  effect	  of	  a	  
drug	   remain	   largely	   a	   black	   box.	   	   One	   additional	   parameter	   that	   is	   important	   for	  
evaluating	   a	  drug	  delivery	   system’s	  potential	   is	   its	   ability	   to	   reach	   the	   tumor	   site.	  	  
This	   parameter,	   tumor	   accumulation	   or	   targeting	   efficiency,	   can	   be	   analyzed	   by	  
evaluation	   of	   the	   fraction	   of	   the	   initial	   dose	   that	   reaches	   the	   tumor	   site	   (%ID).	  	  
Unfortunately,	  this	  parameter	  is	  reported	  relatively	  rarely	  in	  the	  literature	  in	  spite	  
of	  its	  importance.	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Figure	  1-­1.	  Path	  of	  drug	  evaluation.	  
The	  outcomes	  of	  a	  drug,	  namely	  tumor	  size	  and	  patient	  survival,	  are	  primarily	  used	  to	  evaluate	  the	  
drug’s	  potential.	   	  Unfortunately,	  the	  drug’s	  accumulation	  in	  the	  tumor	  largely	  remains	  unknown	  for	  
many	  drug	  delivery	  systems,	  making	  this	  element	  along	  the	  path	   	   to	  nanoparticle	  efficacy	   largely	  a	  
scientific	  “black	  box.”	  
	  
To	   evaluate	   the	   impact	   of	   tumor	   accumulation,	   we	   evaluated	   73	   studies	   that	  
reported	   tumor	   accumulation.[11]	   	   For	   this	   comparison,	   only	   studies	   that	  
quantitatively	   report	   the	   accumulation	   of	   nanoparticles	   in	   a	   tumor	  were	   selected.	  	  
The	  majority	  of	  these	  studies	  normalized	  tumor	  accumulation	  to	  tumor	  volume	  by	  
reporting	  %ID/g	  or	  %ID/cc.	   	  While	   these	   values	   are	   important	   for	   understanding	  
the	  concentration	  of	  a	  drug	  in	  the	  tumor,	  they	  do	  not	  reveal	  how	  much	  of	  the	  initial	  
dose	   actually	   arrived	   at	   its	   preferred	   destination,	   the	   tumor.	   	   These	   71	   studies	  
encompassed	  both	  passive	  targeting	  of	  a	  nanoparticle	  and	  active	  targeting	  through	  
the	  addition	  of	  a	  targeting	  moiety	  to	  the	  surface	  of	  the	  nanoparticle.	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1.1.5	  Targeting	  moieties	  
The	   addition	   of	   active	   targeting	   to	   a	   nanoparticle	   provides	   a	  method	   to	  minimize	  
uptake	   in	  normal	   tissue	  while	   increasing	  accumulation	   in	  the	  tumor.	   	  Strategies	   to	  
actively	  target	  a	  tumor	  include	  the	  targeting	  of	  surface	  membrane	  proteins	  that	  are	  
frequently	  upregulated	  in	  the	  cells	  within	  a	  tumor.	  [40,	  41]	  	  This	  strategy	  is	  widely	  
used;	   however,	   the	   heterogeneity	   in	   tumor	   cell	   expression	   levels	   and	   populations	  
can	   pose	   difficulties.	   	   Standard	   targeting	   moieties	   include	   antibodies	   [42-­‐44],	  
antibody	  fragments	  [45],	  aptamers	  [46,	  47],	  or	  small	  molecules	  (Figure	  1-­‐2).	  
Several	   factors	   can	   impact	   the	   efficacy	   of	   a	   targeting	   moiety	   added	   to	   a	  
nanomedicine.	   	   For	   example,	   accumulation	   of	   any	   delivery	   system—active	   or	  
passive—at	  the	  tumor	  site	  will	  be	  impacted	  by	  the	  concentration	  in	  circulation.	  	  	  
Clearance	  by	   the	  MPS	  or	  uptake	   in	  normal	   tissue	  are	  processes	   that	  will	   decrease	  
the	   circulating	   concentration	   of	   a	   drug	   delivery	   system	   and	   in	   turn	   decrease	   the	  
accumulation	   in	   the	   tumor.	   	   The	   addition	   of	   active	   targeting	   will	   provide	   an	  
additional	   sink	   for	   a	   drug	   delivery	   system	   because	   it	  will	   be	   further	   drawn	   to	   its	  
target.	   	  These	  targets	  are	  generally	  expressed	  in	  high	  levels	  on	  tumor	  cells	  but	  low	  
levels	  on	  other	  cell	  types	  in	  the	  vascular	  system,	  but	  because	  the	  surface	  area	  of	  the	  
vasculature	  is	  so	  much	  greater	  than	  the	  tumor,	  active	  binding	  in	  healthy	  tissue	  may	  
still	  be	  significant,	  even	  if	  the	  target	  is	  expressed	  in	  relatively	  low	  levels	  in	  healthy	  
tissues.[48]	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Figure	  1-­2.	  Examples	  of	  targeting	  molecules.	  
(a)	  Antibodies	  (approximately	  150	  kDa	  or	  15	  x	  5	  nm)	  have	  two	  antigen	  binding	  sites.	  	  (b)	  xPSM-­‐A-­‐10	  	  
(18..5	   kDa	   )is	   an	   aptamer	  with	   a	   binding	   affinity	   of	   about	   10-­‐8	  M-­‐1	   for	   the	   extracellular	   portion	   of	  
prostate-­‐specific	   membrane	   antigen	   (PSMA)	   [49]	   (c)	   The	   glutamate	   lysine	   urea	   small	   molecule	  
targets	  PSMA	  (473	  Da)	   [50]	  (d)	  The	  RGD	  peptide	  sequence	  (604	  Da)	  binds	  to	  cell	  surface	  integrins	  
that	  are	  upregulated	  in	  many	  tumor	  types.	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1.1.6	  Tumor	  accumulation	  of	  nanomedicines	  
Pre-­‐clinical	   trials	   of	   nanomedicines	   are	   usually	   designed	   to	   assess	   efficacy	   by	  
measuring	  changes	  in	  tumor	  size	  and/or	  survival	  rates	  following	  administration	  in	  
an	  animal	  model	  and	  not	  to	  optimize	  the	  design	  of	  the	  delivery	  platform.	  	  Tumor	  size	  
and/or	   survival	   rate	   data	   do	   not	   provide	   insight	   into	   how	   modifications	   to	   the	  
physico-­‐chemical	  properties	  of	  the	  delivery	  platform	  influence	  steps	  in	  the	  delivery	  
process	  (e.g.	  distribution,	  clearance,	  and	  tumor	  accumulation).	  	  Optimization	  of	  the	  
delivery	   platform	   is	   key	   to	   minimizing	   dose	   and	   side	   effects	   while	   maintaining	  
efficacy.	  
To	   assess	   the	   difficulties	   in	   comparing	   delivery	   platforms	   and	   developing	   design	  
rules	  we	  analyzed	  74	  pre-­‐clinical	  studies	  of	  nanomedicine	  delivery	  systems	  of	  both	  
passive	   (Table1-­‐5)	   and	   active	   (Table	   1-­‐6)	   nanomedicine	   systems.	   	   Our	   initial	  
selection	   criterion	  was	   that	   studies	  must	   report	   values	   of	   tumor	   accumulation	   as	  
percent	  of	  initial	  administered	  dose	  (%ID)	  at	  two	  or	  more	  time	  points.	  	  However,	  we	  
were	  only	  able	  to	  find	  7	  studies	  that	  satisfied	  this	  criterion	  and	  hence	  broadened	  the	  
requirements	   to	   reported	   values	   of	   tumor	   accumulation	   as	   percent	   of	   initial	  
administered	   dose	   per	   gram	   of	   tumor	   (%	   ID/g)	   (the	   importance	   of	   these	   units	   is	  
discussed	   below).	   	   Despite	   the	   importance	   of	   pharmacokinetics	   and	   tumor	  
accumulation	   in	   assessing	   the	   efficiency	   of	   delivery	   systems,	   very	   few	  pre-­‐clinical	  
studies	   report	   quantitative	   results	   that	   can	   be	   used	   to	   develop	   design	   rules	   for	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nanomedicines.	   	   Analysis	   of	   these	   pre-­‐clinical	   studies	   highlights	   the	   need	   for	  
guidelines	  to	  improve	  the	  overall	  impact	  of	  research	  in	  this	  field.	  
In	  general,	  nanomedicines	  accumulation	   in	  a	   tumor	   tends	   to	   increase	   immediately	  
after	  injection	  followed	  by	  decreasing	  at	  later	  times.[11]	  	  For	  example,	  	  	  radiolabeled	  
liposomes	   increased	   in	   the	   tumor	  over	   the	   first	  24	  h	   to	  11.3	  %ID/g	   followed	  by	  a	  
decrease	   to	   6.1	   %ID/g	   at	   72	   h.[51]	   	   Quantum	   dot	   tumor	   accumulation	   similarly	  
increased	  to	  13	  %ID/g	  over	  the	  first	  24	  h	  and	  then	  dropped	  to	  11	  %ID/g	  at	  42	  h.[52]	  	  
However,	  this	  trend	  is	  not	  realized	  across	  the	  board.	  	  Pegylated	  micelles	  were	  seen	  
to	  increase	  to	  almost	  18	  %ID/g	  over	  the	  first	  6	  h,	  but	  at	  24	  h	  this	  has	  decreased	  to	  
2	   %ID/g.[53]	   	   Additionally,	   the	   variation	   in	   tumor	   accumulation	   is	   often	   much	  
smaller.	   	   Gold	  nanoparticles	  with	   the	   addition	  of	   active	   targeting	   via	  RGD	  peptide	  
conjugation	  were	  seen	  to	  reach	  3.65	  %ID/g	  within	  the	  first	  hour,	  but	  by	  24	  h	  post-­‐
injection,	  this	  had	  dropped	  slightly	  to	  1.94	  %ID/g.[54]	  	  	  
1.1.7	  Variations	  in	  experimental	  protocol	  
In	   reviewing	   the	  73	   studies	  where	  quantitative	   tumor	  accumulation	  was	   reported	  
(Table	   1-­‐5	   and	   1-­‐6),	   it	   became	   painfully	   obvious	   that	   variations	   in	   experimental	  
protocol	   across	   the	   field	   hindered	   our	   ability	   to	   make	   comparisons	   across	   the	  
studies	  (Table	  1-­‐4).	  	  	  	  Typically,	  each	  nanomedicine	  is	  evaluated	  for	  clinical	  efficacy	  
in	   its	  desired	  application,	   but	   the	  details	   of	   this	   application,	   and	   consequently	   the	  
evaluation	   often	   vary.	   Unfortunately,	   determination	   of	   the	   impact	   of	   a	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nanomedicine’s	   physicochemical	   properties	   is	   stunted	   by	   our	   inability	   to	   make	  
comparisons	  across	  different	  studies.	  
Variations	   that	   affect	   this	   include	   both	   inconsistencies	   in	   experimental	   procedure	  
and	   in	   reporting	  of	   values.[11]	   	  These	  problems	  and	   their	   solutions	   are	  discussed	  
briefly	   in	   Table	   1-­‐3,	   and	   in	   more	   detail	   in	   the	   following	   section,	   1.2	   Suggested	  
Protocol	  for	  Nanomedicine	  Benchmarking.	  	  
In	  short,	  it	  is	  uncommon	  to	  report	  the	  total	  tumor	  accumulation	  of	  a	  nanomedicines	  
(in	   %ID	   or	   mg).	   	   This	   is	   compounded	   by	   a	   lack	   of	   consistent	   explanation	   of	   the	  
tumor	  size,	  making	  it	  impossible	  to	  calculate	  this	  value	  from	  the	  normalized	  %ID/g.	  	  
Both	   values	   are	   important	   and	   should	   be	   given.	   While	   %ID/g	   describes	   the	  
concentration	   of	   the	   drug	   in	   the	   tumor	   and	   is	   ostensibly	   a	   way	   to	   account	   for	  
differences	   in	   tumor	   size,	   it	   is	   considerably	  more	  useful	   if	   the	   tumor	  mass	   is	   also	  
reported.	   	   	   For	   example,	   a	   tumor	   accumulation	  of	   10	  %ID/g	   is	   10	  %	  of	   the	   initial	  
dose	  for	  a	  1	  g	  tumor	  but	  1	  %	  of	  the	  initial	  dose	  for	  a	  0.1	  g	  tumor.	  	  These	  differences	  
are	  significant	  in	  terms	  of	  the	  efficiency	  of	  delivery	  and	  minimizing	  unwanted	  side	  
effects	   in	   normal	   tissue.	   	   In	   some	   cases	   tumor	   characteristics	   such	   as	   tumor	  
diameter	   or	   approximate	   tumor	   volume	   are	   reported,	   however,	   these	   parameters	  
can	  only	  be	  used	  to	  estimate	  the	  absolute	  percentage	  of	  the	  initial	  dose.	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Table	   1-­3.	   Limitations	   to	   pre-­clinical	   studies	   of	   nanomedicines	   that	   hinder	   platform	  
assessment.	  
Problem Solution 
Total tumor accumulation (%ID) is not always 
reported Report tumor accumulation as %ID (and %ID/g) 
Inconsistent reporting of tumor size/weight Report tumor size/weight 
Inconsistent reporting of dose  
Report dose as total number of nanoparticles 
injectedalong with other parameters such as drug 
loading, drug concentration (and/or drug amount), 
and activity of dose (gamma counter) 
Inconsistent reporting of physico-chemical properties  
Report standard physico-chemical properties (e.g. 
size, zeta potential, surface coating, stability under 
physiological conditions)  
Tumor accumulation reported at different time points 
Report tumor accumulation at standard time points 
(e.g. 1 h and 24 h post-injection).  Detailed 
pharmacokinetics (concentration in blood and tumor) 
at multiple time points is preferred. 
Variation in tumor characteristics (type, size, 
vascularization, etc.)  
• Standardize tumor type and size (e.g. C26 or 4T1; 1 
cm diameter) 
• More difficult for active targeting depending on 
target molecule 
Variation in controls used in active targeting 
Report control studies for delivery system with no 
targeting ligand and any differences in physico-
chemical properties.  Report other control studies as 
necessary 
Variation in animal models (mouse, rat, etc.) and 
differences in drug concentration compared to 
humans  
Use mouse xenograft model for initial pre-clinical 
studies 
Different detection methods used to assess tumor 
accumulation Perform validation using other method(s) 
	  
	  
Additionally,	   the	   time	  point	  of	  evaluation	  should	  be	  noted.	   	  The	   time	  of	  maximum	  
tumor	   accumulation	   will	   likely	   vary	   with	   varied	   physicochemical	   platforms,	   but	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introduction	   of	   a	   standardized	   time	   point	   for	   comparison	   will	   bring	   us	   closer	   to	  
direct	  comparison	  of	  platforms.	  	  Even	  with	  this,	  variations	  in	  tumor	  model,	  including	  
tumor	   type	   and	   animal	  will	   prevent	   cross-­‐platform	   evaluation.	   	   To	   truly	   facilitate	  
evaluation	  of	  the	  effect	  of	  a	  nanomedicine’s	  physicochemical	  properties	  on	  its	  ability	  
to	  target	  a	  tumor,	  a	  standardized	  protocol	  must	  be	  introduced.	  
1.2	  Suggested	  Protocol	  for	  Nanomedicine	  Benchmarking	  
The	  ability	   to	   compare	   studies	  of	  different	  drug	  delivery	  platforms	  will	   accelerate	  
progress	   in	   the	   field	   and	   ultimately	   will	   increase	   the	   value	   of	   time	   and	   money	  
invested	  in	  nanomedicines	  research.	  	  Variations	  in	  experimental	  design	  has	  already	  
impacted	   our	   ability	   to	   make	   cross-­‐platform	   comparisons,	   and	   this	   problem	   will	  
only	  magnify	  as	  time	  continues	  without	  the	  introduction	  of	  a	  standardized	  protocol	  
to	  facilitate	  the	  benchmarking	  of	  nanomedicines.	  	  The	  following	  is	  an	  examination	  of	  
variables	   that	   will	   impact	   the	   outcome,	   and	   consequently	   the	   comparison,	   or	  
platform	   evaluation,	   including	   animal	  model,	   tumor	   size,	   dose,	   and	   the	  measured	  
variables	   for	   physico-­‐chemical	   properties,	   pharmacokinetics,	   and	   tumor	  
accumulation.	   	  This	  protocol	  (Table	  1-­‐4),	  proposes	  a	  method	  that	  could	  be	  applied	  
for	  benchmarking	  pre-­‐clinical	  studies	  of	  drug	  delivery	  platforms	  and	  is	  discussed	  in	  
more	  detail	  in	  the	  following	  pages.	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Table	  1-­4.	  Protocol	  for	  benchmarking	  nanomedicines	  for	  the	  treatment	  of	  solid	  tumors.	  
Standardization	  of	  experimental	  procedures	  and	  corresponding	  reporting	  metrics	  will	  enable	  direct	  
comparison	  and	   contribute	   to	   the	  development	  of	  design	   rules	   that	  will	   accelerate	  progress	   in	   the	  
field.	  	  	  
  Guideline Reporting 
Animal model 
LS 174T subcutaneous 
xenografts grown to 8-10 mm in 
athymic nu/nu mouse 
weight (g), diameter (mm) 
Physicochemical 
properties 
size, shape, composition, surface 
chemistry, zeta potential collected 
diameter (nm), shape, composition, surface 
chemistry, zeta potential 
Dose 1013 NP number of NP 
Pharmacokinetics 6, 24, 48 h % ID, mg of drug 
Tumor 
accumulation 6, 24, 48 h % ID, % ID/g 
	  
	  
This	   protocol	   calls	   for	   quantitative	  measurement	   of	   the	   concentration	  of	   the	  drug	  
delivery	  system	  in	  blood	  and	  the	  tumor	  in	  athymic	  Nu/Nu	  mice	  with	  subcutaneously	  
xenografted	   LS	   174T	   cells	   approximately	   8-­‐10	   mm	   in	   diameter.	   	   These	  
measurements	  should	  be	  taken	  at	  a	  minimum	  of	  three	  time	  points	  (6	  h,	  24	  h,	  and	  48	  
h	  post-­‐injection).	  	  Tumor	  accumulation	  should	  be	  reported	  as	  both	  %ID	  and	  %ID/g.	  	  
The	  dose	  administered	  to	  the	  mice	  should	  be	  1013	  particles	  per	  mouse	  with	  7	  mice	  
to	   be	   used	   per	   time	   point.	   	   By	   enacting	   this	   protocol	   across	   pre-­‐clinical	   trials	   of	  
nanomedicines,	   it	   will	   be	   possible	   to	   compare	   the	   impact	   of	   altering	   physico-­‐
chemical	  properties	  on	  the	  deliverability	  of	  the	  nanomedicines.	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1.2.1	  Evaluation	  of	  animal	  model	  for	  establishing	  tumor	  uptake	  
Rodents	   are	   often	   used	   in	   cancer	   research	   for	   therapy	   development,	   carcinogen	  
identification,	   and	   to	   evaluate	   tumor	   growth	   and	   metastasis	   mechanism.	   	   In	  
particular,	   there	  are	  models	  of	  primary	   tumors	   for	  most	  organs	   in	  mice,	   including	  
human	  tumor	  xenografts	  in	  immunocompromised	  mice,	  genetically	  engineered	  mice	  
(GEM),	  and	  environmentally-­‐induced	  tumors	  in	  mice.[55,	  56]	  Difficulties	  using	  mice	  
for	   this	  application	  will	   include	  their	   low	  total	  blood	  volume,	  approximately	  2	  mL,	  
that	  makes	   it	  problematic	   to	  extract	  sufficiently	   large	  blood	  samples	   from	  a	  single	  
animal	  at	  multiple	   time	  points;	  however,	  one	  main	  benefit	  of	  mice	   is	   their	  relative	  
inexpensive	  cost,	  making	  them	  ideal	  for	  benchmarking	  across	  laboratories.	  	  
The	   state-­‐of	   the-­‐art	   in	   animal	  models	   currently	   is	   GEM.	   	   Unfortunately,	   these	   are	  
quite	   expensive,	   technically	   challenging,	   and	   time	   consuming.	   	   They	   are	   and	   will	  
continue	   to	   be	   important	   for	   recapitulation	   of	   many	   aspects	   of	   the	   tumor	  
microenvironment;	   however,	   they	   are	   not	   ideal	   for	   this	   type	   of	   cross-­‐laboratory	  
benchmarking.	   	   For	   this	   application,	   it	   is	   important	   to	   have	   a	   relatively	  
straightforward,	   inexpensive,	   and	   quick	   option.	   	   In	   spite	   of	   their	   shortcomings,	  
subcutaneous	   xenografts	  with	   immortalized	   cell	   lines	   fill	   this	   need	   and	   should	   be	  
used.	  
In	  terms	  of	  cell	   line	  for	  the	  xenograft,	  one	  of	  the	  biggest	  hurdles	   in	  nanomedicines	  
benchmarking	   is	   the	   wide	   variety	   of	   cell	   lines	   currently	   used.	   	   Of	   68	   studies	   of	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quantitative	   tumor	  accumulation	   in	  mouse	   xenografts,	   35	  different	   cell	   lines	  were	  
used	  to	  form	  the	  xenografts.[11]	   	  Commonly	  used	  cell	   lines	  included	  C26,	  4T1,	  KB,	  
and	  LS	  174T.	  	  C26	  colon	  carcinoma	  cells	  are	  also	  known	  to	  induce	  cachexia	  in	  mice,	  
reducing	  body	  mass	  by	  as	  much	  as	  20%.[57]	  	  This	  will	  introduce	  additional	  levels	  in	  
variation	  in	  experiments,	  making	  C26	  not	  suitable	  for	  benchmarking.	   	  KB	  cell	   lines	  
are	  widely	  used	  in	  cancer	  research;	  however,	  this	  cell	  line	  has	  been	  contaminated	  by	  
HeLa	  cells[58]	  and	  are	  no	  longer	  suitable	  for	  benchmarking.	  	  4T1	  is	  a	  highly	  invasive	  
animal	   breast	   cancer	   model	   that	   is	   used	   both	   in	   subcutaneous	   and	   orthotopic	  
xenografts	   that	   readily	  metastasize.[59,	  60]	   	  While	   this	   is	  excellent	   for	  physiologic	  
relevance,	   it	   poses	   significant	   problems	   toward	   the	   quantification	   of	   tumor	  
accumulation,	   making	   this	   also	   unsuitable	   for	   benchmarking.	   	   LS174T	   human	  
colorectal	  adenocarcinoma	  cell	  lines	  grow	  readily	  in	  nude	  mice	  and	  have	  been	  used	  
previously	   in	   studies	   of	   the	   EPR	   effect,	   making	   this	   cell	   line	   suitable	   for	   cross-­‐
platform	  benchmarking.[61]	  
The	  final	  aspect	  of	  the	  mouse	  model	  to	  consider	  is	  the	  size	  of	  the	  subcutaneous	  LS	  
174T	   xenografts.	   	   It	   is	   important	   that	   these	   grow	   large	   enough	   that	   they	   are	  well	  
vascularized	   (≥	  1	  mm3)[62]	  yet	  not	   so	   large	   that	  a	  necrotic	   core	  compromises	   the	  
result.	   	   A	   tumor’s	   ability	   to	   self-­‐vascularize	   will	   impact	   the	   point	   that	   it	   reaches	  
necrosis.	   	   For	   this	   experiment,	   LS	   174T	   subcutaneous	   xenografts	   should	   be	  
approximately	  0.2	  g	  in	  weight,	  about	  8-­‐10	  mm	  in	  diameter.	  	  The	  mass	  of	  the	  tumor	  
should	  be	  documented	  and	  reported.	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1.2.2	  Physicochemical	  properties	  of	  the	  nanomedicines	  
It	  is	  critical	  to	  establish	  the	  physic-­‐chemical	  properties	  that	  must	  be	  reported	  since	  
the	  goal	  of	  this	  is	  to	  elucidate	  the	  relationship	  between	  these	  properties	  and	  a	  drug	  
delivery	  platform’s	   ability	   to	   accumulate	   in	   a	   tumor.	   	   Physico-­‐chemical	   evaluation	  
should	   include	   information	   on	   nanomedicines	   size,	   shape,	   surface	   chemistry,	   and	  
aggregation	   state.[63-­‐65]	   	   These	   parameters	   are	   all	   known	   to	   influence	  
pharmacokinetics,	  uptake,	  and	  trafficking	  of	  nanoparticles.[66-­‐71]	  
1.2.3	  Nanomedicine	  dose	  	  
Standardization	   of	   dose	   for	   pre-­‐clinical	   platforms	   is	   quite	   difficult,	   in	   large	   part	  
because	   of	   inconsistencies	   in	   standard	   practices	   for	   dose	   reporting	   metrics	   for	  
different	   types	   of	   nanomedicines.	   	   Dose	   may	   be	   based	   on	   the	   amount	   of	   drug	  
administered	   (e.g.	   weight	   of	   drug	   per	   body	   weight	   or	   surface	   area)	   or	   may	   be	  
reported	  as	  the	  number	  of	  nanoparticles	  administered.	  	  Rarely	  is	  the	  drug	  loaded	  to	  
the	   nanoparticle	   at	   a	   1:1	   ratio,	   so	   information	   on	   drug	   loading	   (number	   of	   drug	  
molecules	   per	   nanoparticle	   carrier)	   is	   important	   but	   often	   unmentioned.	  	  
Furthermore,	  radio-­‐labeling	  is	  a	  common	  method	  for	  imaging	  and	  determination	  of	  
biodistribution.	  	  In	  fact,	  this	  was	  the	  predominate	  method	  used	  for	  quantification	  of	  
tumor	  accumulation	  in	  our	  recent	  metastudy.[11]	  	  However,	  data	  from	  this	  are	  truly	  
only	   useful	   for	   benchmarking	   if	   there	   is	   a	   quantitative	   calibration	   between	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radioactivity	   units	   (e.g.	   Curies	   or	   Bequerels)	   to	   dose	   as	   absolute	   amount	   of	  
nanomedicines.	  
In	  analyzing	  the	  dose	  used	  for	  quantitative	  studies	  of	  tumor	  accumulation,[11]	  the	  
range	  of	  dose	  was	  quite	   large	   (1011	  –	  1016	  particles/mouse)	  but	  most	  were	   in	   the	  
middle,	   around	   1013	   particles/mouse.	   	   Normalized	   to	   body	   weight,	   this	   dose	   is	  
within	   the	   range	   of	   doses	   of	   FDA-­‐approved	   nanomedicines	   for	   humans.	  	  
Consequently,	  a	  dose	  of	  1013	  particles/mouse	  should	  be	  used	  and	  reported	  both	  as	  
number	   of	   particles,	   mass	   of	   drug,	   and	   mass	   of	   drug	   normalized	   to	   the	   mass	   of	  
animal.	  
1.2.4	  Evaluation	  of	  pharmacokinetics	  and	  tumor	  accumulation	  
Pre-­‐clinical	   trials	   of	   nanomedicines	   sometimes	   include	   pharmacokinetics	   and	  
biodistribution	  properties	  of	  the	  nanomedicine.	  	  The	  clearance	  rate,	  area	  under	  the	  
curve,	   distribution	   volume,	   and	   elimination	   half-­‐time	   are	   pharmacokinetic	  
parameters	   that	  will	   provide	   insight	   into	   the	  nanoparticles	   stability	   in	   circulation,	  
uptake	  in	  healthy	  tissues,	  and	  propensity	  for	  clearance	  by	  the	  kidneys	  and	  the	  MPS.	  	  
Inclusion	  of	  full	  biodistribution,	  including	  accumulation	  in	  organs	  such	  as	  liver	  and	  
spleen,	  will	  provide	  further	  information	  with	  regard	  to	  nanoparticle	  toxicity.	  
Comprehensive	  biodistribution	  and	  pharmacokinetic	  curves	  are	  immensely	  valuble	  
but	   time	   consuming	   and	   expensive,	   and	   therefore	   unrealistic	   for	   benchmarking	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experiments.	  	  Tumor	  accumulation	  is	  one	  parameter	  that,	  while	  not	  widely	  reported,	  
combines	   aspects	   of	   pharmacokinetics	  with	   extravasation	  by	   the	  EPR	  effect.	   	   This	  
makes	  it,	  along	  with	  concentration	  in	  blood,	  an	  ideal	  parameter	  for	  benchmarking.	  
Time	  points	  of	  measurements	  should	  be	  minimized	  to	  minimize	  cost	  and	  maximize	  
accessibility	  of	  benchmarking	  experiments;	  however	  it	  is	  important	  to	  include	  time	  
points	  that	  are	  relevant	  for	  a	  variety	  of	  nanomedicines.	  	  Measurements	  shortly	  after	  
administration,	   at	   6	   h,	   will	   provide	   insight	   for	   systems	   where	   maintenance	   of	  
circulating	   concentration	   is	   not	   required,	   for	   example	   imaging	   applications.	  	  
Measurements	  at	  24	  h	  will	  allow	  for	   insight	  at	  a	  slightly	   later	  time	  point	  when	  the	  
concentration	  in	  circulation	  will	  have	  slightly	  dropped.	  	  Finally	  a	  48	  h	  time	  point	  will	  
allow	  for	  examination	  of	  tumor	  accumulation	  at	  a	  time	  when	  circulating	  drug	  will	  be	  
quite	  low,	  resulting	  in	  a	  concentration	  gradient	  that	  will	  drive	  unbound	  particles	  out	  
of	  the	  tumor	  back	  into	  circulation.	  	  This	  will	  provide	  information	  about	  retention	  of	  
the	   nanoparticle	   in	   the	   tumor.	   	   Measurements	   of	   amount	   of	   nanomedicine	   in	  
circulation	  and	  tumor	  at	  6	  h,	  24	  h,	  and	  48	  h	  will	  therefore	  provide	  a	  large	  amount	  of	  
insight	  into	  the	  nanoparticle	  behavior.	  	  
1.2.5	  Protocol	  for	  pre-­‐clinical	  nanomedicine	  benchmarking	  
Animal	  model.	   	   4-­‐6	  week	   old	   immunodeficient,	   athymic	   Nu/Nu	   female	  mice	   	   	   are	  
maintained	   according	   to	   federal	   guidelines,	   including	   the	  Principles	   of	   Laboratory	  
	   23	  
Animal	  Care	  in	  addition	  to	  regulations	  of	  the	  institution’s	  Committee	  on	  the	  Use	  and	  
Care	  of	  Animals,	  and	  housed	  in	  a	  specific	  pathogen-­‐free	  animal	  facility.	  
Tumor	  preparation.	  LS	  174T	  human	  colorectal	  carcinoma	  cell	  line	  is	  purchased	  from	  
the	  American	  Type	  Culture	  Collection	  (Manassas,	  VA)	  	  and	  maintained	  in	  vitro	  at	  37	  
˚C,	  5%	  CO2	  in	  Eagle's	  Minimum	  Essential	  Medium	  with	  10%	  fetal	  bovine	  serum	  and	  
1%	   penicillin/streptomycin.	   	   Cells	   should	   not	   be	   used	   above	   passage	   15.	  	  
Immediately	   prior	   to	   xenograft	   inoculation	   in	   the	   mice,	   cells	   are	   harvested	   with	  
trypsin-­‐EDTA	   solution,	  washed	   in	  PBS,	   and	   resuspended	  at	   a	   concentration	  of	   5	   x	  
106	  cells	  in	  a	  100	  µL	  solution	  of	  50	  %	  growth	  media	  and	  50%	  growth	  factor	  reduced	  
Matrigel.	  	  Each	  100	  µL	  suspension	  of	  cells	  is	  injected	  subcutaneously	  into	  one	  flank	  
of	  each	  mouse.	   	  Tumors	  are	  grown	  to	  reach	  a	  diameter	  of	  8	  –	  10	  mm	  in	  diameter,	  
approximately	  1.5-­‐2	  weeks.	  	  	  
Physico-­chemical	   properties.	   	   Average	   particle	   size,	   shape,	   composition,	   surface	  
chemistry,	  and	  zeta	  potential	  should	  be	  reported	  for	  each	  drug	  delivery	  system.	  
Drug	   administration.	   	   Dose	   of	   injection	   is	   1013	   nanoparticles	   and	   should	   be	  
injectected	   in	  a	  volume	  of	   less	   than	  200	  µL	   into	   the	   lateral	   tail	   vein	  of	   the	  mouse.	  	  
Dose	  should	  additionally	  be	  reported	   in	  other	  relevant	  metrics	  to	  the	  nanoparticle	  
system	  (drug/radiolabel	  loading,	  total	  drug	  administered,	  etc,)	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Biodistribution	  and	  tumor	  accumulation.	  	  Nanomedicine	  concentration	  in	  both	  blood	  
and	   tumor	   should	  be	  quantitatively	   evaluated	   at	   6	  h,	   24	  h,	   and	  48	  h.	   	   Each	   group	  
should	   include	   a	  minimum	  of	   seven	  mice.	   	   Concentration	   in	  blood	   and	   	   should	  be	  
reported	   as	   absolute	   amount	   %ID	   and	   amount	   (mg).	   	   In	   addition,	   tumor	  
accumulation	   should	   be	   normalized	   to	   the	   weight	   of	   the	   tumor	   and	   reported	  
as	  %ID/g	  tumor.	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Table	  1-­5.	  Quantitative	  studies	  of	  passively	  targeted	  nanoparticles.	  
Nanoparticle	  Type	   Size	   Cargo	   Composition	   Tumor	  type	   Tumor	  size/	  
weight	  
Dose	   Targeting	  Efficiency	   Method	   Ref	  
Block	   copolymer	  
micelles	  
30	  nm	   Adriamycin	   PEG-­‐P(Asp)	   Colon	   26	  
xenografts	   in	  
mice	  
100	  mm3	   10	  mg/kg	   4	   ±	   0.4	   %ID/g	  @	   1	   hr,	   5	   ±	   1	  
%ID/g	  @	   4	   hr,	   9.5	   ±	   1	  %ID/g	  
@	  24	  hr,	  9	  ±	  0.5	  %ID/g	  @	  48	  
hr	  
LSC-­‐1000	   [72]	  
Block	   copolymer	  
micelles	  
58	  nm	   111In	   PEG-­‐e-­‐caprolactone-­‐p-­‐
SCN-­‐Bn-­‐DTPA-­‐111In	  
MDA-­‐MB-­‐231	  
xenografts	   in	  
female	   nude	  
mice	  
150	  mm3	   250	  mg/kg	   9	  ±	  2	  %ID/g	  @	  48	  hr	   MicroSPECT,	   CT,	  
gamma	  counter	  
[73]	  
Carbon	  nanotubes	   41.6	  
nm	  
SWNT	   SWNT+C18-­‐PMH-­‐mPEG	   4T1	   xenografts	  
in	  Balb/c	  mice	  
20-­‐50	  mm3	   200µL	   of	   0.35	  
mg/mL	  
30	  %ID/g	  @	  100	  hr	   Raman	  scattering	   [74]	  
Composite	  
nanodevices	  
5	  nm	   Gold	   PAA	   dendrimers	   +	   gold	  
nanoparticles,	   positively	  
charged	  surface	  
B16F10	  
xenografts	   in	  
male	   mice,	  
MatLyLu	  
xenografts	   in	  
mice	  
500	  mm3	   16	  mg/kg	   2	  ±	  0.1	  %ID/g	  @	  5	  min,	  6	  ±	  0.1	  
%ID/g	  @	  1	  hr,	  6.5	  ±	  1.5	  %ID/g	  










Oxaliplatin,	  FITC	   PIMA-­‐GA-­‐DACH-­‐platinum	   4T1	   xenografts	  
in	  mice	  
50	  mm3	   5mg/kg	   and	   15	  
mg/kg	  
0.02	  %ID/g	  for	  5	  mg/kg	  dose,	  
0.05	  %ID/g	  for	  15	  mg/kg	  dose	  





Boron	   acetal-­‐PEG-­‐b-­‐PLA-­‐MA	   +	  
polymerizable	   carborane	  
crosslinker	  
Colon	   26	  
xenografts	   in	  
mice	  
100	  mm3	   0.2	   mg	   boron	  
atoms/kg	  
Crosslinked:	   5.4	   %ID/g,	  
noncrosslinked:	  1.4	  %ID/g	  
ICP-­‐MS	   [77]	  








Proprietary	   A431	  
xenografts	   in	  
mice	  
8-­‐12	  mm	   in	  
diameter	  
10	   µCi/mouse,	  
1.3	   x	   1012	  
particles/mous
e	  
2.75	  ±	  1	  %ID/g	  @	  4	  hr,	  2.62	  ±	  
0.8	  %ID/g	  @	  24	  hr	  













xenografts	   in	  
female	   nude	  
mice	  
8-­‐10	  mm	   in	  
diameter	  
1	   mg/mouse,	  
195	  µCi	  
8.5	  ±	  1	  %ID/g	  @	  24	  hr,	  8.5	  ±	  2	  
%ID/g	  @	  48	  hr	  (SE)	  




68	  ±	  7	  
nm	  
3H-­‐acetate	   mPEG5k	   +	   mPEG-­‐b-­‐
p(HEMAm-­‐Lacn)	  
14C	   xenografts	  
in	  mice	  
	   200	   µL	   of	   10	  
mg/mL	  micelles	  
Crosslinked:	  5	  %ID/g	  @	  1	  hr,	  6	  
%ID/g	  @	   4	   hr,	   7	   %ID/g	  @24	  
hrs,	   6	   %ID/g	  @	   48	   hr.	   	   Non-­‐
crosslinked:	   3	   %ID/g	  @	   1	   hr,	  
2.5	  %ID/g	  @	  4	  hr,	  1	  %ID/g	  @	  
24	  hr,	  0	  %ID/g	  @	  48	  hr	  









Dexamethasone	   DPPC	   +	   chol	   +	   DSPE-­‐
PEG2k	  
B16F10	  
xenografts	   in	  
male	  mice	  
100	  mm3	   1	  x	  106	  cpm	   10	  %ID/g	  for	  micelles,	  5	  %ID/g	  








50	  nm	   Polypyrrole	   Core-­‐shell	   silica	   and	  
polypyrrole	  
4T1	   xenografts	  
in	  Balb/c	  mice	  
60-­‐70	  mm3	   10	  mg/kg	   5	  %ID/g	  @	  1	  hr,	  5	  %ID/g	  @	  6	  
hr,	  4	  %ID/g	  @	  24	  hr	  
ICP-­‐AES	   [82]	  
Graphene	   50	  nm	   Iron	   oxide	  
nanoparticles,	  
125I	  
RGO-­‐IONP-­‐PEG	   4T1	   xenografts	  
in	  mice	  
50	  mm3	   4	  mg/kg	   5	  %ID/g	  @	  48	  hr	   PET	   [83]	  
Graphene	   50	  nm	   HPPH,	  64Cu	   Graphene-­‐PEG-­‐HPPH	   4T1	   xenografts	  
in	  nude	  mice	  
100	  mm3	   3.7	  MBq	   3	  %ID/g	  @	  24	  hr	   PET	   [84]	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Hybrid	  
nanoparticles	  
100	   ±	  
11	  nm	  
and	  
210	   ±	  
23	  nm	  
125I	   Fe3O4	   core,	   poly(PEGMA)	  
brushes	  
Colon26	  
xenografts	   in	  
mice	  
7	   mm	   in	  
diameter	  
	   21	   %	   ID/g	   for	   high	   MW	  
dendrimer,	   3	   %	   ID/g	   for	   low	  
MW	  dendrimer	  @	  24	  h	  	  
Gamma	  counter	   [85]	  
Liposomes	   	   111In,	  DTPA	   Pegylated,	  proprietary	   KB	   xenografts	  
in	  mice	  
varied	   10-­‐20	  µCi	   mean:	   7.2	   ±	   6.6	   %ID/g	  @	   24	  
hr,	   tumor	   size	   dependence:	  
≤0.1	  g,	  15.1	  ±	  10.8	  %ID/g,	  0.1-­‐
1	  g,	  5.9	  	  ±	  2.2	  %ID/g,	  ≥1	  g,	  3	  ±	  
1.3	  %ID/g	  
Gamma	  counter	   [86]	  








14.8	  MBq	   0.28	   ±	   0.09	   %ID/g	   @	   1	   hr,	  
0.75	   ±	   0.08	   %ID/g	   @	   4	   hr,	  
1.95	   ±	   0.35	   %ID/g	   @	   24	   hr,	  
1.37	   ±	   0.39	   %ID/g	   @	   48	   hr,	  
1.09	   ±	   0.08	   %ID/g	   @	   72	   hr	  
(SD)	  
Gamma	  counter	   [87]	  
Liposomes	   80	  nm	   Iohexol	   and	  
gadoteridol	  
DPPC	   +	   chol	   +	   DSPE-­‐
PEG2k	  
VX2	   xenografts	  




1785	   mg/kg	  
iohexol,	   40	  
mg/kg	  
gadoteridol	  
0.7	   ±	   0.1	  %ID	  @	  24	  hr,	   0.9	   ±	  
0.3	   %ID	   @	   48	   hr,	   0.9	   ±	   0.3	  
%ID	  @	  72	  hr	  (SD)	  
CT	   quantitative	  
imaging	  
[88]	  
Liposomes	   83	  nm	   BMEDA,	   188Re,	   5-­‐
FU	  
Pegylated,	  proprietary	   CT26-­‐luc	  
xenografts	   in	  
mice	  
100	  mm3	   2.96	   MBq,	   100	  
µL	   liposomes,	  
0.44	   µmol	  
phospholipid	  
4.98	   ±	   0.57	   %ID/g	   @	   1	   hr,	  
5.67	   ±	   0.46	   &ID/g	   @	   4	   hr,	  
5.40	   ±	   0.42	   %ID/g	   @	   16	   hr,	  
5.46	   ±	   0.37	   %ID/g	   @	   24	   hr,	  
3.53	   ±	   0.26	   %ID/g	   @	   48	   hr,	  
1.98	   ±	   0.19	   %ID/g	   @	   72	   hr	  
(SEM)	  
Gamma	  counter	   [89]	  
Liposomes	   83	  nm	   188Re,	  BMEDA	   Pegylated,	  proprietary	   LS-­‐174T	  
xenografts	   in	  
mice	  
50-­‐70	  mm3	   2.59	   MBq,	   100	  
µL	   liposomes,	  
0.7	   µmol	  
phospholipid	  
2.61	  ±	  0.6	  %ID/g	  @	  1	  hr,	  4.26	  
±	   0.7	   %ID/g	  @	   4	   hr,	   11.27	   ±	  
0.99	   %ID/g	   @	   24	   hr,	   7.05	   ±	  
0.56	   %ID/g	   @	   48	   hr,	   6.07	   ±	  
0.35	  %ID/g	  @	  72	  hr	  (SE)	  
Gamma	  counter	   [51]	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Liposomes	   90	  nm	   Doxorubicin,	  
186Re	  
Doxil	   HNSCC	  
xenografts	   in	  
nude	  rats	  
1	  g	   555	  MBq/kg	   0.36	  ±	  0.33	  %ID/tumor	  @	  120	  
hrs	  (SD)	  
Gamma	   counter,	  
microSPECT,	  CT	  
[90]	  





Doxil	   Bilateral	   Met1	  
xenografts	   in	  
mice	  
≥100	  mm3	   6	   mg	  
doxorubicin/kg	  
10	  %ID/g	  	   ICP-­‐MS	   [91]	  
Liposomes	   100	  
nm	  




tumors	   in	  
hamsters	  
2	   mm	   in	  
diameter	  
	   3.5	  ±	  1.4	  %ID/cc	  @	  24	  hr	   PET	   [92]	  
Liposomes	   110	  
nm	  
177Lu	   DTPA/PEG	   Colon	   26	  
xenografts	   in	  
mice	  
562	   ±	   142	  
mm3,	  20	  g	  	  
3.7	  MBq	   0.61	   ±	   0.32	   %ID/g	   @	   1	   hr,	  
1.53	  ±	  0.6	  %ID/g	  @	  4	  hr,	  3.97	  
±	  1.75	  %ID/g	  @	  24	  hr,	  4.68	  ±	  
1.55	   %ID/g	   @	   48	   hr,	   3.23	   ±	  
1.7	  %ID/g	  @	  72	  hr	  (SD)	  
Gamma	  counter	   [93]	  




165Ho	   MCM-­‐41	  +	  165Ho	   A549-­‐luciferase	  
orthotopic	  
injection	   in	  
mice	  
	   150	  µCi	   4.5	  ±	  3.9	  %ID/g	  @	  24	  hr,	  58.8	  
±	  34.7	  %ID/g	  @	  1	  week	  
Gamma	  counter	   [94]	  
Micelles	   30	  nm	   β-­‐lapachone	   PEG-­‐PLA	   A549	  
orthotopic	   lung	  
cancer	  in	  mice	  
200	  mm3	   30-­‐50	  mg/kg	   1.8	  ±	  0.2	  %ID/g	  @	  2	  hr,	  1.9	  ±	  
0.2	  %ID/g	  @	  24	  hr	  (SE)	  




Micelles	   43	   ±	  
24	  nm	  
Etoposide,	  99mTc	   Polysorbate	  20	   Dalton's	  
lymphoma	  
xenografts	   in	  
Balb/c	  mice	  
1	  cm3	   100	  µCi	   10.5	  ±	  2	  %ID	  @	  1	  hr,	   5.5	  ±	  2	  
%ID	  @	  6	  hr,	  5	  ±	  1	  %ID	  @	  24	  hr	  
(SD)	  
Gamma	   ray	  
spectrometry	  
[96]	  
Micelles	   100	  
nm	  
Thiostrepton	   Amphiphilic	  lipid-­‐PEG	  
MDA-­‐MB-­‐231	  
and	   HepG2	  
xenografts	   in	  
mice	  
0.25	  g	   1.8	   mg	  
thiostrepton/	  
animal	  
16	  ±	  4	  %ID	  @	  4	  hr,	  35	  ±	  2	  %ID	  
@	  24	  hr	  (SEM)	  
LC/MS	   [97]	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Micelles	   110	  
nm	  
IFF,	  111In	   PEG-­‐PDLLA	   AR42J	  
xenografts	   in	  
mice	  
1	  cm3	   100	   µL	   of	  
micelle	  
solution	  
1	  %ID/g	  up	  to	  120	  mins	   Gamma	  counter	   [98]	  
Micelles	   192	   ±	  
13	  nm	  
Camptothecin	   PEG-­‐poly(benzyl	  
aspartate)	  
C26	   xenografts	  
in	  mice	  
100	  mm3	   2.5	  mg/kg	   1.3	  %ID/g	  @	  24	  hr	   HPLC	   [99]	  
Nanoparticles	   1.9	  
nm	  
Gold	   Gold,	  proprietary	   EMT-­‐6	  
xenografts	   in	  
mice	  
5	   mm	   in	  
diameter	  
0.01	   mL/g	   of	  
270	  mg	  Au/cm3	  
4.2	   ±	   0.25	  %ID/g	  @	  20	  mins,	  
2.5	   ±	   0.1	   %ID/g	  @	   1	   hr,	   3	   ±	  
0.1	  %ID/g	  @	  5.5	  hr,	  3.2	  ±	  0.5	  
%ID/g	   @	   11	   hr,	   2.7	   ±	   0.1	  
%ID/g	  @	  24	  hr	  




Nanoparticles	   50	  nm	   Iron	  oxide	   Iron	   oxide	   +	   PEG-­‐poly(4-­‐
vinylbenzylphosphonate)	  
C-­‐26	   xenografts	  
in	  mice	  
˃100	  mm3	   84	  mg	  Fe/kg	   1	  %ID/g	  @	  5	  mins,	  5	  %ID/g	  @	  
1	   hr,	   17	   %ID/g	   @	   4	   hr,	   17	  
%ID/g	  @	   24	   hr,	   15	   %ID/g	  @	  
48	  hr,	  14	  %ID/g	  @	  96	  hr	  
ICP-­‐MS	   [101]	  
Nanorods	   13x47	  
nm	  
Gold	   Gold,	  PEG	   MDA-­‐MB-­‐435	  	  
xenografts	   in	  
mice	  
	   20	  mg	  Au/kg	   7	  %ID/g	  @	  72	  hr	   ICP-­‐MS	   [102]	  
Nanorods	   24	  x	  7	  
nm	  
Gold	   Gold+mPEG-­‐SH	   A431	  
xenografts	   in	  
mice	  
8-­‐10	  mm	   in	  
diameter	  
2	   x	   1011	  
particles/µL	  




Nanoshells	   120	  
nm	  
Gold	   Colloidal	   silica	   +	   gold	   +	  
SH-­‐PEG	  
A431	  
xenografts	   in	  
mice	  
8-­‐10	  mm	   in	  
diameter	  
2.74	   x	   108	  
particles/µL	  






1	  µm	   Doxorubicin	   DPPC	   +	   DPPG	   +	   DPPE-­‐
PEG2k	  
DSL6A	  
xenografts	   in	  
Lewis	  rats	  
5-­‐8	   mm	   in	  
diameter	  
140	   µg	  
doxorubicin	  
0.9	  ±	  1	  %ID/g	   HPLC	   [104]	  





siRNA	   VEGF	  siRNA-­‐PEG/PEI	   PC3	   xenografts	  
in	   female	   nude	  
mice	  
50	  mm3	   3	  nmol	  siRNA	   0.3	  ±	  0.01	  %ID/g	  @	  4	  hr,	  0.5	  ±	  







30	  nm	   Aluminum	  
chloride	  
phthalocyanine	  
NIPAM	   +	   N-­‐vinyl-­‐2-­‐
pyrrolidone	  
EMT-­‐6	  
xenografts	   in	  
male	  mice	  
25	  mm3	   2	   µmol/kg	   of	  
drug	  
1	  %ID/g	  @	  1	  hr,	  1	  %ID/g	  @	  24	  






42	  nm	   Gadolinium	   PEG-­‐b-­‐poly(L-­‐lysine)	   Colon	   26	  




0.05	   mmol	  
Gd/kg	  
6.1	  ±	  0.3	  %ID/g	  @	  24	  hr	   ICP	   [107]	  
Quantum	  dots	   14-­‐28	  
nm	  
64Cu	   CdSe/ZnS	  +	  PEG	   U87MG	  
xenografts	   in	  
mice	  
100	  mm3	   25	  µg	  QDs	   5	  ±	  1	  %ID/g	  @	  1	  hr,	  12.5	  ±	  5	  
%ID/g	   @	   17	   hr,	   13.5	   ±	   4	  
%ID/g	  @	  24	  hr,	  11	  ±	  3	  %ID/g	  
@	  42	  hr	  
PET,	  ICP-­‐MS	   [52]	  
SWNTs	   200	  
nm	  
PMHC18	   SWNT-­‐PEG-­‐PMHC18	   4T1	   xenografts	  
in	  Balb/c	  mice	  
50-­‐100	  
mm3	  
200	   µL	   of	   0.5	  
mg/mL	  solution	  
17	   %ID/g	   for	   100%-­‐2kPEG-­‐
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Table	  1-­6.	  Quantitative	  studies	  of	  actively	  targeted	  nanoparticles.	  
NP	  Type	   Size	   Cargo	   Targeting	   Composition	   Dose	   Tumor	  type	   Tumor	  
size/weight	  
Targeting	  Efficiency	   Method	   Ref	  
Graphene	   27.0	   ±	  
0.9	   nm	  
with	  Ab	  
64Cu	   aCD105	  
antibody	  
PEG	   5-­‐10	  MBq	  (	  =	  135-­‐
270	  µCi)	  
4T1	  xenografts	  in	  
mice	  
5-­‐8	   mm	   in	  
diameter	  
4.5	  ±	  0.6	  %ID/g	  with	  Ab,	  2.7	  ±	  
0.3	  %ID/g	  blocked,	   	  ~2.5%	  @	  
24h	  (SD)	  
PET,	   gamma	  
counter	  
[109]	  
Graphene	   64	  nm	   111In	   aHER2	  
(trastuzumab)	  
	   10	  µg	  (5	  MBq,	  135	  
µCi)	  
231/H2N	  
xenografts	   in	  
mice	  
500	  μL	   15.0	   ±	   3.7	   %ID/g	   without	  
blocking,	   1.45	   ±	   0.04	   %ID/g	  
with	   blocking,	   0.11	   ±	   0.04	  




Graphene	   22.3	   ±	  
3.2	  nm	  
64Cu	   aCD105	  
antibody	  
PEG	   5-­‐10	  MBq	   4T1	  xenografts	  in	  
mice	  
6-­‐8	   mm	   in	  
diameter	  	  
4	  .5	  ±	  0.4	  %ID/g	  RGO-­‐TRC105,	  	  	  	  	  
2.5	   ±	   0.2	  %ID/g	   RGO-­‐TRC105	  














111In	   aEGFR	   C225	  
Antibody	  
Gold	  	   10	   μCi/mouse	  
(7.3x1010	  
particles/mL	   in	  
0.13	  mL)	  
A431	   xenografts	  
in	  mice	  
4-­‐6	   mm	   in	  
diameter	  
6.81	   ±	   2.64	   %ID/g	   C225-­‐
HauNS,	   4.60	   ±	   1.31	   %ID/g	  
















(40	   μCi/mouse	   in	  
0.2mL)	  
B16/F10	  
xenografts	   in	  
mice	  
4-­‐6	   mm	   in	  
diameter	  
12.6	  ±	  3.1	  %ID/g	  targeted,	  4.3	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Hollow	  
nanospheres	  
45	  nm	   si-­‐RNA,	  64Cu	   Folate	   Gold,	  PEG	   0.25	   μmol	  
SiRNA/kg	  
HeLa	   xenografts	  
in	  mice	  
<1.2	  cm	   5.26	  ±	  1.25	  %ID/g	  F-­‐NP,	  1.11	  





Liposomes	   ~120	  
nm	  	  
64Cu	   Somastatin	  
peptide	  
analog	   TATE	  




10	  mg	  lipid/kg	  	   NCI-­‐H727	  
xenografts	   in	  
female	  mice	  
<	  0.5	  g	  	   1.7	   ±	   0.1	   %ID/g	   @	   1h	   TATE,	  
2.7	  ±	  0.2	  %ID/g	  @	  8h	  TATE	  
5.1	  ±	  0.3	  %ID/g	  @	  24h	  TATE,	  
5.0	  ±	  0.4	  %ID/g	  @	  48h	  TATE,	  	  
1.9	   ±	   0.1	   %ID/g	   @	   1h	   CTRL,	  
3.0	   ±	   0.2	   %ID/g	   @	   8h	   CTRL	  
5.9	  ±	  0.2	  %ID/g	  @	  24h	  CTRL,	  















18.5-­‐37	  MBq	   (0.5-­‐
1	  mCi)	  
M28	   epithelial	  
and	   VAMT1	  
sarcomoid	  
xenografts	   in	  
mice	  
3-­‐5	   mm	   in	  
diameter	  
3.24	   ±	   0.24	   %ID/g	   @	   24h	  
M28,	   4.01	   ±	   0.39	   %ID/g	   @	  
48h	  M28,	   0.97	   ±	   0.48	   %ID/g	  
@	  48h	  M28	  CTRL,	  3.86	  ±	  0.23	  
%ID/g	  @	  24h	  VAMT1,	   4.69	   ±	  
0.72	   %ID/g	   @	   48h	   VAMT1,	  
0.4	   ±	   0.42	   %ID/g	   @	   48h	  




Liposomes	   and	  
Micelles	  
97	   ±2	  
nm;	   20	  
±	   24	  
nm	  








12.5	   μg	  
liposome/kg	   rat;	  






~2.5	   %ID/g	   @	   1h,	   4h,	  
liposome	   and	   micelle;	   ~0.75	  










PEG	   5-­‐10	  MBq	   4T1	  xenografts	  in	  
mice	  
5-­‐8	   mm	   in	  
diameter	  
5.4	  ±	  0.4	  %ID/g	  silica-­‐TRC105,	  	  	  	  	  





Micelles	   60	   nm	  
and	   15	  
nm	  
111In	   hEGF	  Fab	   PEG-­‐PCL	  
block	  
copolymer	  
250	   mg/kg	   (5-­‐7	  
MBq/mouse)	  
MDA-­‐MB-­‐468	  
xenografts	   in	  
female	   nude	  
mice	  
5-­‐10	  mm	   in	  
diameter	  
2.0	  %ID/g	  15	  nm	  no	  hEGF,	  0.5	  
%ID/g	   15	   nm	  with	   hEGF,	   4.1	  
%ID/g	   60	   nm	   no	   hEGF,	   0.7	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RGD	  peptide	   PLA-­‐PEG	   15	  mg/kg	   MDA-­‐MB-­‐435	  




/2	  in	  mg	  
300	  mm3	  
3.53	   ±	   0.14	   %ID/g	   PLA-­‐PEG-­‐













200	  μg/mouse	   OV-­‐90	  




~14	   %ID/g	   @	   1.5h,	   17.6	  















PC-­‐3M	   prostate	  
(EHB4+)	   and	  
A549	  lung	  (EHB4-­‐
)	   xenografts	   in	  
mice	  
5-­‐6	   mm	   in	  
diameter	  
2.87	   %ID/g	   PC3-­‐M,	   1.42	  
%ID/g	   PC-­‐3M	   blocked,	   1.37	  









5x1013	  NP/	  mouse	   EL4	   lymphoma	  
and	   MDA-­‐MB-­‐
468	   breast	  
xenograft,	  
pretreated	   with	  
cyclophosphami
de	  and	  etoposide	  
for	   apoptosis,	   in	  
mice	  
5-­‐6	   mm	   in	  
diameter	  
8.01	   %ID/g	   	   pretreated	   for	  
apoptosis,	   3.2	   %ID/g	  




Micelles	   35	  nm	   125I	   Cyclic	  RGD	   PEG-­‐PLA	   35	  μCi	   U87MG	  
xenografts	   in	  
mice	  
0.4-­‐0.6	   cm	  
in	  diameter	  
1.4	   ±	   0.086	   %ID/g	   not	  
blocked,	   0.44	   ±	   0.087	   %ID/g	  








Folate	   LDP	  micelles,	  
pegylated	  




5	   ±	   0.4	   %ID/g	   @	   5	   min	   NP-­‐
folate,	  	  	  10	  ±	  2	  %ID/g	  @	  3	  day	  
NP-­‐folate,	  	  	  	  	  5	  ±	  0.5	  %ID/g	  @	  
5	   min	   NP-­‐CTRL,	   	   	   	   	   1	   ±	   0.3	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Micelles	   65	  nm	   Doxorubicin	  
and	  64Cu	  





5-­‐10	  MBq	   U87MG	  
xenografts	   in	  
mice	  
6-­‐8	   mm	   in	  
diameter	  	  
4.1	  ±	  0.5	  %ID/g	  @	  30	  min	  NP-­‐
cRGD,	  5.7	  ±	  1.2	  %ID/g	  @	  4	  h	  
NP-­‐cRGD,	   3.7	   ±	   0.8	  %ID/g	  @	  
16	   h	   NP-­‐cRGD,	   3.1	   ±	   0.2	  
%ID/g	   @	   24	   h	   NP-­‐cRGD,	   2.5	  




Nano	  tripods	   20	  nm	   64Cu	   cRGD	   Gold,	   PEG,	  
Platinum	  
200	  pmol/kg	   U87MG	  




7.9	  %ID/g	  Au-­‐PEG-­‐RGD,	   2.6%	  
ID/g	   Au-­‐PEG,	   3.8%	   ID/g	  
blocked	  (SE)	  
PET	   [126]	  
Nanoemulsions	   120	  nm	   Aclacinomyci
n	  A	  (ACM)	  
Folate	   DSPE-­‐PEG2k,	  
chol,	   vitamin	  
E,	  pegylated	  
5	  mg	  ACM/kg	   KB	   xenografts	   in	  
mice,	   folate	  
deficient	  diet	  
~600	  mm3	   0.1	  %ID/g	  without	   folate,	  0.2	  
%ID/g	  with	  folate	  
HPLC	   [127]	  
Nanoparticles	   21.7	   ±	  
0.07	  
nm	  
99mTc	   Cyclic	  RGD	   Gold	   3.7	  MBq	   C6	   xenografts	   in	  
mice	  
0.1-­‐0.3	  g	   3.48	   ±	   0.21	   %ID/g	   @	   0.5h,	  
3.65	  ±	  0.19	  %ID/g	  @	  1h,	  2.49	  
±	   0.13	   @	   3h,	   1.94	   ±	   0.13	  
%ID/g	   @	   24h,	   1.46±0.23	  





Nanoparticles	   85	   ±	   9	  
nm	  
111In	   Folate	   PEG,	  
gadolinium	  	  
10	  mg/kg	  mouse	   KB	   xenografts	   in	  
mice	  
0.82	  ±	  0.2	  g	   5	  %ID/tumor	  with	  folate	  @	  5	  
h,	  7	  %ID/tumor	  with	  folate	  @	  
8	   h,	   4	   %ID/organ	   without	  
folate	   @	   5	   hr,	   9	   %ID/organ	  




Nanoparticles	   7	  nm	   Cy5+PEG+124I	   cRGD	  peptide	   Silica,	  
pegylated	  
20	  μCi/mouse	   M21	   xenografts	  
in	  mice	  
200	  mm3	   1.5	  %ID/g	  with	  RGDY,	  1	  %ID/g	  




Nanoparticles	   30	  nm	   siRNA	   EPPT	  peptide	   PEG,	   iron	  
oxide	  
10	  mg/kg	  Fe	   BT-­‐20	   xenografts	  
mice	  
~0.5	   cm	   in	  
diameter	  
20	  %ID/g	   Gamma	  
counter	  
[130]	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198Au	   BBN	  peptide	   Gold	   100	  μL	  of	  3	  mg/mL	   PC-­‐3	   xenografts	  
in	  mice	  	  





Nanoparticles	   80	  nm	   	   Transferrin	   PEG,	  gold	   4.5x1011	  particles	   neuro2A	  
xenografts	   in	  
mice	  
	   2-­‐3	   %ID	   (no	   difference	   with	  
and	   without	   transferrin)	  
@24h	  
ICP-­‐MS	   [132]	  
Nanoparticles	   20,	   200	  
nm	  
64Cu,	  NIR	  dye	   Aptamer	   to	  
nucleolin	  
Silica,	  PEG	   30	  µCi	   4T1	  xenografts	  in	  
mice	  
	   14.6	  %ID/g	  NP-­‐Apt,	  6.2	  %ID/g	  
NP-­‐nonspecific	  Ctrl	  (20nm)	  
PET,	   gamma	  
counter	  
[133]	  
Nanoparticles	   54.2	   ±	  
1.9	   nm	  
with	  Ab	  
111In	   aHER2	  
(trastuzumab)	  
PEG,	  gold	   10-­‐12	  MBq	   (=650-­‐
863	  µg	  Au)	  
MDA-­‐MB-­‐361	  
xenografts	   in	  
mice	  
	   1.23	  ±	  0.20	  %ID/g,	  2.20	  ±	  0.23	  	  
without	   Ab,	   1.22	   ±	   0.27	  







10	  nm	   Dye	   (DY-­‐670	  
or	  DY-­‐676)	  






2.5	   nmol	  
dye/mouse	  
BxPC3	   (poorly	  
leaky)	   and	   CT26	  
(highly	   leaky)	  
xenografts	   in	  
mice	  
~8	   mm	   in	  
diameter	  
~6	  %ID/g	  CT26	  @	  24,	  48,	  72	  h	  	  
~3	  %ID/g	  BxPC3	  @24,	  48,	   72	  
h	  
FMT	   and	  
micro-­‐CT	  
[135]	  
Quantum	  Dots	   10-­‐20	  
nm	  





200	  pmol/mouse	   U87MG	  




10.7	  ±	  1.5	  %ID/g	  QD-­‐RGD,	  2.9	  
±	  0.3	  %ID/g	  QD-­‐PEG,	  4.0	  ±	  0.5	  
%ID/g	  QD-­‐RAD	  (SD)	  







20	   ±	   3	  
nm	  
64Cu	   Folate	   TETA-­‐labeled	  
folate	  
functionalize




s	  +	  64Cu	  
370-­‐440	   kBq	   (3-­‐5	  
mg/kg	  mouse)	  
KB	   xenografts	   in	  
mice	  
10-­‐100	   mg	  
for	  
biodistribut
ion,	   0.3-­‐0.6	  
g	   for	  
autoradiogr
aphy	  
3.4	  ±	  1.2	  %ID/g	  with	  folate	  @	  
10	  min,	  2.3	  ±	  0.7	  %ID/g	  with	  
folate	  @	  1	  h,	  5.9	  ±	  2.8	  %ID/g	  
with	   folate	  @	   4	   h,	   2.9	   ±	   3.1	  
%ID/g	  with	  folate	  @	  24	  h,	  2.2	  
±	  0.3	  %ID/g	  without	  folate	  @	  
10	   min,	   3.2	   ±	   0.7	   %ID/g	  
without	   folate	   @	   1	   h,	   6.0	   ±	  
1.9	  %ID/g	  without	  folate	  @	  4	  
h,	   5.6	   ±	   0.9	   %ID/g	   without	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SPIO	  micelles	   75	  ±	  11	  
nm	  
3H	   cRGD	  peptide	   PEG-­‐PLA	  
copolymer	  
micelle	  




1.3	  ±	  0.3	   	  %ID/g	  cRGD-­‐SPPM,	  
0.6	   ±	   0.3	   %ID/g	   cRGD-­‐free	  





SPIONS	   10	   nm	  
bare	  
SPIO,	  








SPIONS	   5-­‐10	  MBq	   U87MG	  
xenografts	   	   in	  
mice	  
6-­‐8	   mm	   in	  
diameter	   ≈	  
200	  mm3	  
5.4	   ±	   2.1	   %ID/g	   cRGD-­‐SPIO,	  
2.5%ID/g	   cRGD-­‐free	   SPIO	   @	  
24	  hr	  (SD)	  
PET,	   gamma	  
counter	  
[139]	  
SPIONS	   20	  nm	   111In	   aChL6	   Dextran,	  PEG	  	   20-­‐25	  μCi	   HBT	   3477	  




9	   %ID/g,	   0.5	   %ID/g	   without	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Chapter	  2 :	   Quantification	   of	   the	   Enhanced	   Permeability	  
and	  Retention	  Effect	  
	  
2.1	  Introduction	  
The	   field	   of	   nanomedicine	   has	  made	   great	   strides	   over	   the	   past	   60	   years	   (Figure	  
2-­‐1).	   	   Liposomes,	   spherical	   vesicles	   consisting	   of	   at	   least	   one	   lipid	   bilayer,	   were	  
initially	  discovered	  in	  1965.	  [141,	  142]	  Gabizon	  and	  Barenholz	  did	  a	  large	  amount	  of	  
work	   optimizing	   liposomal	   doxorubicin	   for	   treatment	   of	   solid	   tumors.[12]	   	   The	  
chemotherapeutic	  drug	  doxorubicin	  is	  loaded	  into	  the	  liposome	  with	  an	  ammonium	  
sulfate	  gradient	  to	   form	  an	  encapsulated	  doxorubicin	  crystal	  precipitate.[15]	   	  Only	  
thirty	  years	  after	   initial	  reports	  of	   liposomes,	  Doxil	  was	  FDA-­‐approved	  in	  1995	  for	  
AIDS-­‐related	   Kaposi’s	   sarcoma,	   with	   metastatic	   ovarian	   carcinoma	   and	   multiple	  
myeloma	  later	  also	  approved	  for	  Doxil	  treatment.	  
Doxil	   is	  approximately	  100	  nm	   in	  diameter.	   	   Its	   lipid	  bilayer	   is	  composed	  of	  60	  %	  
dual-­‐acyl	   chain	   lipids	   and	   40	   %	   cholesterol.	   The	   addition	   of	   polyethylene	   glycol	  
(PEG)	   on	   the	   head	   group	   of	   a	   portion	   of	   the	   lipids	   facilitates	   the	   evasion	   of	   the	  
mononuclear	  phagocyte	  system	  (MPS).	   	  Modifying	   the	   liposome	  surface	   to	   include	  
PEG	   increases	   the	   elimination	  half-­‐life	   and	   consequently	   the	   time	   that	   the	  drug	   is	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Figure	  2-­1.	  Timeline	  of	  Doxil	  creation	  and	  FDA-­approval.	  
Liposomes	   were	   initially	   discovered	   in	   1965.[141,	   142]	   	   Just	   under	   20	   years	   after	   that,	   the	   first	  
liposomal	  trials	  began	  using	  doxorubicin	  encapsulated	  within	  a	  liposome.	  	  In	  1986,	  Maeda	  discovered	  
the	   mechanism	   of	   the	   EPR	   effect.[4]	   	   Pegylation	   of	   liposomes	   for	   evasion	   of	   the	   MPS	   was	   first	  
reported	  in	  1990.[143]	  	  Five	  years	  after	  that,	  Doxil	  achieved	  FDA	  approval	  and	  was	  able	  to	  enjoy	  15	  
years	  on	  the	  market	  prior	  to	  its	  patent	  expiring.	   	  However,	  a	  generic	  was	  not	  FDA-­‐approved	  until	  3	  
years	  later,	  in	  2013.	  
	  
The	  systemic	  delivery	  of	  a	  drug	  to	  a	  solid	  tumor	  involves	  several	  steps	  that	  occur	  in	  
series	   and	   ultimately	   determine	   drug	   efficacy	   and	   survival.	   	   Extravasation	   from	  
circulation	   at	   the	   tumor	   site	   is	   a	   critical	   step	   in	   the	   delivery	   process	   since	   it	  
determines	  tumor	  accumulation	  (percentage	  of	  initial	  dose	  in	  the	  tumor,	  %ID)	  and	  
yet	  it	  effectively	  remains	  “back	  box.”	  	  Striking	  evidence	  in	  support	  of	  this	  “back	  box”	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argument	   is	   that	   in	   classic	   pharmacokinetics,	   tumor	   accumulation	   is	   bundled	   into	  
the	  other	   clearance	  pathways	   for	   analysis,	   i.e.	   the	   rate	   constant	   for	   clearance	   (kel)	  
includes	  tumor	  accumulation	  along	  with	  clearance	  by	  the	  kidneys,	  clearance	  by	  the	  
mononuclear	  phagocyte	  system	  (MPS),	  and	  any	  other	  mechanisms.	  [144]	  
The	   accumulation	   of	   nanomedicines	   in	   a	   tumor	   is	   modulated	   by	   the	   enhanced	  
permeability	   and	   retention	   (EPR)	   effect.	   In	   the	   tumor,	   leaky,	   underdeveloped	  
vasculature	   enables	   passively	   enhanced	   permeability	   while	   underdeveloped	  
lymphatic	   systems	   reduce	   clearance	   from	   the	   tumor,	   which	   enables	   enhanced	  
retention.[4]	   	   Combined,	   these	   lead	   to	   an	   increase	   in	   accumulation	   of	  
macromolecules	  and	  nanomedicines	  in	  the	  tumor.[4]	  	  	  
Encapsulation	   of	   doxorubicin	   within	   a	   pegylated	   liposome	   increases	   the	   drug’s	  
elimination	  half	  life	  from	  about	  10	  h	  for	  free	  doxorubicin	  to	  about	  45	  h	  for	  Doxil.[14]	  	  
This	  increased	  time	  in	  circulation	  provides	  a	  longer	  reservoir	  with	  which	  to	  feed	  the	  
tumor.	   	   The	   further	   benefit	   of	   encapsulating	   the	   doxorubicin	   is	   a	   decreased	  
cardiotoxicity	   seen	   in	   patients	   due	   to	   the	   lipids	   providing	   a	   protective	   boundary	  
between	  the	  doxorubicin	  and	  the	  endothelium.[145]	  	  	  
In	  2010,	  the	  patent	  on	  Doxil	  expired,	  yet	  it	  was	  not	  until	  2013	  before	  a	  generic	  drug	  
received	   approval.	   	   In	   this	   gap,	   there	  was	   significant	   discussion	  on	   the	   reason	   for	  
this	   delay,	   and	   it	   was	   generally	   believed	   that	   a	   lack	   of	   understanding	   of	   the	  
interaction	  between	  the	  physico-­‐chemical	  properties	  of	  Doxil	  and	  its	  ability	  to	  target	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a	  tumor	  contributed	  to	  the	  inability	  to	  quickly	  replicate	  Doxil.[12,	  146]	   	  Improving	  
our	   knowledge	   of	   the	   link	   between	   the	   properties	   of	   Doxil	   and	   their	   effect	   on	   its	  
ability	   to	   reach	   the	   tumor	   site	  will	   facilitate	   a	   greater	   knowledge	   of	   nanoparticle-­‐
tumor	  interactions	  and	  the	  EPR	  effect.	  	  The	  first	  step	  towards	  accomplishing	  this	  is	  
to	  establish	  the	  baseline	  for	  Doxil	  behavior	  in	  systems	  both	  with	  and	  without	  tumor	  
presence.	  
In	   drug	   development,	   information	   about	   accumulation	   at	   the	   tumor	   site	   remains	  
sparse.[11]	   	   While	   some	   studies	   do	   provide	   this	   information,	   they	   are	   limited;	  
however,	   information	   about	   a	   drug’s	   ability	   to	   reach	   the	   tumor	   is	   important	   to	  
understanding	   its	   ability	   to	   affect	   and	   kill	   the	   cells	  within	   this	   tumor.	   	  While	   this	  
information	   would	   provide	   excellent	   feedback	   for	   drug	   development,	   it	   remains	  
largely	  a	  “black	  box”.	  	  
To	   shed	   light	   on	  how	  a	  nanomedicine	   accumulates	   in	   a	   tumor,	  we	  will	   focus	  on	   a	  
single	   drug	   delivery	   system:	   pegylated	   liposomes.	   	   While	   selection	   of	   a	   single	  
platform	   limits	   the	  number	  of	   comparisons	   that	  we	   can	  make	   in	   terms	  of	   varying	  
physicochemical	   properties,	   it	  maximizes	   the	   scope	   of	   the	   project	   in	   terms	   of	   the	  
number	  of	  questions	  that	  we	  can	  address.	  The	  rationale	  for	  selecting	  liposomes	  is:	  
(1)	  liposomal	  doxorubicin	  (Doxil)	  is	  an	  FDA-­‐approved	  nanomedicine,	  (2)	  liposomes	  
can	  be	  functionalized	  with	  various	  moieties,	  and	  (3)	   liposomes	  can	  be	   loaded	  with	  
other	   cargo	   (genes,	   contrast	   agent,	   etc.)	   for	   in	   vivo	   imaging	   (Chapter	   4).[16,	   147-­‐
156]	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In	  this	  section,	  we	  aim	  to	  establish	  an	  understanding	  of	  how	  liposomal	  doxorubicin	  
accumulates	   in	   a	   tumor.	   	   To	   accomplish	   this,	   the	   pharmacokinetics	   are	   first	  
evaluated	   in	   tumor-­‐free	   mice	   to	   establish	   a	   baseline	   understanding	   of	   the	  
nanoparticle’s	  behavior	   in	  vivo.	   	  Then,	  upon	   introduction	  of	  a	  subcutaneous	   tumor	  
both	  pharmacokinetics	  and	  tumor	  accumulation	  are	  evaluated.	  	  Further,	  we	  apply	  a	  
pharmacokinetic	  model	   of	   the	   drug’s	  movement	   between	   the	   vascular	   and	   tumor	  
compartments,	  and	  we	  optimize	  this	  model	   to	  our	  data	   in	  order	  to	  determine	  rate	  
constants	   that	   describe	   the	   drug’s	   behavior,	   hence	   quantifying	   the	   effect	   of	   the	  
tumor.	  	  Finally,	  we	  aim	  to	  establish	  and	  compare	  tumor	  accumulation	  in	  3	  different	  
tumor	   types.	   	  This	  will	   facilitate	  an	  understanding	  of	   the	   impact	  of	   tumor	   type	  on	  
tumor	   accumulation	   and	   nanoparticle	   efficacy.	   Establishing	   this	   baseline	  
information	   in	   Doxil	   will	   provide	   a	   quantitative	   foundation	   for	   assessing	   and	  
designing	  new	  platforms,	  and	  will	  contribute	  to	  more	  efficient	  use	  of	  resources	  for	  
research	  and	  development.	  
2.1.1	  Doxil	  physicochemical	  properties	  
Doxil	   is	  known	  to	  consist	  of	  spherical	  vesicles	   just	  under	  100	  nm	  in	  diameter.[12]	  	  
The	  dual	  acyl	  chain,	  zwitterionic	  hydrogenated	  soy	  phosphatidylcholine	  lipid	  makes	  
up	   90%	   w/w	   of	   the	   lipid	   composition	   with	   the	   remaining	   10%	   w/w	   from	   the	  
pegylated	   dual	   acyl	   chain	   N-­‐(carbonyl-­‐methoxypolyethylene	   glycol	   2000)-­‐1,2-­‐
distearoyl-­‐sn-­‐glycero-­‐3-­‐phosphoethanolamine.	   	   The	   methoxy-­‐PEG	   group	   on	   the	  
latter	   lipid	   yields	   a	   very	   slightly	   negative	   zeta	   potential.[12]	   	   The	   lipid	   bilayer	   is	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made	   of	   60%	   lipids,	   with	   the	   remaining	   40%	   w/w	   composed	   of	   cholesterol	   to	  
increase	   liposome	   cohesion.	   	   Doxorubicin	   is	   loaded	   via	   an	   ammonium	   sulfate	  
gradient	  to	  form	  long	  crystals	  within	  the	  liposome.	  
2.2	  Materials	  and	  Methods	  
2.2.1	  Cell	  culture	  
All	  cells	  were	  cultured	  according	  to	  the	  cell	  culture	  guidelines	  put	  forth	  in	  American	  
Type	   Cell	   Culture’s	   (ATCC’s)	   corresponding	   protocols.	   	   LS	   174T	   colorectal	  
adenocarcinoma	   cells	   were	   obtained	   from	   ATCC.	   	   LS	   174T	   cells	   were	   grown	   in	  
Eagle’s	   Minimum	   Essential	   Medium	   (EMEM)	   (Quality	   Biological)	   with	   10%	   fetal	  
bovine	  serum	  (FBS)	  (Life	  Technologies)	  and	  1%	  penicillin	  streptomycin	  (P/S)	  (Life	  
Technologies).	   Capan-­‐1	   pancreatic	   adenocarcinoma	   cells	   were	   purchased	   from	  
ATCC	  and	  grown	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  (Life	  Technologies)	  
with	   20%	   FBS	   and	   1%	   P/S.	   	   MDA-­‐MB-­‐231	   breast	   adenocarcinoma	   cells	   were	  
obtained	   from	  ATCC	  and	  grown	   in	  DMEM	  with	  10%	  FBS	  and	  1%	  P/S.	   	   Cells	  were	  
maintained	  in	  a	  humidified	  incubator	  at	  5%	  CO2	  and	  37°C.	  
2.2.2	  Animal	  models	  
All	  experiments	  were	  approved	  by	  and	  performed	  in	  accordance	  with	  the	  guidelines	  
and	  regulations	  of	  the	  Animal	  Care	  and	  Use	  Committee	  for	  Johns	  Hopkins	  University.	  	  
Athymic	  nu/nu	  mice	  4-­‐6	  weeks	  old	  were	  purchased	  from	  Charles	  River.	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2.2.3	  Xenograft	  
Approximately	  5	  million	  cells	  were	  suspended	  in	  100	  µL	  of	  50%	  growth	  media	  and	  
50%	  growth-­‐factor-­‐reduced	  Matrigel	  (Corning).	   	  Cell	  suspensions	  were	  maintained	  
on	  ice	  until	  subcutaneous	  inoculation	  in	  the	  right	  flank	  of	  a	  mouse.	  	  Xenografts	  were	  
grown	  to	  8-­‐10	  mm	  in	  diameter	  or	  approximately	  0.2	  g	  in	  weight.	  	  	  
2.2.4	  Drug	  administration	  
Liposomal	  doxorubicin	  (Avanti	  Polar	  Lipids)	  was	  injected	  at	  6	  mg/kg	  via	  lateral	  tail	  
vein	  injection.	  
2.2.5	  Plasma	  and	  tumor	  collection	  
At	   6	   time	   points	   post	   injection	   (5	   min,	   30	   min,	   1	   h,	   6	   h,	   24	   h,	   48	   h)	   mice	   were	  
anesthetized	  with	  a	  lethal	  dose	  of	  isoflurane	  for	  sample	  collection.	  	  After	  the	  mouse	  
was	  asleep	  but	  its	  heart	  was	  still	  beating,	  blood	  was	  collected	  via	  cardiac	  puncture	  
and	  immediately	  centrifuged	  to	  separate	  and	  collect	  the	  plasma	  samples.	  	  Mice	  were	  
returned	   to	   an	   isoflurane	   chamber	   for	   at	   least	   2	   min	   to	   ensure	   euthanization.	  	  
Tumors	   were	   surgically	   removed	   promptly	   after	   mice	   were	   sacrificed	   and	   then	  
homogenized	   in	   300	   µL	   mouse	   plasma	   (Innovative	   Research)	   for	   30	   m	   using	   a	  
cordless	  pestle	  motor	  (VWR).	  	  Cell	  matter	  was	  then	  removed	  via	  centrifugation.	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2.2.6	  Preparation	  for	  HPLC	  
To	  plasma	  samples	  (100	  µL	  from	  the	  mouse	  blood	  and	  then	  entire	  amount	  from	  the	  
tumor),	  1	  µL	  of	  	  daunorubicin	  was	  added	  as	  a	  standard	  control	  and	  10	  µL	  of	  Triton-­‐X	  
was	  added	  to	  burst	  the	  liposomes	  and	  free	  the	  doxorubicin	  for	  chemical	  evaluation.	  	  
Acetonitrile	  was	  then	  added	  and	  vials	  were	  vigorously	  rocked	  for	  10	  min.	  	  Samples	  
were	  then	  centrifuged	  for	  10	  min	  at	  8000	  rpm	  and	  the	  supernatant	  was	  extracted.	  	  
This	   supernatant	  was	   subsequently	   dried	   under	   flow	   of	   argon	   in	   a	  water	   bath	   at	  
37	   °C.	   	  When	   the	   sample	   appears	  dry,	   it	   is	   placed	   in	   a	   vacuum	  chamber	   for	  3	  h	   –	  
overnight	   to	   confirm	   removal	   of	   liquid.	   	   The	   sample	   is	   then	   resuspended	   in	   30%	  
methanol,	  70%	  water	  for	  running	  on	  the	  HPLC.	  These	  samples	  are	  run	  at	  1	  mL/min	  
using	   70%	   methanol	   and	   30%	   water	   with	   0.1%	   formic	   acid	   through	   a	   C18	   BDS	  
Hypersil	   column.	   	   The	   output	   from	   these	   experiments	   will	   be	   the	   doxorubicin	  
concentration	  in	  blood	  and	  the	  tumor.	  	  The	  workflow	  for	  measurement	  and	  analysis	  
is	  outlined	  in	  Figure	  2-­‐2.	  
2.2.7	  Statistical	  analysis	  
Statistical	  significance	  was	  determined	  using	  a	  Student’s	  t-­‐test.	  ***	  P	  ≤	  0.001,	  **	  P	  ≤	  
0.01.	  	  *	  P≤	  0.05.	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Figure	  2-­2.	  	  Workflow	  in	  analysis	  of	  tumor	  accumulation.	  
(1-­‐2)	  Data	  for	  amount	  of	  drug	  in	  blood	  (Nbl)	  in	  non	  tumor-­‐bearing	  mice	  are	  fit	  to	  obtain	  values	  of	  kel,	  
kp,	  and	  kd.	   	  (3-­‐4)	  Data	  for	  drug	  concentration	  in	  blood	  in	  tumor	  bearing	  mice	  are	  fit	  using	  the	  same	  
values	  of	  kel,	  kp,	  and	  kd	  to	  verify	  that	  tumor	  accumulation	  does	  not	  significantly	  change	  the	  clearance	  
rate.	  	  Differences	  are	  only	  expected	  for	  very	  high	  values	  of	  tumor	  accumulation.	  	  If	  the	  clearance	  rate	  
varies	  significantly,	  then	  the	  data	  are	  fit	  to	  give	  a	  revised	  value	  for	  kel.	   	  (5-­‐6)	  These	  values	  of	  kel,	  kp,	  
and	  kd	  are	  then	  used	  to	  fit	  to	  the	  data	  for	  tumor	  accumulation	  (Nt)	  in	  tumor-­‐bearing	  mice	  to	  obtain	  
values	  for	  kepr	  and	  kb.	  	  The	  rate	  constants	  for	  kepr	  and	  kb	  describe	  the	  kinetics	  of	  tumor	  uptake	  by	  the	  
EPR	  effect.	  	  (7-­‐9)	  The	  values	  for	  the	  rate	  constants	  may	  then	  used	  to	  make	  quantitative	  comparisons	  
between	   experiments	   or	   to	   make	   predictions	   of	   how	   changing	   pharmacokinetic	   parameters	   will	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The	  time-­‐dependent	  concentration	  of	  a	  drug	  in	  circulation	  is	  often	  analyzed	  using	  a	  
two-­‐compartment	   pharmacokinetic	   model,	   with	   a	   central	   compartment	  
(vasculature	  and	  highly	  perfused	  tissue)	  and	  a	  peripheral	  tissue	  compartment.[157]	  	  
This	  model	   works	   well	   when	   a	   drug	   is	   intraveneously	   injected	   and	   subsequently	  
follows	   a	   bi-­‐exponential	   decay.[157]	   	   The	   first	   order	   distribution	   rate	   constants	  
between	   the	   two	   compartments,	   kp	   and	   kd,	   in	   addition	   to	   an	   elimination	   rate	  
constant,	   kel,	   describe	   the	   drug	   behavior	   (Figure	   2-­‐2).	   	   The	   rate	   constant	   kel	  
represents	  all	  elimination	  pathways	  and	  includes	  clearance	  by	  the	  kidneys	  and	  the	  
mononuclear	  phagocyte	  system	  (MPS).	  	  	  
	  
Figure	  2-­3.	  Schematic	  illustrations	  of	  pharmacokinetic	  models.	  
(a)	   Two	   compartment	   pharmacokinetic	  model	  with	   first	   order	   rate	   constants	   describing	   exchange	  
between	  vascular	   (blood)	   compartment	  and	  peripheral	   tissue	   (kp	  and	  kd)	  and	  elimination	   (kel).	   (b)	  
Three	  compartment	  model	  with	  an	  additional	  tumor	  compartment.	  	  To	  account	  for	  exchange	  into	  and	  
out	  of	  this	  tumor	  compartment,	  the	  first	  order	  rate	  constants	  kepr	  and	  kb	  are	  defined,	  respectively.	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Evaluation	   of	   a	   mass	   balance	   for	   each	   compartment	   yields	   the	   following	   base	  













	   	   	   	   	   	   	  
Equation	  2-­2	  
where	  Vb	  is	  the	  volume	  of	  blood	  (typically	  5-­‐6	  L),	  Vp	  is	  the	  volume	  of	  the	  peripheral	  
compartment,	   cb	   is	   the	   concentration	   in	   blood,	   cp	   	   is	   the	   concentration	   in	   the	  
peripheral	   compartment,	  kp	   is	   the	   rate	   constant	   for	   transport	   from	   the	  blood	   into	  
the	  peripheral	  tissue,	  kd	  is	  the	  rate	  constant	  for	  transport	  from	  the	  peripheral	  tissue	  
back	  into	  circulation,	  and	  kel	  is	  the	  rate	  constant	  for	  elimination.	  






+ Bcb = 0
	   	   	   	   	   	   	  
Equation	  2-­3	  
The	  solutions	  to	  equation2-­‐3	  	  is	  of	  the	  form:	  	  
€ 
Cb (t) = Ae
−αt + Be−βt 	   	   	   	   	   	   	   	   Equation	  2-­4	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where	  A	  and	  B	  describe	  the	  y-­‐intercept	  for	  the	  distribution	  and	  elimination	  phases,	  
respectively,	   and	   α	   and	   β	   describe	   the	   half	   lives	   of	   distribution	   and	   elimination,	  
respectively.	  	  From	  mass	  balance,	  A+B	  is	  equal	  to	  the	  initial	  dose	  (at	  time	  equals	  0).	  	  
The	  parameters	  A,	  B,	  α,	  and	  β	  can	  then	  be	  determined	  by	  the	  shape	  of	  the	  curve.	  	  By	  
solving	   the	   mass	   balance	   equations,	   it	   is	   possible	   to	   relate	   these	   terms	   to	   the	  
physiologically	  relevant	  term	  kel,	  kp,	  and	  kd:	  	  
€ 





A + B 	  	   	   	   	   	   	   	   	  
Equation	  2-­6	  
€ 
αβ = kelkd 	   	   	   	   	   	   	   	   	   Equation	  2-­7	  
€ 
α + β = kd + kel + kp 	   	   	   	   	   	   	   	   Equation	  2-­8	  
In	  applying	  pharmacokinetic	  models	  to	  drug	  delivery	  to	  solid	  tumors,	  conventional	  
models	   include	   accumulation	   in	   the	   tumor	   in	   the	   elimination	   rate	   constant.	   	   To	  
evaluate	  tumor	  accumulation	  we	  have	  developed	  a	  three-­‐compartment	  model	  with	  
the	  addition	  of	  a	  tumor	  compartment	  (Figure	  2-­‐3B)	  that	  will	  allow	  for	  quantitative	  
evaluation	  of	  the	  EPR	  effect	  on	  pharmacokinetics.	  [158]	  	  	  
The	  rate	  equations	  for	  the	  three-­‐compartment	  model	  (Figure	  2-­‐3b)	  are:	  





=Vpkdcp −Vbkpcb +Vtkbct −Vbkeprcb −Vbkelcb














	   	   	   	   	   	   	  
Equation	  2-­11	  
where	  Vt	  is	   the	   tumor	  volume,	  ct	   is	   the	  concentration	   in	   the	   tumor,	  kepr	  is	   the	   rate	  
constant	   for	   transport	   into	   the	   tumor	   compartment	   from	   the	   blood,	   and	   kb	  
represents	  transport	  from	  the	  tumor	  compartment	  back	  into	  circulation.	  	  The	  drug	  
concentration	   in	   the	   blood	   and	   the	   tumor	   compartments	   are	   represented	   by	   the	  





















	   	   	   	   	   	  
Equation	  2-­13	  
The	   general	   solutions	   to	   the	   concentration	   in	   blood	   (Equation	   2-­‐14)	   and	   in	   the	  
tumor	  (Equation	  2-­‐15)	  are	  of	  the	  form:	  
€ 
cb (t) = Ae
−αt + Be−βt +Ce−γt 	   	   	   	   	   	   	   Equation	  2-­14	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€ 
ct (t) = Ae
−αt + Be−βt +Ce−γt 	   	   	   	   	   	   	   Equation	  2-­15	  
Similarly,	   the	  sum	  of	   the	  constants	  A,	  B,	   and	  C	   in	   the	  blood	  are	  constrained	   to	   the	  
initial	  dose	  of	  drug,	  and	  using	  the	  differential	  equations	  from	  the	  mass	  balance,	  we	  
can	  relate	  A,	  B,	  and	  C	  back	  to	  the	  rate	  constants.	  
€ 
A = kp + kd + kel + kepr + kb 	   	   	   	   	   	   	   Equation	  2-­16	  
€ 
B = kbkp + kbkel + keprkd + kd kb + kd kel 	   	   	   	   	   Equation	  2-­17	  
€ 
C = kbkd kel 	   	   	   	   	   	   	   	   	   Equation	  2-­18	  
Further	  evaluation	  of	  this	  solution	  yields	  the	  complex	  solutions	  for	  α,	  β,	  and	  γ:	  	  
€ 










































2 	   	   	   	  
Equation	  2-­20	  





































2 	  	   	   	   	  
Equation	  2-­21	  




















































2.3.1	  Analysis	  of	  in	  vivo	  data	  
In	   order	   to	   elucidate	   rate	   constants	   describing	   drug	   distribution	   and	   tumor	  
accumulation,	  we	   first	   utilize	   the	   two-­‐compartment	  model	   for	   tumor-­‐free	  mice	   to	  
obtain	  values	  for	  kp,	  kd	  and	  kel.	  	  It	  can	  be	  assumed	  that	  kp,	  kd,	  and	  kel	  remain	  constant	  
for	   experiments	   in	   tumor-­‐bearing	  mice	  on	  administration	  of	   the	   same	  drug	  at	   the	  
same	  concentration.	  	  Using	  this	  assumption,	  there	  are	  two	  unknown	  rate	  constants	  
for	  tumor	  bearing	  mice:	  kepr	  and	  kb.	   	  Fits	  of	  experimental	  data	  to	  the	  mass	  balance	  
equations	  were	  performed	  using	  Matlab.	  	  The	  rate	  constants	  were	  determined	  by	  an	  
error	  minimization	  method.	  	  For	  each	  data	  point,	  the	  error	  was	  determined	  to	  be	  the	  
difference	  between	  the	  experimentally	  obtained	  value	  and	  the	  predicted	  value	  and	  
was	   then	  normalized	   to	   the	   average	   experimental	   value	   for	  both	  pharmacokinetic	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and	   tumor	  accumulation	  data.	   	  The	  normalized	  error	   for	  all	  data	  points,	   including	  
both	   pharmacokinetic	   and	   tumor	   accumulation	   data,	   was	   then	   added	   together	   to	  
yield	  a	  total	  normalized	  error.	  	  For	  iterative	  values	  of	  kepr	  and	  kb,	  we	  determined	  the	  
total	  normalized	  error,	  and	  the	  instance	  of	  minimum	  error	  provides	  the	  best	  fit	  and	  
yields	  rate	  constants	  to	  evaluate	  liposome	  distribution.	  	  
	  
	  
Figure	  2-­4.	  Optimization	  of	  fit	  to	  3-­compartment	  model.	  
To	   optimize	   fit	   of	   the	   3-­‐compartment	   model	   to	   our	   data,	   the	   error	   for	   fits	   over	   a	   course	   of	   rate	  
constants	  are	  normalized	  to	  concentration	  in	  (a)	  blood	  or	  (b)	  tumor.	  	  These	  values	  are	  summed	  to	  get	  
the	  total	  normalized	  error	  that	  is	  minimized	  to	  provide	  the	  best	  values	  for	  kepr	  and	  kb.	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2.4	  Results	  
2.4.3	  Tumor-­‐free	  model	  
To	  determine	  a	  baseline	  for	  liposome	  pharmacokinetics,	  we	  first	  perform	  a	  standard	  
2-­‐compartment	  pharmacokinetics	  model	  on	  a	  tumor	  free	  mouse.	  	  For	  this	  evaluation,	  
the	   primary	   compartment	   is	   the	   vasculature	   and	   the	   second	   compartment	   is	   the	  
peripheral	   tissue.[157]	   	   Evaluation	   of	   concentration	   in	   blood	   (Figure	   2-­‐5)	   at	   the	  
selected	   time	  points	   (5	  min,	   30	  min,	   2	  h,	   6	  h,	   24	  h,	   and	  48	  h)	   and	   fitting	   to	   these	  
enables	  determination	  of	  kinetic	  rate	  constants,	  kel	  =	  0.01	  h-­‐1,	  kp	  =	  17.6	  h-­‐1,	  and	  kd	  =	  
16.3	  h-­‐1.	  
	  
Figure	  2-­5.	  Pharmacokinetics	  of	  liposomal	  doxorubicin	  in	  tumor-­free	  mice.	  
Concentration	   of	   doxorubicin-­‐loaded	   liposomes	   in	   blood	   following	   tail-­‐vein	   administration	   in	   non-­‐
tumor-­‐bearing	  mice.	  	  The	  solid	  line	  is	  a	  fit	  to	  the	  data	  using	  the	  2-­‐compartment	  model	  from	  which	  we	  
can	  extract	  the	  rate	  constants	  kel,	  kp,	  and	  kd.	  	  n	  =	  10	  mice	  per	  time	  point.	  	  Data	  represents	  mean	  ±	  SE.	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2.4.4	  Tumor-­‐bearing	  model	  
To	   next	   evaluate	   the	   EPR	   effect,	   pharmacokinetics	   and	   tumor	   accumulation	   are	  
evaluated	   in	   a	   tumor-­‐bearing	  mouse.	   	   The	   same	   time	  points	   are	   repeated	   in	  mice	  
with	   LS	   174T	   colorectal	   adenocarcinoma	   subcutaneous	   xenografts,	   and	   the	  
concentration	   of	   doxorubicin	   in	   the	   blood	   (Figure	   2-­‐6A)	   and	   tumor	   (Figure	   2-­‐6B)	  
are	  reported.	   	  To	  model	   the	   tumor-­‐bearing	  mouse,	  a	   third,	   tumor,	  compartment	   is	  
introduced	  into	  the	  model,	  and	  drug	  extravasation	  into	  this	  tumor	  compartment	  is	  
described	   by	   the	   rate	   constant	   kepr	   while	   intravasation	   from	   the	   tumor	   back	   into	  
circulation	  is	  described	  by	  the	  rate	  constant	  kb.	  	  The	  rate	  constants	  kel,	  kp,	  and	  kd	  are	  
held	  constant	  to	  allow	  determination	  of	  kepr	  and	  kb	  from	  simultaneous	  optimization	  
of	  the	  model	  to	  both	  the	  pharmacokinetic	  and	  tumor	  accumulation	  data.	  
Measurements	   of	   accumulation	   of	   liposomal	   doxorubicin	   in	   the	   resected	   tumors	  
show	  a	  maximum	  accumulation	  of	  0.84	  ±	  0.23	  %ID	  (1.8	  ±	  0.43	  %ID/g)	  at	  24	  h.	   	  At	  
longer	   times,	  we	   see	   the	   doxorubicin	   in	   the	   tumor	  decrease	   as	   the	   amount	   in	   the	  
blood	  decreases,	  and	  hence	  the	  driving	  force	  for	  extravasation	  is	   increased.	   	  Based	  
on	  the	  curve	  determined	  by	  optimization	  of	  fit,	  the	  maximum	  tumor	  accumulation	  is	  
at	  approximately	  15	  h.	   	  By	   this	  point,	   the	   liposomal	  doxorubicin	   in	  circulation	  has	  
reduced	  to	  20	  %ID.	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Figure	  2-­6.	  Pharmacokinetics	  and	   tumor	  accumulation	  of	   liposomal	  doxorubicin	   in	  LS	  174T	  
xenografts.	  
Concentration	   of	   doxorubicin-­‐loaded	   liposomes	   in	   (a)	   blood	   and	   (b)	   tumors	   following	   tail-­‐vein	  
administration	   in	   tumor-­‐bearing	  mice.	   	   The	   solid	   line	   is	   a	   fit	   to	   the	  data	  using	   the	  3-­‐compartment	  
model.	  	  Using	  the	  rate	  constants	  kel,	  kp,	  and	  kd	  extracted	  from	  the	  non-­‐tumor-­‐bearing	  mice	  we	  can	  use	  
these	  fits	  to	  determine	  values	  for	  the	  rate	  constants	  kepr	  and	  kb.	   	  n	  =	  7-­‐9	  mice	  per	  time	  point.	   	  Data	  
represents	  mean	  ±	  SE.	  
Comparison	   of	   the	   liposomal	   doxorubicin	   in	   circulation	   between	   the	   LS	   174T	  
bearing	  and	  tumor	  free	  mice	  reveals	  that	  the	  impact	  of	  the	  tumor	  is	  not	  sufficient	  to	  
decrease	  the	  amount	  in	  circulation	  (Figure	  2-­‐7).	  	  The	  tumor	  represents	  only	  a	  small	  
portion	   of	   the	   overall	   volume	   in	   circulation,	   and	   consequently,	   the	   pull	   from	   that	  
volume	  is	  not	  noticeable	  on	  the	  overall	  pharmacokinetics	  of	  the	  drug.	  	  If	  the	  tumor	  
in	   question	   grows	   to	   a	   size	   large	   enough	   to	   have	   an	   effect	   on	   the	   overall	   drug	  
pharmacokinetics,	  it	  may	  further	  alter	  this	  model.	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Figure	  2-­7.	  Concentration	  in	  blood	  comparing	  tumor-­free	  and	  LS	  174T-­bearing	  mice.	  
Concentration	   in	   blood	   of	   doxorubicin-­‐loaded	   liposomes	   in	   (blue)	   tumor-­‐free	   and	   (red)	   LS	   174T	  
tumor-­‐bearing	   mice.	   The	   solid	   lines	   are	   fits	   to	   the	   data.	   	   The	   rate	   constants	   kel,	   kp,	   and	   kd	   are	  
determined	  from	  fits	  to	  the	  tumor-­‐free	  mice	  and	  held	  constant	  in	  fits	  to	  the	  LS	  174T	  tumor-­‐bearing	  
mice.	  	  The	  values	  for	  kepr	  and	  kb.	  found	  for	  the	  LS	  174T	  tumor-­‐bearing	  mice	  are	  insufficiently	  large	  to	  
alter	  the	  pharmacokinetics	  of	  liposomal	  doxorubicin	  in	  a	  quantifiable	  manner.	  	  	  n	  =	  10	  mice	  per	  time	  
point	  for	  tumor-­‐free	  mice,	  and	  n	  =	  7-­‐9	  mice	  per	  time	  point.	  	  Data	  represents	  mean	  ±	  SE.	  
The	  rate	  constants	  determined	  for	  liposomal	  doxorubicin	  in	  athymic	  mice	  are	  
found	  in	  Table	  2-­‐1.	  	  These	  first	  order	  rate	  constants	  are	  determined	  in	  experiments	  
of	  both	  tumor-­‐bearing	  and	  tumor-­‐free	  mice.	  	  To	  determine	  kp,	  kd,	  and	  kel,	  tumor-­‐free	  
mice	   are	   used	   and	   pharmacokinetic	   data	   is	   fit	   to	   a	   2-­‐compartment	   model.	   	   This	  
yields	   the	   rate	   constants	   kp	   =	   17.6	   h-­‐1,	   ke	   =	   16.3	   h-­‐1,	   and	   kel	   =	   0.1	   h-­‐1.	   	   Then,	  
introduction	  of	  subcutaneous	  LS	  174T	  xenografts	   into	  athymic	  mice	  and	  fit	   to	  a	  3-­‐
compartment	  model	   using	   tumor	   accumulation	   data	   facilitates	   fits	   to	   kepr	   and	   kb.	  
This	  yields	  the	  rate	  constants	  kb	  =	  0.068	  h-­‐1,	  kepr	  =	  0.003	  h-­‐1.	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Table	  2-­1.	  Rate	  constants	  for	  pharmacokinetic	  modeling	  of	  liposomal	  doxorubicin.	  
The	  first	  order	  rate	  constants	  for	  modeling	  liposomal	  doxorubicin	  in	  mice.	  	  All	  values	  are	  in	  h-­‐1.	  	  The	  
elimination	  rate	  constant,	  kel,	  and	  the	  rate	  constants	  that	  describe	  movement	  between	  the	  vascular	  
and	  peripheral	  compartments,	  kp	  and	  kd,	  are	  determined	  with	  fits	  to	  data	  obtained	  in	  tumor-­‐free	  mice.	  	  
These	  are	  then	  held	  constant	  to	  model	  data	  from	  LS	  174T	  tumor-­‐bearing	  mice	  to	  determine	  values	  
for	   the	   rate	   constant	   to	  describe	  movement	   into	   the	   tumor	   compartment	   from	   the	   circulation	   and	  
back,	  kepr	  and	  kb,	  respectively.	  
	  
	  
2.4.5	  Comparison	  of	  tumor	  type	  
To	  further	  elucidate	  the	  impact	  of	  the	  EPR	  effect,	  three	  tumor	  types	  were	  compared	  
to	  determine	  the	  variation	  in	  tumor	  accumulation	  after	  administration	  of	  the	  same	  
dose	   of	   liposomal	   doxorubicin.	   	   Mice	   with	   subcutaneous	   breast	   adenocarcinomas	  
(MDA-­‐MB-­‐231)	  and	  mice	  with	  subcutaneous	  pancreatic	  adenocarcinomas	  (Capan-­‐1)	  
were	  compared	  with	   the	  LS	  174T	  colorectal	  adenocarcinoma	  data	  at	  6	  h	  and	  24	  h	  
(Figure	   2-­‐8).	   	   	   The	   highest	   tumor	   accumulation	   occurs	   in	   the	   LS	   174T	   xenograft	  
(0.84%	   ±	   0.23),	   almost	   a	   20-­‐fold	   increase	   over	   the	   Capan-­‐1	   pancreatic	  
adenocarcinoma	   xenograft	   (0.04%	   ±	   0.01)	   at	   24	   h.	   	   The	   maximum	   tumor	  
accumulation	  seen	  in	  MDA-­‐MB-­‐231	  is	  moderate	  (0.18%	  ±	  0.06).	  	  Of	  note	  is	  that	  the	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statistically	   significant.	   	   Comparing	   tumor	   accumulation	   normalized	   to	   tumor	  
weight	   (%ID/g)	   yields	   statistical	   significance	   between	   LS	   174T	   and	   Capan-­‐1	  
xenografts	  along	  with	  MDA-­‐MB-­‐231	  and	  Capan-­‐1	  at	  24	  h.	   	  The	  difference	  between	  
LS	  174T	  and	  MDA-­‐MB-­‐231	  tumor	  accumulation	  is	  not	  statistically	  significant	  when	  
normalized	  to	  tumor	  weight.	  
	  
Figure	  2-­8.	  Comparison	  of	  tumor	  accumulation	  for	  different	  tumor	  types.	  
Tumor	  accumulation	  in	  subcutaneous	  xenografts	  at	  6	  and	  24	  h	  post	  injection	  of	  doxorubicin-­‐loaded	  
liposomes	   from	   three	  different	   cell	   lines	   is	   compared	  and	  reported	  as	   (a)	   total	  accumulation,	  %ID,	  
and	  (b)	  accumulation	  normalized	  to	  tumor	  weight,	  %ID/g.	   	  n=7-­‐9	  mice.	   	  Data	  represent	  mean	  ±	  SE.	  	  
Statistical	  significance	  was	  determined	  using	  a	  Student’s	  t-­‐test.	  	  ***	  p	  ≤	  0.001,	  **	  p	  ≤	  0.01,	  *	  p	  ≤	  0.05.	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With	   the	   decrease	   in	   tumor	   accumulation	   for	   the	   Capan-­‐1	   and	   MDA-­‐MB-­‐231,	   it	  
becomes	   obvious	   that	   the	   rate	   constant	   for	   modeling	   Doxil	   extravasation	   to	   the	  
tumor,	   kepr,	   will	   be	   lower.	   	   While	   this	   study	   does	   not	   encapsulate	   sufficient	   time	  
points	   to	   determine	   all	   pharmacokinetic	   parameters	   to	   full	   accuracy	   for	   Capan-­‐1	  
and	  MDA-­‐MB-­‐231,	  it	  is	  possible	  to	  hone	  in	  on	  the	  rate	  constant	  for	  extravasation	  to	  
the	  tumor,	  kepr,	  and	  to	  determine	  its	  magnitude	  by	  fitting	  to	  the	  data.	  	  	  
For	   this	   fit,	   two	   strategies	   were	   tried.	   	   The	   first	   fixed	   the	   ratio	   of	   kepr	   to	   kb	  and	  
allowed	  kepr	  to	  decrease.	   	  This	   strategy	  unfortunately	  did	  not	   appear	   to	  match	   the	  
data	  as	  the	  fit	  initially	  increased	  too	  slowly	  while	  at	  longer	  times	  the	  fit	  had	  too	  high	  
of	  tumor	  accumulation	  as	  compared	  with	  the	  data.	   	  The	  second	  strategy	  fixed	  kb	  to	  
the	  value	  obtained	  from	  the	  LS	  174T	  data	  and	  solely	  optimized	  kepr.	  	  This	  appeared	  
to	   provide	   excellent	   fits	   to	   the	   experimental	   data	   for	   both	  Capan-­‐1	   and	  MDA-­‐MB-­‐
231	   (Figure	   2-­‐9).	   	   The	   rate	   constants	   decrease	   from	  kepr=0.003	  h-­‐1	  for	   LS	   174T	   to	  
kepr=0.00054	  h-­‐1	  for	  MDA-­‐MB-­‐231	  	  and	  kepr=0.00022	  h-­‐1	  for	  Capan-­‐1.	  	  Over	  an	  order	  
of	  magnitude	  of	  variation	  can	  be	  seen	  between	  kepr	   for	   tumors	   that	  have	  high	  and	  
low	  efficacy	   of	   nanoparticle	   delivery,	   demonstrating	   that	   variations	   in	   tumor	   type	  
can	   have	   significant	   impact	   on	   a	   nanomedicine’s	   ability	   to	   extravasate	   into	   the	  
tumor.	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Figure	  2-­9.	  Approximation	  of	  kepr	  with	  tumor	  type	  variation.	  	  
Tumor	  accumulation	  in	  subcutaneous	  xenografts	  of	  doxorubicin-­‐loaded	  liposomes	  in	  subcuctaneous	  
xenografts	   of	   (red)	   LS	   174T	   colorectal	   adenocarcinoma,	   (green)	   MDA	   MB	   231	   breast	  
adenocarcinoma,	  and	  (blue)	  Capan-­‐1	  pancreatic	  adenocarcinoma.	  	  Corresponding	  rate	  constants	  that	  
describe	   the	   impact	   of	   the	   EPR	   effect	   for	   each	   cell	   type	   are	   included.	   n=7-­‐9	  mice.	   	   Data	   represent	  
mean	  ±	  SE.	  	  	  
2.4.6	  Discussion	  
Tumor	   accumulation	   is	  mediated	   by	   the	   EPR	   effect,	   however,	   the	   leakiness	   of	   the	  
tumor	   vasculature	   is	   dependent	   on	   the	   tumor	   type.	   	   We	   have	   shown	   a	   20-­‐fold	  
difference	   in	   tumor	   accumulation	   of	   doxorubicin-­‐loaded	   liposomes	   in	   different	  
tumor	  types.	  	  This	  implies	  that	  the	  kinetics	  of	  tumor	  accumulation	  are	  modulated	  by	  
the	   tumor-­‐specific	   vascular	   architecture.	   	   Therefore,	   elucidating	   the	   relationships	  
between	  vascular	  structure,	   the	  EPR	  effect,	  and	  tumor	  accumulation	  will	  be	  key	  to	  
improved	   treatment	   of	   solid	   tumors,	   and	   could	   contribute	   to	   advancing	  
individualized	  care.	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These	   results	   highlight	   two	   important	   points.	   	   (1)	   The	   large	   differences	   in	   tumor	  
accumulation	  provide	  evidence	  that	  drug	  accumulation	  (for	  the	  same	  drug	  and	  same	  
size	  tumor)	  is	  tumor	  specific.	  (2)	  Comparison	  of	  drug	  delivery	  systems	  can	  only	  be	  
made	   if	   pre-­‐clinical	   trials	   are	   performed	   under	   identical	   conditions:	   i.e.	   drug	  
delivery	   system	   A	   in	   tumor	   X	   cannot	   be	   compared	   to	   drug	   delivery	   system	   B	   in	  
tumor	  Y.	  	  	  In	  addition,	  the	  numerical	  value	  of	  tumor	  accumulation	  in	  units	  of	  %ID/g	  
has	   become	   synonymous	  with	   the	   delivery	   efficiency	   of	   a	   delivery	   platform.	   	   Our	  
results	   show	   that	   this	   dogma	   can	   be	   very	  misleading	   unless	   differences	   in	   tumor	  
type	  can	  be	  accounted	  for.	  	  
2.5	  Conclusions	  
To	   validate	   our	  model	   for	   tumor	   accumulation	  we	   have	   performed	   a	   preliminary	  
study	   measuring	   the	   concentration	   in	   blood	   and	   tumor	   accumulation	   in	  
subcutaneous	   LS174T	   xenografts	   (8	   -­‐	   10	   mm)	   in	   Nu/Nu	   mice	   using	   following	  
administration	  of	  Doxil	  at	  6	  time	  points	  (5	  min,	  30	  min,	  1	  h,	  6,	  h,	  24	  h,	  and	  48	  h)	  at	  a	  
dose	  of	   0.15	  mg	   (6	  mg/kg).	   	   Comparison	  of	   the	   amount	   of	   the	  drug	   in	   circulation	  
between	   tumor-­‐bearing	   mice	   and	   non-­‐tumor	   bearing	   mice	   shows	   that	   tumor	  
accumulation	  is	  not	  sufficiently	  large	  to	  decrease	  the	  amount	  in	  circulation	  (Figure	  
2-­‐7).	   	   Measurements	   of	   accumulation	   of	   Doxil	   in	   the	   resected	   tumors	   show	   a	  
progressive	  increase	  to	  a	  maximum	  of	  0.84	  %ID	  (1.8	  %ID/g)	  followed	  by	  a	  decrease	  
at	  longer	  times	  (Figure	  2-­‐6).	  	  To	  analyze	  the	  data,	  we	  first	  fit	  the	  drug	  concentration	  
in	  blood	  in	  animals	  with	  no	  tumor	  to	  obtain	  values	  for	  kel,	  kp,	  and	  kd.	  	  These	  values	  
are	   then	   used	   to	   fit	   to	   the	   data	   for	   tumor	   accumulation	   in	   tumor	   bearing	  mice	   to	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obtain	  values	  for	  kepr	  and	  kb	  using	  a	  non-­‐linear	  least	  squares	  fit.	  	  The	  rate	  constants	  
for	  kepr	  and	  kb	  describe	  the	  kinetics	  of	  tumor	  uptake	  by	  the	  EPR	  effect.	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Chapter	  3 :	   Evaluation	   of	   the	   Impact	   of	   Pharmacokinetic	  
Parameters	  on	  the	  EPR	  Effect	  
3.1	  Introduction	  
	  
Chemotherapeutics	  are	  inherently	  toxic	  and	  hence	  treatment	  is	  invariably	  a	  balance	  
between	   inducing	   cancer	   cell	   death	   and	   minimizing	   the	   adverse	   side	   effects	  
associated	   with	   drug	   accumulation	   in	   normal	   tissue	   and	   other	   organs.[159,	   160]	  	  
Combination	   products	   and	   nanotechnology	   provide	   the	   possibility	   of	   creating	  
delivery	   systems	   where	   the	   design	   constraints	   are	   decoupled,	   allowing	   new	  
approaches	  for	  reducing	  the	  unwanted	  side	  effects	  of	  systemic	  delivery,	   increasing	  
tumor	   accumulation,	   and	   improving	   efficacy.[161-­‐166]	   	   The	   development	   and	  
translation	   of	   new	  nanomedicines	   is	   extremely	   challenging	   and	  hence	  progress	   in	  
the	   field	   has	   been	   relatively	   slow.	   	   Of	   the	   6	   FDA-­‐approved	   nanomedicines	   for	  
treatment	   of	   solid	   tumors,	   two	   are	   antibody-­‐drug	   conjugates,	   3	   are	   liposomal	  
formations	   of	   anti-­‐cancer	   drugs,	   and	   one	   is	   a	   protein-­‐drug	   complex.[5]	  	  
Unfortunately,	  while	  drug	  delivery	   systems	  are	  evaluated	   for	   clinical	   efficacy,	  pre-­‐
clinical	  trials	  often	  omit	  optimization	  of	  the	  platform	  itself.	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As	  a	  specific	  example	  of	  how	  pre-­‐clinical	   trials	  are	  designed	   to	  assess	  efficacy	  and	  
not	   optimize	   the	   delivery	   platform,	   pharmacokinetic	   models	   for	   data	   analysis	  
(Figure	   2-­‐3)	   lump	   tumor	   accumulation	   into	   the	   rate	   constant	   for	   clearance	   (kel),	  
which	   includes	   clearance	   by	   the	   kidneys,	   clearance	   by	   the	   MPS,	   and	   any	   other	  
clearance	   mechanisms.[167]	   	   Tumor	   accumulation	   is	   an	   important	   parameter	   in	  
developing	  a	  delivery	  platform	   for	   two	   reasons:	   (1)	   it	   can	  be	  optimized	  by	   tuning	  
physico-­‐chemical	   properties,	   and	   (2)	   by	   optimizing	   tumor	   accumulation	   it	   is	  
possible	  to	  decrease	  the	  dose	  and	  minimize	  unwanted	  side	  effects	  due	  to	  uptake	  in	  
normal	   tissue.	   	   These	   considerations	   are	   not	   applicable	   for	   small	   molecule	  
therapeutics	   since	   the	   intrinsic	   properties	   of	   the	   molecule	   itself	   determine	  
pharmacokinetic	   properties	   and	   cannot	   usually	   be	   tuned	   independently.	   	   Many	  
small	  molecule	  chemotherapeutics	  are	  extremely	  toxic	  and	  are	  taken	  up	  in	  normal	  
tissues	   as	   evidenced	   by	   large	   distribution	   volumes.[168]	   	   A	   recently	   developed	  
model	  introduces	  a	  tumor’	  compartment,	  allowing	  for	  quantitative	  analysis	  of	  tumor	  
accumulation.[169]	  
Building	  a	  knowledge	  base	  is	  key	  to	  advancing	  a	  scientific	  field	  since	  it	  enables	  the	  
development	   of	   design	   rules	   that,	   in	   turn,	   accelerate	   the	   translation	   of	   new	  
technologies.	  In	  Chapter	  2,	  we	  have	  (1)	  determined	  the	  kinetics	  of	  accumulation	  of	  
Doxil,	  an	  FDA-­‐approved	  liposomal	  nanomedicine,	  in	  LS174T	  tumors,	  (2)	  applied	  a	  3-­‐
compartent	  model	  to	  model	  to	  quantitatively	  assess	  tumor	  accumulation	  by	  defining	  
a	   “tumor	   compartment”,	   and	   (3)	   shown	   that	   tumor	   accumulation	   of	   Doxil	   is	  
dependent	  on	  tumor	  type	   in	  a	  murine	  model.	   	  The	  development	  of	  nanomedicines	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has	  been	  largely	  empirical,	  and	  hence	  there	  is	  a	  lack	  of	  robust	  design	  rules	  that	  can	  
be	  used	  to	  develop	  and	  optimize	  new	  platforms.	  	  In	  order	  to	  address	  this	  knowledge	  
gap,	  we	  aim	  to	  predict	  the	  impact	  that	  variations	  in	  physico-­‐chemical	  properties	  of	  
nanomedicines	  will	  have	  on	  the	  model	  used	  for	  tumor	  accumulation,	  and	  hence	  the	  
impact	  these	  variation	  will	  have	  on	  efficiency	  of	  nanomedicine	  delivery	  to	  the	  tumor.	  
The	  accumulation	  of	  a	  drug	  delivery	  system	  in	  a	  solid	  tumor	  is	  mediated	  by	  the	  EPR	  
effect,	   which	   describes	   the	   increased	   permeability	   of	   the	   tumor	   vasculature	   and	  
increased	  retention	  associated	  poor	  lymphatic	  drainage.[2,	  3,	  61,	  162,	  170-­‐176]	  	  	  In	  
a	  growing	  solid	  tumor,	  the	  combination	  of	  hypoxic	  environment	  and	  inflammatory	  
response	  leads	  to	  the	  formation	  of	  new	  vessels,	  local	  removal	  of	  smooth	  muscle	  cells,	  
and	  degradation	  of	   basement	  membrane	  and	  extracellular	  matrix	   (ECM).[62,	   177]	  
At	   the	   same	   time,	   the	   proliferation	   of	   tumor	   cells	   causes	   expansion	   of	   the	  
microenvironment	  and	  generates	  local	  compressive	  forces.[1]	  	  Expansion	  increases	  
the	  average	  spacing	  between	  vessels,	  reducing	  the	  supply	  of	  nutrients,	  and	  creating	  
hypoxic	  regions	  in	  the	  tumor.	   	  The	  compressive	  forces	  generated	  by	  tumor	  growth	  
lead	   to	   contraction	   of	   blood	   vessels,	   increased	   resistance	   to	   blood	   flow,	   poor	  
lymphatic	  drainage,	  and	  increased	  interstitial	  fluid	  pressure.[1]	  
Accumulation	   of	   a	   drug	   or	   nanomedicine	   in	   a	   solid	   tumor	   by	   the	   EPR	   effect	   is	  
dependent	   on	   the	   time-­‐dependent	   concentration	   in	   blood,	   and	   hence	   requires	  
knowledge	  of	  the	  pharmacokinetics.	  	  The	  standard	  two	  compartment	  model	  (central	  
and	  peripheral	  compartments)	  combines	  tumor	  accumulation	  with	  clearance	  by	  the	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kidneys	  and	  the	  MPS	  (Figure	  2-­‐3A).[144]	  To	  distinguish	  tumor	  accumulation	  by	  the	  
EPR	   effect	   from	   other	   elimination	   pathways,	   a	   model	   has	   been	   developed	  
incorporating	   a	   tumor	   compartment	   and	   define	   rate	   constants	   specifying	   drug	  
accumulation	  and	  removal	  from	  the	  tumor	  (Figure	  2-­‐3B).	  [158]	  Drug	  extravasation	  
into	   the	   tumor	   by	   the	   EPR	   effect	   is	   described	   by	   the	   rate	   constant	   kepr,	   and	  
intravasation	   from	   the	   tumor	   back	   into	   circulation	   is	   described	   by	   kb.	   	   The	   rate	  
constant	  kel	  describes	  elimination	  by	  the	  kidneys,	  MPS,	  and	  any	  mechanisms	  other	  
than	  tumor	  uptake.	   	  The	  amount	  of	  drug	  is	  defined	  in	  the	  different	  compartments:	  
Nbl,	  Np,	  and	  Nt	  represent	  the	  amount	  (in	  mg)	  of	  drug	  in	  blood,	  peripheral	  tissue,	  and	  
tumor	  tissue,	  respectively.	  	  	  This	  model	  has	  been	  used	  to	  analyze	  data	  from	  human	  
clinical	   trials	  of	  Doxil,	   a	   liposomal	   formation	  of	  doxorubicin,	  and	   free	  doxorubicin.	  
From	   fits	   to	   pharmacokinetic	   data,	   kp,	   kd,	   and	   kel	   are	   extracted,	   and	   then	  
extrapolation	  of	  different	  values	  of	  kepr	  and	  kb	  determine	   their	   influence	  on	   tumor	  
accumulation.[158]	   	   This	   work	   shows	   how	   tumor	   accumulation	   can	   be	   analyzed	  
quantitatively.	  
3.1.2	  Design	  rules	  for	  drug	  delivery	  systems	  
Over	   the	   past	   10	   years	   there	   have	   been	  more	   than	   17,000	   publications	   with	   the	  
word	   “nanomedicine(s)”	   in	   the	   title	   or	   abstract,	   and	   around	   8,000	   with	   both	  
“nanomedicine(s)”	   and	   “cancer”.	   	  Despite	   the	   large	  number	  of	  pre-­‐clinical	   trials	  of	  
drug	  delivery	  systems,	  surprisingly	  few	  report	  quantitative	  data	  that	  that	  would	  be	  
useful	   in	   developing	   design	   rules.	   	   In	   a	   recent	   meta-­‐study	   we	   reviewed	   74	   pre-­‐
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clinical	  trials	  of	  drug	  delivery	  platforms	  that	  reported	  quantitative	  values	  of	  tumor	  
accumulation[11]	   and	   showed	   how	   the	   variability	   in	   experimental	   design	  
significantly	  limits	  the	  ability	  to	  make	  the	  comparisons	  necessary	  to	  develop	  design	  
rules.	   	   	   Specific	   problems	   include:	   variability	   in	   the	   tumor	   model,	   inconsistent	  
reporting	   of	   tumor	   size/weight,	   inconsistent	   reporting	   of	   dose,	   inconsistent	  
reporting	  of	  physico-­‐chemical	  properties,	  tumor	  accumulation	  reported	  at	  different	  
time	   points,	   and	   variability	   in	   controls	   (especially	   for	   active	   targeting).	   	   This	  
variability	   inhibits	   the	   development	   of	   specific	   design	   rules	   for	   nanomedicine	  
development.	  
Several	   groups	   have	   used	   intravital	   microscopy	   to	   image	   extravasation	   of	  
fluorescently	  labeled	  dextrans	  from	  the	  tumor	  vasculature.[61,	  171,	  175,	  178,	  179]	  	  
These	   studies	   are	   limited	   to	   the	   tumor	   periphery	   due	   to	   the	   poor	   depth	   of	  
penetration	   and	   hence	   do	   not	   provide	   insight	   into	   extravasation	   and	   uptake	  
throughout	  the	  tumor.	  	  Nonetheless,	  an	  important	  observation	  from	  these	  studies	  is	  
that	  the	  cut-­‐off	  size	  for	  extravasation	  from	  the	  tumor	  vasculature	  in	  animal	  models	  
varies	  from	  200	  nm	  to	  1.2	  µm	  depending	  on	  the	  tumor	  type.[61,	  171,	  175]	  	  Based	  on	  
these	   studies,	   a	   diameter	   of	   about	   200	   nm	   is	   often	   considered	   an	   upper	   limit	   for	  
successful	  drug	  delivery.[162,	  176]	  	  We	  note	  that	  this	  is	  one	  of	  the	  few	  design	  rules	  
to	   emerge	   from	   basic	   nanomedicine	   research.	   	   In	   the	  most	   sophisticated	   of	   these	  
intravital	   microscopy	   studies,	   the	   Chilkoti	   group	   used	   a	   model	   with	   a	   tumor	  
compartment	  for	  semi-­‐quantitative	  analysis	  of	  the	  extravasation	  and	  tumor	  uptake	  
of	   fluorescently	   labeled	   dextrans.[180]	   In	   summary,	   the	   kinetics	   of	   the	   EPR	   effect	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are	  poorly	  understood	  despite	  being	  key	  to	  systemic	  delivery	  of	  drugs	  (and	  contrast	  
agents)	  to	  solid	  tumors.	  
In	   this	   chapter,	   we	   aim	   to	   use	   this	   model	   to	   determine	   how	   variations	   in	  
physicochemical	  properties	  of	  the	  nanomedicines	  might	  impact	  the	  rate	  constants	  ,	  
kp,	  kepr,	  and	  kel,	  and	  hence	  how	  these	  will	  ultimately	  affect	  the	  	  tumor	  accumulation	  
in	   the	   model.	   	   This	   can	   improve	   the	   design	   of	   nanomedicine	   optimization	   by	  
providing	  insight	  into	  the	  physicochemical	  properties	  that	  may	  be	  smarter	  to	  focus	  
on	  optimizing.	  	  This	  section	  will	  provide	  quantitative	  tools	  and	  mathematical	  models	  
necessary	  to	  accelerate	  the	  development	  and	  translation	  of	  drug	  delivery	  systems.	  
3.2	  Methods	  
3.2.1	  Model	  
The	   pharmacokinetics	   and	   tumor	   accumulation	   are	   evaluated	   using	   the	   3-­‐
compartment	  model	  described	  in	  Chapter	  2.	  	  In	  short,	  the	  drug	  is	  administered	  into	  
the	   vascular	   compartment	   and	   travels	   between	   that	   compartment,	   a	   peripheral	  
tissue	   compartment,	   and	   a	   tumor	   compartment	   (Figure	   2-­‐3).	   	   The	   drug	   exchange	  
between	   the	   vascular	   and	  peripheral	   tissue	   compartment	   is	   described	  by	   the	   rate	  
constants	   kp	   and	   kd	   while	   the	   drug	   exchange	   between	   the	   vascular	   and	   tumor	  
compartments	   is	  described	  by	   the	   rate	   constants	   kepr	   and	  kb.	  The	   rate	   constant	  of	  
elimination,	   kel,	   encompasses	   all	   clearance	   pathways	   including	   the	  MPS	   and	   renal	  
clearance.	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3.2.1	  Data	  used	  for	  initial	  fits	  
Current	   pharmacokinetic	   parameters	   are	   determined	   for	   pegylated,	   doxorubicin-­‐
loaded	   liposomes	  and	  free	  doxorubicin.	   	  We	  have	  optimized	  the	  parameters	  kp,	  kd,	  
kepr,	  kb	  and	  kel	  in	  athymic	  nu/nu	  mice	  with	  subcutaneous	  LS	  174T	  tumors	  in	  Chapter	  
2	  and	  will	  use	  these	  values	  as	  a	  starting	  point	  for	  evaluation	  of	  the	  change	  in	  each	  
value.	  
To	  additionally	  address	  how	  this	  might	  impact	  human	  patients,	  this	  will	  additionally	  
be	   compared	  with	  data	   from	  human	  clinical	   trials.[14]	  This	  data	  was	  obtained	   for	  
Doxil	  in	  1994	  in	  patients	  suffering	  from	  a	  range	  of	  tumor	  types,	  including	  pancreatic	  
cancer,	  ovarian	  cancer,	  mesothelioma,	  soft	   tissue	  sarcoma,	  breast	  cancer,	  and	  non-­‐
small	  cell	  lung	  carcinoma.[14]	  This	  study	  reports	  values	  describing	  the	  shape	  of	  the	  
pharmacokinetic	  curve	  that	  are	  then	  used	  to	  obtain	  kb,	  kp,	  and	  kel	  for	  Doxil.	  	  Tumor	  
accumulation	  is	  not	  reported	  in	  humans,	  so	  these	  values	  are	  estimated	  using	  the	  kepr	  
and	  kb	  determined	  in	  murine	  data.	  
3.2.1	  Evaluation	  of	  altering	  pharmacokinetic	  parameters.	  
In	   this	   section,	   we	   hone	   in	   on	   the	   rate	   constants	   kp,	   kepr,	   kb	   and	   kel.	   Each	   rate	  
constant	   is	   decreased	   by	   the	   same	   factors:	   1	   (no	   change),	   2,	   5,	   and	   10	   and	   the	  
pharmacokinetics	  and	  tumor	  accumulation	  are	  compared.	  For	  each	  parameter,	   the	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physical	   significance	   is	   discussed	   to	   determine	   the	   impact	   of	   changing	   the	  
nanomedicine	  at	  various	  time	  points.	  
3.3	  Results	  
3.3.1	  Impact	  of	  altering	  kp	  
By	  altering	  the	  drive	  for	  a	  medicine	  to	  accumulate	  in	  the	  peripheral,	  healthy	  tissues,	  
not	   only	   will	   more	   of	   the	   drug	   will	   be	   available	   for	   delivery	   to	   the	   tumor,	   less	  
chemotherapeutics	  will	  reach	  and	  harm	  the	  healthy	  tissues.	   	  This	  decrease	  in	  drug	  
that	   arrives	   at	   healthy	   tissues	   could	   be	   accomplished	   by	   increasing	   the	   size	   of	   a	  
medicine,	   for	   example	   through	   incorporation	   of	   a	   drug	   into	   a	   nanoparticle,	   or	  
changing	  the	  medicine’s	  charge	  or	  surface	  properties.	  	  To	  model	  this,	  we	  evaluated	  a	  
reduction	  in	  kp,	  the	  rate	  constant	  into	  the	  peripheral	  compartment.	  	  	  
Evaluation	  of	  this	  decrease	  in	  humans	  with	  respect	  to	  free	  doxorubicin	  in	  circulation	  
from	  Gabizon	  [14]	  can	  be	  seen	  in	  Figure	  3-­‐1.	  	  Initially,	  this	  leads	  to	  increased	  drug	  in	  
circulation;	  however,	   at	   a	  point	   the	  amount	   in	   circulation	  decreases	  due	   to	  higher	  
availability	   for	   elimination	   pathways.	   	   In	   parallel	   with	   this,	   the	   reduction	   in	  
peripheral	  rate	  constant	  initially	  leads	  to	  increased	  accumulation	  in	  the	  tumor,	  but	  
as	  the	  concentration	  gradient	  moves	  to	  drive	  the	  drug	  out	  of	  the	  tumor,	  the	  amount	  
in	  the	  tumor	  is	  reduced.	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Figure	  3-­1.	  	  Impact	  of	  altering	  kp	  for	  free	  doxorubicin	  in	  humans.	  	  
Reducing	   the	   rate	   constant	   for	   extravasation	   into	   peripheral	   tissues,	   kp,,	   initially	   increases	   the	  
amount	  in	  (a)	  blood	  and	  (b)	  tumor.	  	  At	  longer	  time	  points,	  the	  concentration	  in	  blood	  and	  tumor	  for	  
decreased	  kp	  is	  also	  reduced.	  (c)	  Tumor	  accumulation	  change	  with	  respect	  to	  change	  in	  kp	  highlighted	  
at	  6	  h,	  12	  h,	  24	  h,	  and	  48	  h.	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Decreasing	  kp	  for	  doxorubicin	  may	  be	  best	  compared	  with	  doxorubicin	  encapsulated	  
in	  an	  unpegylated	  liposome,	  for	  example	  Myocet.	  	  The	  pharmacokinetics	  of	  	  	  Myocet	  
has	   been	   compared	   with	   doxorubicin	   in	   humans,	   and	   compared	   with	   free	  
doxorubicin,	   Myocet	   sees	   a	   shorter	   distribution	   phase	  with	   a	   steeper	   elimination	  
half	   life.	   [181]	   	  These	   trends	  are	   	  both	   indicative	  of	  a	  decrease	   in	  kp	   that	  we	  have	  
anticipated	  due	  to	  the	  increase	  in	  size.	  	  While	  there	  may	  be	  additional	  interactions	  at	  
play	  here,	   these	   general	   trends	   are	   confirmation	  of	   the	   effects	   of	   altering	   the	   rate	  
constant	  kp.	  	  If	  these	  trends	  hold	  true,	  we	  may	  expect	  that	  the	  amount	  of	  Myocet,	  and	  
consequently	  the	  amount	  of	  doxorubicin,	  in	  the	  tumor	  will	  be	  higher	  up	  until	  shortly	  
after	   the	   time	  where	   the	  amount	  Myocet	   in	  blood	  would	  dip	  below	   the	  amount	  of	  
free	  doxorubicin.	   	  This	   appears	   to	  happen	  around	   the	   fourth	  day	  post-­‐injection	   in	  
the	   case	   of	   Myocet	   [181],	   seemingly	   providing	   4	   days	   of	   sustainably	   higher	  
chemotherapeutic	  delivery	  to	  the	  tumor.	  
To	   evaluate	   a	   further	   decrease	   in	   peripheral	   tissue,	   we	   assessed	   the	   impact	   of	  
further	  reducing	  the	  uptake	  in	  peripheral	  tissue	  in	  a	  nanoparticle.	  	  For	  nanoparticles,	  
uptake	   in	  peripheral	   tissue	   is	   already	   low	  and	   renal	   clearance	   reduced	  due	   to	   the	  
increase	  in	  size.	  	  In	  this	  instance,	  the	  general	  trends	  mimic	  the	  reduction	  seen	  in	  the	  
free	   doxorubicin:	   initial	   increase	   in	   distribution	   in	   circulation	   and	   the	   tumor	  
followed	  by	  subsequent	  drop	  off.	  	  This	  can	  be	  seen	  for	  data	  both	  from	  human	  clinical	  
trials	  (Figure	  3-­‐2)	  and	  from	  fits	  to	  the	  murine	  data	  (Figure	  3-­‐3).	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Figure	  3-­2.	  Impact	  of	  altering	  kp	  for	  liposomal	  doxorubicin	  in	  humans.	  	  
Similar	  to	  free	  doxorubicin,	  reducing	  the	  rate	  constant	  for	  extravasation	  into	  peripheral	  tissues,	  kp,,	  
initially	   increases,	  yet	  at	   longer	   time	  points	  decreases,	   the	  amount	   in	   (a)	  blood	  and	  (b)	   tumor.	   	   (c)	  
Tumor	  accumulation	  change	  with	  respect	  to	  change	  in	  kp	  highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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Figure	  3-­3.	  Impact	  of	  altering	  kp	  for	  liposomal	  doxorubicin	  in	  mice.	  	  
In	  mice,	  reducing	  the	  rate	  constant	  for	  extravasation	  into	  peripheral	  tissues,	  kp,,	  yields	  similar	  results	  
as	   in	   humans.	   The	   amount	   in	   (a)	   blood	   and	   (b)	   tumor	   initially	   increases	  with	   and	   at	   longer	   times	  
decreases	  with	   respect	   to	   the	   initial.	   (c)	   Tumor	   accumulation	   change	  with	   respect	   to	   change	   in	   kp	  
highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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3.3.2	  Impact	  of	  altering	  kb	  
When	   a	   targeting	   ligand	   is	   added	   to	   a	   nanoparticle,	   the	   alteration	   in	   the	  
nanoparticle’s	  behavior	  will	  depend	  on	  the	  mechanism	  of	  the	  targeting	  ligand	  itself.	  
Many	  targeting	  ligands	  seek	  out	  and	  adhere	  to	  elements	  in	  the	  tumor	  itself.	  	  In	  this	  
instance,	   the	  addition	  of	   targeting	  may	  not	   alter	   the	  extravasation	   into	   the	   tumor.	  	  
Instead,	   the	   addition	   of	   targeting	   will	   reduce	   the	   release	   back	   into	   circulation	  
because	  the	  nanomedicine	  will	  have	  bound	  to	  the	  tumor.	  	  	  
To	  model	  this,	  we	  focus	  on	  decreasing	  the	  rate	  constant	  for	  modeling	  kinetics	  from	  
the	  tumor	  compartment	  back	  into	  the	  vasculature,	  kb.	  The	  result	  of	  these	  fits	  to	  data	  
from	  human	  clinical	   trials	   can	  be	  seen	   in	  Figure	  3-­‐4.	   	   If	   the	   targeting	  ability	   could	  
reduce	  this	  rate	  constant	  by	  a	  factor	  of	  5,	  then	  the	  tumor	  accumulation	  in	  the	  tumor	  
24	  h	  is	   increased	  by	  a	  factor	  of	  1.2,	  at	  48	  h	  is	   increased	  by	  a	  factor	  of	  2.7,	  and	  this	  
trend	  continues	  even	  at	  longer	  times.	  
To	  compare	  the	  model	   for	  human	  trials	   to	  data	  derived	  from	  murine	  experiments,	  
we	  also	  applied	  this	  to	  the	  experimental	  data	  from	  experiments	  in	  mice	  (Figure	  3-­‐5).	  	  
The	  trends	  seen	  here	  mimic	  those	  from	  human	  data.	  	  With	  addition	  of	  targeting	  to	  a	  
nanomedicine,	   the	  amount	  of	  nanomedicine	   in	  blood	  over	   time	   is	  not	   significantly	  
altered,	  yet	  the	  amount	  in	  the	  tumor	  is	  substantially	  increased.	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Figure	  3-­4.	  Impact	  of	  altering	  kb	  for	  liposomal	  doxorubicin	  in	  humans.	  	  
(a)	  Decreasing	  the	  rate	  constant	  for	  transport	  from	  the	  tumor	  back	  into	  circulation	  has	  minimal	  effect	  
on	   the	   amount	   of	   liposome	   in	   circulation.	   (b)	   Tumor	   accumulation	   is	   increased	   compared	   with	  
decreasing	   kb,	   especially	   at	   longer	   time	   points	   when	   compared	   with	   no	   change	   in	   kb.	   (c)	   Tumor	  
accumulation	  change	  with	  respect	  to	  change	  in	  kb	  highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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Figure	  3-­5.	  Impact	  of	  altering	  kb	  for	  liposomal	  doxorubicin	  in	  mice.	  	  
(a)	  As	  with	  fits	  to	  human	  data,	  decreasing	  the	  rate	  constant	  for	  transport	  from	  the	  tumor	  back	  into	  
circulation	  has	  minimal	  effect	  on	  the	  amount	  of	   liposome	  in	  circulation.	  (b)	  Tumor	  accumulation	  is	  
increased	  compared	  with	  decreasing	  kb.	  (c)	  Tumor	  accumulation	  change	  with	  respect	  to	  change	  in	  kb	  
highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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3.3.3	  Impact	  of	  altering	  kel	  
Evasion	  of	  elimination	  pathways	  will	   increase	  the	  drug	  available	  in	  circulation	  and	  
consequently	  the	  amount	  of	  drug	  delivered	  to	  the	  tumor.	  	  One	  method	  to	  reduce	  the	  
elimination	   pathways	   is	   avoidance	   of	   renal	   clearance;	   this	   is	   a	   primary	   draw	   of	  
nanoparticles	  themselves	  since	  particles	  in	  circulation	  greater	  than	  approximately	  8	  
nm	   have	   been	   shown	   to	   evade	   clearance	   via	   the	   kidneys.[182,	   183]	   	   It	   is	   an	  
important	  caveat,	  however,	  that	  this	  is	  both	  a	  benefit	  and	  a	  curse	  of	  nanomedicine.	  	  
Ultimately,	   removal	   of	   nanomedicines	   from	   the	   body	   is	   desirable	   since	  
nanoparticles	  remaining	  in	  the	  body	  for	  long-­‐term	  periods	  of	  time	  is	  not	  ideal.	  	  	  
Additional	  reduction	  in	  elimination	  is	  achieved	  through	  reduction	  in	  elimination	  via	  
the	   MPS.	   	   This	   is	   often	   accomplished	   through	   altering	   surface	   properties	   of	   a	  
nanomedicines.	  	  Pegylation,	  for	  example,	  is	  known	  as	  a	  “stealth”	  coating	  for	  this	  very	  
reason.	  	  To	  evaluate	  the	  effect	  of	  additional	  reduction	  in	  this	  clearance,	  we	  model	  a	  
reduction	  in	  the	  elimination	  rate	  constant,	  kel.	  	  The	  effect	  that	  this	  reduction	  would	  
have	  had	  on	   the	  human	  clinical	   trial	  data	  can	  be	  seen	   in	  Figure	  3-­‐6.	  This	  does	  not	  
impact	  the	  distribution	  phase	  of	  the	  pharmacokinetics	  in	  a	  significant	  manner,	  but	  it	  
does	  increase	  the	  amount	  of	  drug	  in	  circulation	  in	  circulation	  during	  the	  elimination	  
phase.	   	   For	   example,	  with	   a	  5-­‐fold	   reduction	   in	   this	   elimination	   rate	   constant,	   the	  
amount	  of	  liposomal	  doxorubicin	  expected	  in	  the	  tumor	  increases	  by	  1.2-­‐fold	  at	  24	  h	  
and	  1.5-­‐fold	  at	  48	  h.	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Figure	  3-­6.	  Impact	  of	  altering	  kel	  for	  liposomal	  doxorubicin	  in	  humans.	  	  
(a)	  The	  concentration	   in	  blood	   is	   increased	  as	   the	  elimination	  rate	  constant,	  kel,	  decreases.	   (b)	  The	  
increase	   in	   blood	   concentration	   leads	   to	   increased	   tumor	   accumulation	   over	   time.	   (c)	   Tumor	  
accumulation	  change	  with	  respect	  to	  change	  in	  kel	  highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	  
The	  impact	  of	  the	  reduction	  in	  the	  elimination	  rate	  constant	  can	  also	  be	  seen	  in	  the	  
model	   to	   the	  murine	  data	   (Figure	  3-­‐7).	   	  The	   trends	  between	   fitting	   to	  murine	  and	  
human	  data	  are	  highly	  similar	  due	  to	  the	  fits	  being	  obtained	  with	  the	  same	  model.	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Figure	  3-­7.	  Impact	  of	  altering	  kel	  for	  liposomal	  doxorubicin	  in	  mice.	  	  
(a)	  As	  kel	  decreases,	   the	  elimination	  half-­‐time	   is	   increased,	   leading	   to	  higher	  amounts	  of	   liposomal	  
doxorubicin	  in	  blood	  at	  longer	  time	  points.	  (b)	  The	  increase	  in	  blood	  concentration	  leads	  to	  increased	  
tumor	   accumulation	   over	   time.	   (c)	   Tumor	   accumulation	   change	   with	   respect	   to	   change	   in	   kel	  
highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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3.3.4	  Impact	  of	  altering	  kepr	  
As	  the	  tumor	  microenvironment	  changes,	  one	  common	  difference	  between	  tumors	  
is	   the	   extent	   of	   vascularization.	   	   Less	   vascularized	   tumors	  may	   be	   represented	   in	  
this	  model	  with	  a	  decrease	  in	  kepr	  (Figure	  3-­‐8).	  In	  fact,	  we	  have	  shown	  in	  Chapter	  2	  
that	  varying	  a	  tumor	  model	  can	  be	  approximated	  in	  this	  model	  by	  altering	  kepr.	   	   In	  
this	  clinical	  trial,	  patients	  had	  6	  different	  tumor	  types:	  breast	  cancer,	  non-­‐small	  cell	  
lung	  carcinoma,	  ovarian	  cancer,	  mesothelioma,	  soft	   tissue	  sarcoma,	  and	  pancreatic	  
cancer.	  	  The	  result	  shown	  in	  Figure	  3-­‐8	  demonstrates	  that	  the	  pharmacokinetic	  data	  
obtained	  from	  blood	  samples	  will	  be	  minimally	  impacted	  by	  the	  variation	  in	  tumor	  
type.	   	   However,	   this	   result,	   taken	   with	   the	   result	   comparing	   tumor	   types	   from	  
Chapter	  2	  indicates	  that	  the	  liposome	  delivery	  may	  have	  varied	  greatly	  for	  patients	  
with	   different	   types	   of	   tumors.	   	   As	   a	   consequence,	   efficacy	   in	   patients	   may	  
additionally	  have	  been	  impacted.	  
To	   harness	   the	   fact	   that	   kepr	   will	   vary	   to	   an	   experimental	   advantage,	   	   it	   is	   first	  
important	   to	   acknowledge	   that	   different	   tumors	   will	   be	   better	   candidates	   for	  
nanomedicine	  therapy	  than	  others.	  	  For	  tumors	  that	  are	  candidates,	  it	  may	  be	  useful	  
to	   examine	   the	   extent	   of	   nanomedicine	   extravasation	   for	   a	   patient	   in	   order	   to	  
personalize	   nanomedicine	   dosage	   information.	   	   This	   could	   be	   accomplished	   with	  
whole	  body	  imaging	  of	  an	  inert	  nanoparticle	  (Chapter	  4).	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Finally,	   kepr	   could	   potentially	   be	   altered	   by	   temporarily	   increasing	   a	   patient’s	  
systemic	  blood	  pressure.	   	  This	  has	  been	   investigated	   for	  nanomedicine	  delivery	  to	  
lesser-­‐vascularized	   tumors,	   for	   example	   pancreatic	   tumors.[184]	   	   In	   modeling,	   it	  
would	   be	   important	   to	   note	   that	   increasing	   the	   blood	   pressure	   may	   additionally	  
impact	  other	  rate	  constants	   in	  this	  3-­‐compartment	  model.	   	  Transport	   into	  healthy,	  
peripheral	  tissues	  would	  also	  be	  increased,	  modeled	  by	  kp.	   	   In	  this	  instance,	  tumor	  
accumulation	  may	  even	  be	  further	  increased	  by	  a	  decrease	  in	  kb.	  
3.4	  Summary	  
By	   altering	   the	   rate	   constants	   associated	   with	   nanomedicine	   pharmacokinetics,	  
tumor	   accumulation	   will	   be	   altered	   (Table	   3-­‐1).	   	   Reducing	   kepr	   similarly	   reduces	  
tumor	  accumulation.	   	  Reducing	  kb	  will	   increase	   tumor	  accumulation	  as	   less	  of	   the	  
nanomedicine	   is	   transported	   from	  the	   tumor	  back	   into	  circulation.	   	  A	  reduction	   in	  
kel	   will	   increase	   tumor	   accumulation,	   slightly	   at	   first	   and	   more	   substantially	   at	  
longer	   time	   points.	   	   A	   reduction	   in	   kp	   will	   also	   increase	   tumor	   accumulation	   at	  
shorter	  time	  points,	  yet	  at	  longer	  times	  tumor	  accumulation	  is	  reduced.	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Figure	  3-­8.	  	  Impact	  of	  altering	  kepr	  for	  liposomal	  doxorubicin	  in	  human.	  	  
(a)	  As	  kepr	  decreases,	  the	  amount	  of	  liposomal	  doxorubicin	  in	  circulation	  is	  not	  significantly	  altered.	  
(b)	  The	   tumor	  accumulation	  decreases	  with	  decreasing	  kepr.	   	   (c)	  Tumor	  accumulation	   change	  with	  
respect	  to	  change	  in	  kepr	  highlighted	  at	  24	  h,	  48	  h,	  72	  h,	  and	  96	  h.	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Rate	  constant	   Action	   Δ	  Accumulation	  at	  24	  h	  
kepr	   ÷	  5	   x	  0.28	  
kb	   ÷	  5	   x	  1.6	  
kel	   ÷	  5	   x	  1.2	  
kp	   ÷	  5	   x	  1.2	  
	  
Table	  3-­1.	  Effect	  of	  altering	  the	  rate	  constants	  on	  tumor	  accumulation	  at	  24	  h.	  
Variations	  in	  kepr	  are	  indicate	  variations	  in	  tumor	  “leakiness.”	  	  Decreasing	  kb	  by	  5	  shows	  the	  highest	  
increase	   in	   tumor	   accumulation	   at	   24	   h,	   indicating	   that	   increasing	   tumor	   targeting	   will	   aid	   in	  
nanoparticle	  retention	  in	  the	  tumor.	   	  At	  24	  h,	  the	  increase	  in	  tumor	  accumulation	  for	  decreasing	  kel	  
and	  kp	  are	  identical;	  however,	  at	  longer	  time	  points,	  kel	  will	  give	  greater	  tumor	  accumulation.	  
	  
3.5	  Future	  Directions	  
Based	  on	  the	  predictions	  above,	   it	   is	   logical	  to	  focus	  the	  first	  step	  of	  nanomedicine	  
optimization	   on	   improving	   (i.e.	   reducing)	   the	   rate	   constant	   of	   elimination.	   	   The-­‐
state-­‐of-­‐the-­‐art	  for	  MPS	  evasion	  is	  pegylation.	   	  Pegylated	  liposomes	  have	  relatively	  
long	   clearance	   half-­‐time,	   typically	   1	   -­‐	   4	   days	   in	   patients.[16,	   147,	   149,	   168]	  	  
Pegylation	   is	   inexpensive	   and	   FDA-­‐approved,	   but	   delays	   rather	   than	   suppresses	  
opsonization	   and	   clearance	   by	   the	   MPS,	   and	   can	   eventually	   stimulate	   antibody	  
generation.[17,	  185]	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Various	   alternative	   strategies	   for	   increasing	   circulation	   time	   have	   been	   explored,	  
such	   as	   the	   use	   of	   exosomes	   created	   from	   host	   red	   blood	   cells[186-­‐189]	   and	  
marker-­‐of-­‐self	   proteins	   such	   as	   CD47	   or	   CD200.[190-­‐192]	   	   CD47	   binds	   to	   the	  
immune	   inhibitory	   receptor	   SIRPα	   (signal	   inhibitory	   protein)	   found	   on	  
macrophages	   and	   is	   exploited	   by	   host	   red	   blood	   cells	   and	   invading	   cells,	   such	   as	  
leukemia	  cells,	  melanoma	  cells,	  and	  leukocytes,	  that	  are	  known	  to	  avoid	  the	  immune	  
system.[193-­‐195]	   	   The	   ability	   of	   CD47	   to	   facilitate	   evasion	   of	   the	   immune	   system	  
could	  provides	  an	  excellent	  metric	  with	  which	  to	  	  explore	  a	  potential	  decrease	  in	  kel	  
and	   confirm	   the	   impact	   that	   may	   have	   on	   the	   pharmacokinetics	   and	   tumor	  
accumulation	  of	  a	  particle	  and	  use	  these	  to	  confirm	  the	  applicability	  of	  the	  model.	  
This	   data	   also	   demonstrates	   that	   inclusion	   of	   active	   targeting	   will	   provide	   an	  
advantage	   for	   tumor	   accumulation.	   	   Evaluation	   of	   how	   the	   pharmacokinetic	  
parameters	   change	   with	   the	   addition	   of	   active	   targeting	   ligands,	   for	   example	  
antibodies	   or	   aptamers,	   will	   provide	   insight	   into	   the	   extent	   of	   their	   impact	   on	  
targeting	  efficiency.	  	  	  
Another	  future	  direction	  is	  expansion	  of	  this	  model	  to	  include	  other	  parameters,	  for	  
example	   direct	   clearance	   from	   the	   tumor.	   	   At	   present,	   our	   understanding	   of	   the	  
tumor	   microenvironment	   is	   not	   extensive	   enough	   to	   evaluate	   this	   parameter	  
independently.	   	   In	   the	  3-­‐compartment	  model,	   clearance	   from	  the	   tumor	   is	   lumped	  
into	   kb.	   Improving	   imaging	   and	   understanding	   of	   nanomedicines	   in	   the	   tumor	  
microenvironment	  will	  allow	  for	  better	  modeling	  of	  this	  behavior.	   	  For	  example,	  to	  
	   86	  
what	  extent	  are	  nanomedicines	  cleared	  by	  the	  lymphatic	  system?	  	  Additionally,	  how	  
are	  nanomedicines	  digested	  within	  the	  tumor?	  	  Answers	  to	  these	  questions	  may	  be	  
found	  with	  further	  imaging	  and	  chemical	  analysis	  of	  the	  tumor	  after	  administration	  
of	  nanomedicines.	   	   Improving	  our	  understanding	  of	  clearance	   from	  the	   tumor	  will	  
enable	  further	  refinement	  of	  the	  3-­‐compartment	  model.	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Chapter	  4 :	   Evaluation	   of	   the	   Impact	   of	   Pharmacokinetic	  
Parameters	  on	  the	  EPR	  Effect	  
4.1	  Motivation	  
4.1.1	  Improved	  nanomedicine	  evaluation	  
Information	   regarding	  a	  nanomedicine’s	   ability	   to	   arrive	  at	   the	   tumor	  and	   sustain	  
presence	   there	   over	   time	   is	   important	   to	   determine	   if	   a	   nanoparticle	   is	   a	   good	  
candidate	   for	   cancer	   nanomedicine.	   	   Unfortunately,	   this	   information	   is	   expensive	  
and	   time	   consuming	   to	   obtain.	   	   For	   this	   reason,	   many	   labs	   shy	   away	   from	   these	  
experiments.	   	   It	  would	  be	  advantageous	   to	  establish	  a	  platform	   to	  minimize	   these	  
costs	  by	  facilitating	  the	  use	  of	  one	  mouse	  for	  the	  entire	  time	  course.	  	  The	  following	  is	  
a	  preliminary	  evaluation	  of	  dye-­‐loaded	  liposomes	  for	  evaluation	  of	  their	  affinity	  for	  
a	  tumor.	  	  This	  could	  be	  used	  for	  a	  more	  rapid	  nanoparticle	  evaluation	  feedback	  loop	  
for	  drug	  development.	  	  	  
Quantitative	   tools	   for	   analysis	   of	   tumor	   accumulation	   will	   accelerate	   the	  
development	  and	  translation	  of	  drug	  delivery	  systems.	  	  If	  dye-­‐loaded	  liposone	  could	  
be	   used	   to	   test	   predictions	   of	   how	   pharmacokinetic	   parameters	   (e.g.	   distribution	  
volume	   or	   clearance	   half-­‐time)	   modulate	   tumor	   accumulation,	   it	   would	   allow	  
researchers	  to	  make	  more	  rapid	  rational	  decisions	  on	  platform	  design.	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To	  accelerate	  optimization	  of	  drug	  and	  gene	  delivery	  platforms,	  we	  will	  assess	  the	  
feasibility	  of	  pharmacokinetic	  imaging.	  	  For	  delivery	  platforms	  where	  an	  IR	  dye	  can	  
be	   incorporated	   into	   the	   platform	   (e.g.	   liposomes),	   information	   on	   tumor	  
accumulation	   and	  other	  pharmacokinetic	   parameters	   can	  be	  obtained	   from	  whole	  
body	  imaging.	  	  We	  will	  explore	  the	  limits	  of	  this	  approach	  as	  a	  tool	  to	  accelerate	  the	  
development	  of	  drug	  delivery	  systems.	  	  As	  a	  proof-­‐of-­‐principle,	  we	  will	  examine	  the	  
correlation	   between	   the	   pharmacokinetics	   and	   tumor	   accumulation	   of	   dye-­‐loaded	  
liposomes	  with	  the	  quantitative	  data	  from	  doxorubicin-­‐loaded	  liposomes.	   	  The	  use	  
of	  these	  dye-­‐loaded	  liposomes	  could	  provide	  insight	  that	  is	  important	  in	  guiding	  the	  
development	  of	  nanomedicines	   in	  a	  much	  more	  expedient	  manner,	   representing	  a	  
feasible	  shift	  from	  empirical	  design	  to	  a	  rational	  design	  process.	  
For	   the	   criteria	   of	   evaluation	   of	   alterations	   in	   nanoparticle	   properties	   on	   tumor	  
uptake,	   it	   will	   be	   important	   to	   introduce	   an	   imaging	   agent	  while	  maintaining	   the	  
surface	  properties	  of	  the	  particle.	  	  In	  this	  instance,	  the	  dye	  cannot	  be	  attached	  to	  the	  
surface	  on	  the	  chance	  that	  it	  will	  alter	  the	  properties	  even	  slightly.	  	  Encapsulation	  of	  
an	  imaging	  agent	  within	  the	  particle	  may	  allow	  for	  determination	  of	  a	  nanoparticle’s	  
biodistribution	  and	  tumor	  accumulation	  via	  whole	  body	  imaging.	  	  Then,	  by	  altering	  
the	   surface	   properties	   of	   said	   nanoparticle,	   it	   will	   be	   possible	   to	   visualize	   the	  
variations	  that	  occur	  as	  a	  direct	  result	  of	  that	  property’s	  change.	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4.1.2	  Improved	  patient	  dosing	  parameters	  
The	   scientific	   insight	   and	   quantitative	   models	   of	   tumor	   accumulation	   developed	  
thus	   far	   could	   be	   implemented	   in	   the	   clinic	   as	   part	   of	   the	   shift	   towards	  
individualized	   medicine.	   	   For	   example,	   imaging	   of	   an	   inert	   tracer	   (e.g.	   liposome	  
containing	   a	   contrast	   agent)	   could	   be	   used	   to	   assess	   the	   leakiness	   of	   a	   patient’s	  
tumor	   and	  models	  used	   to	  design	   the	  dosing	   regimen	   for	   that	  patient	   to	  optimize	  
tumor	  accumulation	  and	  minimize	  unwanted	  side	  effects.	  
Extravasation	   from	   circulation	   and	   tumor	   accumulation	   are	   mediated	   by	   the	  
Enhanced	   Permeability	   and	   Retention	   (EPR)	   effect.	   	   Evidence	   from	   intravital	  
microscopy	   studies	   suggests	   that	   the	   “leakiness”	   of	   tumor	   vasculature	   in	   mice	   is	  
tumor	   specific.[61,	   175,	   196]	   	  While	   a	   correlation	   has	   not	   been	   established,	   these	  
studies	  suggest	  that	  the	  accumulation	  of	  a	  drug	  delivery	  platform	  is	  tumor	  specific.	  	  
A	  consequence	  of	   the	  hypothesis	   that	   tumor	  accumulation	   is	   tumor	  specific	   is	   that	  
dosing	  of	  chemotherapeutic	  should	  be	  based,	  in	  part,	  on	  the	  “leakiness”	  of	  the	  tumor.	  
Every	  tumor	  develops	  in	  a	  unique	  manner,	  yielding	  one	  further	  reason	  that	   in	  vivo	  
imaging	  could	  prove	  useful.	  	  Each	  patient’s	  tumor	  may	  vary	  in	  vascularization,	  hence	  
they	  may	   have	   varied	   levels	   of	   leakiness	   and	   varied	   response	   to	   treatment.	   	   If	   an	  
individual’s	  tumor	  could	  be	  evaluated	  prior	  to	  treatment	  to	  determine	  the	  efficiency	  
of	  nanomedicine	  delivery,	   then	  a	  more	  exact	  understanding	  of	  doses	  necessary	  for	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efficacy	   could	   be	   determined.	   	   This	   could	   be	   accomplished	   with	   an	   analogous	  
nanomedicine	  with	  inert	  imaging	  ability.	  
4.2	  Materials	  and	  Methods	  
4.2.1	  Cell	  culture	  
LS	  174T	  colorectal	  adenocarcinoma	  cells	  were	  purchased	  from	  American	  Type	  Cell	  
Culture	   (ATCC)	   and	   cultured	   according	   to	   the	   corresponding	   guidelines.	   	   LS	   174T	  
cells	  were	  grown	  in	  Eagle’s	  Minimum	  Essential	  Medium	  (EMEM)	  (Quality	  Biological)	  
with	   10%	   fetal	   bovine	   serum	   (FBS)	   (Life	   Technologies)	   and	   1%	   penicillin	  
streptomycin	  (P/S)	  (Life	  Technologies).	  Cells	  were	  maintained	  at	  5%	  CO2	  and	  37°C	  
in	  a	  humidified	  incubator.	  
4.2.2	  Animal	  models	  
All	  experiments	  were	  approved	  by	  and	  performed	  in	  accordance	  with	  the	  guidelines	  
and	  regulations	  of	  the	  Animal	  Care	  and	  Use	  Committee	  for	  Johns	  Hopkins	  University.	  	  
Athymic	  nu/nu	  female	  mice	  4-­‐6	  weeks	  old	  were	  purchased	  from	  Charles	  River.	  
4.2.3	  Xenograft	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Subcutaneous	  xenografts	  were	   inoculated	   in	   the	  right	   flanks	  of	  nude,	   female	  mice.	  	  
Approximately	  5	  million	  cells	  were	  suspended	  in	  100	  µL	  of	  50%	  growth	  media	  and	  
50%	  growth-­‐factor-­‐reduced	  Matrigel	  (Corning).	   	  Cell	  suspensions	  were	  maintained	  
on	   ice	   until	   subcutaneous	   inoculation.	   	   Xenografts	   were	   grown	   to	   8-­‐10	   mm	   in	  
diameter	  or	  approximately	  0.2	  g	  in	  weight	  prior	  to	  use	  in	  exeriments.	  
4.2.4	  Liposome	  synthesis	  
Pegylated	   liposomes	   will	   be	   synthesized	   from	   90	   mol%	   hydrogenated	   soybean	  
phosphatidylcholine	   (HSPC)	   and	   10	   mol%	   1,2-­‐distearoyl-­‐sn-­‐glycero-­‐3-­‐
phosphoethanolamine-­‐N-­‐[amino(polyethylene	   glycol)-­‐2000]	   (DSPE-­‐mPEG2k),	  with	  
a	   1.6:1	   lipid	   to	   cholesterol	   ratio,	   corresponding	   to	   the	   composition	   of	   Doxil	  
liposomes.	   	  Briefly,	   lipids	  are	  mixed	  and	  dried	  under	  vacuum.	   	  Then,	  0.5	  mL	  of	  0.1	  
mg/mL	  near-­‐IR	  dye	  (ADS740WS)	  is	  added	  to	  the	  dry	  lipids	  for	  encapsulation	  within	  
the	   liposomes.	   	  This	  solution	   is	   then	  subjected	   to	  10	   freeze-­‐thaw	  cycles	  where	   the	  
vial	   is	   dunked	   in	   alternating	   liquid	   nitrogen	   and	   room	   temperature	   water	   with	  
intermittent	  agitation	   to	   loosen	   the	   lipids	   from	  the	  vial.	   	   	  The	  resulting	  solution	   is	  
mechanically	   extruded	   10	   times	   back	   and	   forth	   through	   a	   100	   nm	   filter	   to	   form	  
liposomes	  of	  a	  more	  uniform	  size	  distribution.	   	  The	  liposomes	  are	  then	  purified	  by	  
gel	   chromatography	   using	   a	   Sepharose	   CL-­‐4B	   column	   equilibrated	   in	   phosphate	  
buffered	   saline	   (PBS)	   to	   remove	   all	   free	  dye	  molecules	   that	   have	  not	   been	   loaded	  
into	  the	  liposomes.	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4.2.5	  Liposome	  administration	  
NIR-­‐dye	   loaded	   liposomes	   are	   injected	   in	   200	   µL	   volume	   via	   lateral	   tail	   vein	  
injection.	  
4.2.6	  Animal	  imaging	  
Following	  administration	  of	  NIR-­‐dye	  loaded	  liposomes,	  individual	  mice	  are	  sedated	  
with	  isoflurane	  gas	  anesthesia	  at	  time	  points	  corresponding	  to	  tumor	  accumulation	  
data	  for	  doxorubicin-­‐loaded	  liposomes	  (Chapter	  2).	  	  This	  is	  at	  5	  min,	  30	  min,	  1	  h,	  6	  h,	  
24	  h,	  and	  48	  h	  post	  injection.	   	  Mice	  are	  then	  imaged	  on	  the	  LI-­‐COR	  Pearle	  Impulse	  
NIR	  Imager.	  	  Each	  mouse	  undergoes	  two	  single	  mouse	  scans,	  one	  on	  the	  dorsal	  side	  
and	   one	   on	   the	   ventral	   side.	   	   All	   images	   for	   either	   the	   dorsal	   or	   ventral	   side	   of	   a	  
single	   mouse	   are	   linked	   together	   to	   normalize	   intensity	   for	   direct	   comparison	   of	  
fluorescent	  intensity.	  	  
4.2.7	  Analysis	  
Fluorescence	   intensity	   is	   obtained	   from	   two	   regions	   of	   interest	   corresponding	   to:	  
(1)	   the	   tumor	  and	  (2)	   the	  uppermost	   region	  of	   the	  mouse’s	   tail	   in	  order	   to	  obtain	  
fluorescence	   from	   the	   same	   tail	   vein	   portion	   on	   each	  mouse.	   	   These	   data	  will	   be	  
compared	   to	   the	   tumor	   accumulation	   of	   doxorubicin-­‐loaded	   liposomes	   from	  
resected	   tumors	   at	   the	   same	   time	   points	   (Chapter	   2)	   to	   assess	   the	   feasibility	   of	  
pharmacokinetic	   imaging.	   	   The	   objective	   is	   to	   obtain	   the	   correlation	   coefficient	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between	  tumor	  accumulation	  of	  doxorubicin-­‐loaded	  liposomes	  obtained	  from	  HPLC	  
analysis	   of	   resected	   tumors	   and	   tumor	   accumulation	   obtained	   from	   fluorescence	  
imaging.	  	  
4.3	  Results	  
4.3.1	  NIR	  imaging	  data	  
Mice	  bearing	  LS	  174T	  subcutaneous	  xenografts	  were	  injected	  via	  the	  lateral	  tail	  vein	  
with	  near-­‐infrared	   (NIR)	  dye	   loaded	   liposomes	   and	   imaged	  at	  6	   time	  points	  post-­‐
injection	  (5	  min,	  30	  min,	  2	  h,	  6	  h,	  24	  h,	  and	  48	  h).	  These	  time	  points	  were	  chosen	  so	  
that	   data	   can	   be	   compared	   with	   quantitative	   data	   from	   doxorubicin-­‐loaded	  
liposomes	   (Chapter	   2).	   Two	  mice	  were	   imaged,	   the	   dorsal	   and	   ventral	   images	   for	  
both	  mice	  are	  included	  in	  Figure	  4-­‐1.	  	  From	  analysis	  of	  the	  images	  (Figure	  4-­‐1),	  the	  
signal-­‐to-­‐noise	   ratio	  at	   the	   shortest	   time	  point	   (≈	  0.3	  %ID)	   is	   about	  30,	   indicating	  
that	  the	  resolution	  is	  sufficient	  for	  semi-­‐quantitative	  analysis.	  
Comparing	   this	   data	  with	   the	   quantitative	   data	   for	   doxorubicin-­‐loaded	   liposomes	  
(Figure	  2-­‐6),	  we	  realize	  several	  similarities.	  By	  only	  five	  minutes	  post-­‐injection	  we	  
had	  already	  seen	  a	  drop	  in	  circulating	  liposomes.	  	  Whole	  body	  imaging	  reveals	  that	  
by	  this	  point,	  a	  significant	  portion	  of	  the	  liposomes	  have	  already	  accumulated	  in	  the	  
body,	  shedding	  light	  on	  the	  liposome	  biodistribution.	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Figure	  4-­1.	  NIR	  dye	  loaded	  liposomes	  in	  mice	  over	  48	  h.	  
Semi-­‐quantitative	   real-­‐time	   pharmacokinetics.	   	  Whole	   body	   fluorescence	   imaging	   of	   a	  mouse	  with	  
one	   subcutaneous	  LS174T	   flank	   xenograft	   in	   the	   right	   flank	   following	   administration	  of	   liposomes	  
loaded	   with	   a	   near-­‐IR	   dye.	   Data	   shown	   for	   (a)	   mouse	   1	   and	   (b)	   mouse	   2.	   	   Near-­‐IR	   dye	   (green),	  
autofluorescence	  (red).	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Looking	  ahead	  in	  the	  imaging	  to	  six	  hours	  post-­‐injection	  reveals	  that	  the	  liposomes	  
have	   colocalized	   in	   the	   stomach	   and	   intestines.	   	   At	   24	   h	   and	   48	   h	   post-­‐injection,	  
liposome	  concentration	  has	  decreased	  greatly,	  but	  the	  liposomes	  are	  still	  present	  in	  
organs	  including	  liver,	  spleen,	  and	  intestines.	  	  
Tumor	   accumulation	   is	   not	   identical	   between	   the	  mice,	   indicative	   of	   variations	   in	  
tumor	  architecture.	   	  The	  tumors	  are	  on	  the	  right	   flank,	  seen	  on	  the	  ventral	  side	  of	  
each	   mouse.	   	   In	   the	   mouse	   seen	   in	   Figure	   4-­‐1A,	   the	   accumulation	   in	   the	   tumor	  
increases	   to	   a	   maximum	   at	   48	   h,	   while	   in	   Figure	   4-­‐1B,	   the	   maximum	   tumor	  
accumulation	   is	  seen	  at	  2	  h.	   	   In	  both	   instances,	   tumor	  accumulation	  at	  48	  h	   is	  still	  
observable	  and	  significant.	  
The	   main	   deterrent	   seen	   in	   these	   images	   is	   the	   renal	   accumulation	   that	   can	   be	  
visualized	  on	  the	  mid-­‐left	  region	  of	  each	  mouse’s	  ventral	  side.	   	  Renal	  accumulation	  
does	   not	   occur	   in	   liposomes	   as	   large	   as	   100	   nm,	   so	   uptake	   in	   the	   kidneys	   is	   a	  
possible	  indication	  of	  dye	  leakage	  from	  the	  liposomes.	  	  	  
Overall,	  whole	   body	   imaging	   sheds	   light	   on	   the	   liposomes’	   biodistribution.	   	  While	  
tumor	   accumulation	  will	   vary	   for	   different	   tumors,	   but	   the	   biodistribution	   trends	  
seen	  in	  each	  mouse	  are	  similar.	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4.3.2	  Correlation	  of	  NIR	  imaging	  to	  HPLC	  analysis	  of	  doxorubicin-­‐loaded	  liposomes	  
	  For	   each	   mouse,	   the	   intensity	   in	   the	   tail	   region	   and	   in	   the	   tumor	   region	   was	  
determined	  at	  each	  time	  point	  and	  normalized	  to	  1	  at	  the	  maximum	  for	  each.	  	  These	  
values	  were	  averaged	  at	  each	  time	  point	  and	  then	  re-­‐normalized	  at	  the	  maximum	  to	  
provide	  the	  trends	  shown	  in	  Figure	  4-­‐2.	   	  These	  intensities	  follow	  the	  same	  general	  
trends	  as	  for	  the	  pharmacokinetics	  and	  tumor	  accumulation	  of	  doxorubicin-­‐loaded	  
liposomes	   determined	   from	   HPLC	   analysis	   of	   doxorubicin	   in	   resected	   tumors	  
(Figure	  2-­‐6).	  	  	  
The	  tail	  region	  is	  selected	  to	  ensure	  it	   is	  sufficiently	  far	  from	  the	  tail	  vein	  injection	  
site	   so	   as	   not	   to	   have	   interference	   from	   residues	   left	   from	   any	   injection	  
abnormalities.	   	   The	   tail	   is	   a	   region	   with	   a	   large	   vein	   and	   as	   such	   this	   region	   is	  
representative	  of	   the	  concentration	  of	   liposome	  in	  blood	  (Figure	  4-­‐2A).	   	  Similar	  to	  
the	   trend	   for	   liposomal	   doxorubicin	   determined	   in	   Chapter	   2,	   this	   sees	   an	   initial	  
decrease	   to	   roughly	   half	   at	   2	   h	   followed	   by	   a	  more	   gradual	   decrease	   through	   the	  
elimination	  phase.	  
Similarly,	  the	  total	  intensity	  from	  the	  tumor	  (Figure	  4-­‐2B)	  follows	  the	  same	  general	  
trend	  as	  for	  the	  tumor	  accumulation	  of	  liposomal	  doxorubicin	  (Chapter	  2).	  	  Here,	  the	  
accumulation	  at	  30	  min	  is	  roughly	  half	  of	  the	  accumuation	  reached	  at	  24	  h	  with	  the	  
maximum	  seeming	  to	  appear	  between	  6	  h	  and	  24	  h.	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Figure	  4-­2.	  Evaluation	  of	  NIR	  liposome	  intensity	  in	  mice	  over	  48	  h.	  	  
(a)	   The	   intensity	   in	   the	   tail	   of	   the	  mice	   normalized	   to	   1	   at	   5	  min.	   	   (b)	   The	   intensity	   in	   the	   tumor	  
normalized	  to	  1	  at	  the	  maximum	  intensity.	  	  Data	  represents	  mean	  ±	  SE,	  n=2.	  
	  
At	   each	   time	   point,	   the	   NIR-­‐liposome	   intensity	   is	   plotted	   vs.	   the	   anticipated	  
quantitative	   data	   for	   the	   pharmacokinetic/tail	   image	   data	   (Figure	   4-­‐3A)	   and	   the	  
tumor	  accumulation	  data	   (Figure	  4-­‐3B).	   	   In	  each	  case,	   the	  a	   linear	   fit	   is	   calculated	  
with	  an	  intercept	  at	  zero,	  as	  would	  be	  expected	  for	  an	  ideal	  correlation	  between	  the	  
semi-­‐quantitative	   imaging	  data	   for	  NIR-­‐dye	   loaded	   liposomes	  and	   the	  quantitative	  
data	   from	   doxorubicin-­‐loaded	   liposomes.	   	   The	   Pearson	   correlation	   coefficient	  
between	   the	   fluorescence	   intensity	  obtained	   from	  whole	  body	   imaging	  and	   tumor	  
accumulation	   from	  HPLC	  (Figure	  4-­‐3)	   is	  0.95,	   suggesting	   that	   tumor	  accumulation	  
can	  be	  obtained	  from	  imaging.	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Figure	   4-­3.	   	   Calibration	   of	   NIR	   liposome	   data	   to	   quantitative	   HPLC	   data	   obtained	   from	  
doxorubicin-­loaded	  liposomes.	  
4.4	  Future	  Work	  
This	  semi-­‐quantiative	  imaging	  data	  provides	  a	  foundation	  for	  the	  use	  of	  dye-­‐loaded	  
nanoparticles	   for	   assessing	   tumor	   accumulation	   variations	   in	   nanomedicine	  
optimization.	  	  This	  can	  provide	  a	  relatively	  expedient	  method	  to	  facilitate	  systematic	  
nanomedicine	  development.	  
The	  next	  step	   in	   this	  work	   is	   to	  use	  dye-­‐loaded	   liposomes	  to	  assess	  how	  liposome	  
modification	   will	   affect	   nanomedicine	   efficiency.	   	   For	   example,	   in	   Chapter	   3,	   we	  
discussed	  the	  benefits	  of	  functionalizing	  liposomes	  with	  CD47	  to	  aide	  the	  liposomes	  
with	   evasion	   of	   the	   immune	   system.	   	   To	   rapidly	   test	   this	   theory	   in	   vivo,	   we	  
recommend	   assessing	   biodistribution	   and	   tumor	   uptake	   of	   NIR-­‐dye	   loaded	  
liposomes	  with	  and	  without	  incorporation	  of	  CD47	  in	  the	  lipid	  bilayer.	  	  If	  the	  CD47	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does	  in	  fact	  facilitate	  immune	  system	  evasion,	  fluorescent	  intensity	  in	  the	  liver	  may	  
be	  noticeably	  decreased	  while	  tumor	  intensity	  over	  time	  will	  be	  increased.	  
Additionally,	   whole	   body	   imaging	   has	   proven	   useful	   for	   comprehension	   of	   tumor	  
variations.	   	   As	   discussed	   previously,	   this	   information	   would	   prove	   valuable	   in	  
identifying	   a	   patient’s	   tumor	   “leakiness”	   and	   consequently	   identifying	   the	   correct	  
dosage	  for	  the	  patient.	  	  At	  present,	  NIR-­‐dye	  is	  not	  FDA-­‐approved;	  however,	  there	  are	  
FDA-­‐approved	  radiolabel-­‐imaging	  agents.	   	  By	  adapting	  this	  model	  to	   incorporate	  a	  
radiolabel	  in	  place	  of	  the	  dye,	  this	  platform	  could	  be	  used	  to	  identify	  patient-­‐specific	  
dosages	  for	  liposomal	  nanomedicines.	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  and	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   Thesis:	  Synthesis	   of	   nanoparticles	   for	   quantitative	  
evaluation	   of	   the	   enhanced	   permeability	   and	  
retention	  (EPR)	  effect	  in	  vivo	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May	  2009	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  Engineering	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  activity	  of	  cationic	  antiseptics	  in	  
Layer-­by-­Layer	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  assemblies	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May	  2007	   	   ROSE-­‐HULMAN	  INSTITUTE	  OF	  TECHNOLOGY	  	  	  	  Terre	  Haute,	  IN	  
	   	   	   B.S.	  -­‐	  Mechanical	  Engineering,	  Summa	  Cum	  Laude	  	  
	   	   	   Minors:	  	  Spanish,	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  &	  Literature	   	  
GPA	  3.92/4.0	  
Research	  Experience	  
Johns	  Hopkins	  University	  	   	   	   	   	   	   July	  2009	  –	  Present	  
- Evaluation	  of	  nanoparticles	  for	  delivery	  of	  drugs	  and	  imaging	  agents	  to	  solid	  
tumors.	  
- Analysis	   of	   the	   effect	   of	   a	   tumor	   on	   the	   pharmacokinetics	   of	   liposomal	  
doxorubicin.	  
- Performed	  a	  macro	  study	  of	  nanoparticles	  for	  targeting	  solid	  tumors	  in	  order	  
to	  create	  a	  standardized	  protocol	  for	  nanoparticle	  comparison.	  
- Synthesis	  and	  characterization	  of	  nanoparticles	   including	  quantum	  dots	  and	  
liposomes.	  	  	  
- Tailoring	  of	  nanoparticle	  surface	  by	  altering	  the	  charge,	  pegylation,	  and	  active	  
groups	   for	   subsequent	   conjugation	   to	   various	   ligands	   for	   active	   tumor	  
targeting.	  	  
- Research	  responsibilities	  include	  analysis	  of	  nanoparticle	  size,	  zeta	  potential,	  
targeting	  efficacy	  both	  in	  vitro	  and	  targeting	  to	  solid	  tumors	  in	  vivo,	  including	  
pharmacokinetic	  and	  biodistribution	  studies.	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Texas	  A&M	  University	   	   	   	   	   August	  2007	  -­‐	  June	  2009	  
- Developed	  antimicrobial	  thin	  films	  to	  be	  used	  as	  a	  coating	  to	  improve	  sterility	  
of	  medical	  devices,	  bandaging,	  and	  other	  products.	  
- Characterization	   of	   antimicrobial	   thin	   films	   prepared	   using	   layer-­‐by-­‐layer	  
(LbL)	  assembly.	  	  	  
- Analysis	   of	   the	   effects	   of	   ionic	   strength,	   pH,	   and	   antimicrobial	   agents	   on	  
inhibition	  against	  both	  gram-­‐negative	  and	  gram-­‐positive	  bacteria.	  	  
	  
Los	  Alamos	  National	  Laboratory,	  Los	  Alamos,	  NM	  	   	   	   Summer	  
2007	  
- Worked	  in	  a	  larger	  team	  investigating	  a	  novel	  AuZn	  alloy.	  
-­‐	   	   	   	   	   	   Mechanical	   characterization	   and	   analysis	   with	   tensile	   testing	   and	   other	  
methods.	  
	  
NASA-­John	  Glenn	  Research	  Center,	  Cleveland,	  OH	   	   	   	   Summers	  
2004-­‐2006	  
-­‐	  	  	  	  	  2006:	  	  Modeling	  of	  foam	  cells	  used	  in	  shuttle	  missions.	  
-­‐	  	  	  	  	  2006:	  Failure	  analysis	  via	  optical	  and	  electron	  microscopy.	  
-­‐	  	  	  	  	  2004-­‐2005:	  	  Mechanical	  testing	  of	  polymers	  composites.	  
	  
Awards	  and	  Honors	  
- MVP	  for	  leadership	  role	  in	  Thread,	  a	  local	  nonprofit,	  2014	  
- Donald	   S.	   Rodbell	   Memorial	   Graduate	   Research	   Fellowship	   in	   Materials	  
Science	  and	  Engineering,	  2011-­present	  
- National	  Science	  Foundation	  (NSF)	  Graduate	  Research	  Fellowship,	  2008-­2011	  
- Texas	  A&M	  University	  Graduate	  Diversity	  Fellowship	  Recipient	  August	  2007	  –	  
2009	  





	   115	  
Leadership	  Activities	  
Thread	  (formerly	  Incentive	  Mentoring	  Program)	  
- Program	  Coordinator:	  	  Support	  project	  managers	  as	  they	  lead	  teams	  to	  build	  
up	  a	  “family”	  of	  mentors	  to	  a	  struggling	  high	  school	  student.	  	   	  
- Work	  with	   the	   site	   director	   and	   project	  managers	   to	   develop	   project	   plans	  
and	  timelines.	  	  
- Develop	  new	  and	  current	  leaders	  and	  supports	  division	  morale.	  
	  
Johns	  Hopkins	  University	  
- Organized,	   hosted,	   and	   led	   a	   symposium	   for	   scientific	   presentations	   and	  
discussions,	  2014.	  
- Led	  laboratory	  graduate	  level	  courses	  in	  synthesis	  of	  gold	  nanoparticles.	  
- Planned	   and	   conducted	   summer	   workshops	   for	   high	   school	   teachers	   on	  
nanoparticle	  synthesis	  and	  applications.	  
- Planned,	  organized,	  and	  operated	  an	  exhibit	  on	  the	  National	  Mall	  for	  the	  USA	  
Science	  and	  Engineering	  Festival,	  2010.	  
	  
Texas	  A&M	  University	  
- Led	   laboratories	  and	  grading	   for	  a	   junior	   level	  materials	  and	  manufacturing	  
course	  and	  grading	  for	  a	  senior	  level	  polymer	  properties	  course.	  
	  
Rose-­Hulman	  Institute	  of	  Technology	  
- Learning	   Center.	   	   Responsibilities	   included	   tutoring	   and	   preparing	   review	  
packets	   for	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